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If therefore anyone wishes to search out the truth of things in 
serious earnest, he ought not to select one special science; for all 
the sciences are conjoined with each other and interdependent; he 
ought rather to think how to increase the natural light of reason, 
not for the purpose of resolving this or that difficulty of scholastic 
type, but in order that his understanding may enlighten his will to 
its proper choice in all contingencies of life. In a short time he will 
see with amazement that he has made more progress than those 
who are eager about particular ends, and that he has not only 
obtained all that they desire, but even higher results than fall 
within his expectation.  
 
-   Descartes   -  
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SUMMARY   
 
 Investigations into the neurobiology of obsessive-compulsive disorder (OCD) 
have provided useful insights into this prevalent and disabling disorder in recent 
decades. Encouraging advances have also been made in the pharmacological treatment 
of OCD. This has improved the quality of life for many who typically endure chronic 
unremitting symptoms. Despite the widespread use of first-line agents selective for the 
serotonergic system in OCD, relatively little is known about the neurobiology of 
treatment response, the specific components of the serotonin system involved in 
symptom modulation, and the overlapping and distinct brain regions impacted by 
alternative treatment options. Despite the advance that selective serotonin re-uptake 
inhibitors have been, a significant proportion of patients still fail to respond adequately to 
these agents, and alternative pharmacological interventions are required. The use of 
dopamine antagonists, a strategy which until recently has had only limited supporting 
data, presents one such alternative. Little however, is known about which subsets of 
patients are most likely to respond to these agents.   
 
 In this thesis, I will present a series of six studies that use pharmacological 
treatments and single photon emission computed tomography (SPECT) to make 
contributions to three primary areas in OCD namely; neurobiology, treatment and the 
intersection of the two. First, I address OCD neurobiology by examining the impact of 
OCD on resting brain function. I then examine the effects of pharmacological challenge 
of the serotonin 1B receptor using sumatriptan on regional cerebral blood flow (rCBF) 
and clinical symptomatology. Second, I examine the intersection of neurobiology and 
treatment as I explore the changes in rCBF in response to treatment with inositol, a 
precursor of the phosphoinositol second messenger system. I then examine the distinct 
and overlapping effects on rCBF of treatment for 12 weeks with the selective serotonin 
re-uptake inhibitor (SSRI) citalopram across anxiety disorders. Third, I address treatment 
of OCD by examining the efficacy of controlled augmentation of serotonin re-uptake 
inhibitors with quetiapine, a dopamine antagonist, in treatment refractory OCD. I then 
combine this data with a second similar dataset to derive a predictive model for 
treatment outcome with quetiapine augmentation of SRIs.  
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  I demonstrate that rCBF in OCD differs significantly from normal controls, is 
correlated with severity in frontal brain regions, and remains an important line of 
investigation for OCD pathophysiology that has yet to fully delineated. Pharmacological 
challenge of the 5HT1B autoreceptor with the selective agonist sumatriptan results in 
heterogeneous behavioural and regional brain perfusion changes in OCD. Attenuation of 
pre-frontal perfusion following 5HT1B agonist administration is in line with the effects of 
SRIs. This work suggests that direct or indirect effects of SRIs on the 5HT1B receptor 
may be involved in mediating a clinical response in OCD. 
 
  In the section exploring the intersection of neurobiology and treatment, I show 
that changes in rCBF partially parallel treatment response to SSRIs across a range of 
anxiety disorders. These data suggest that a degree of overlap exists in the 
neurobiology of treatment response or indeed core neurobiology across different anxiety 
disorders. I then show that effective treatment with inositol in OCD results in rCBF 
changes that are partially in line with the effects of SRIs on brain perfusion. These data 
support suggestions that second messengers may form part of the common pathway of 
action for effective anti-obsessional compounds.  
 
 In the study in which we augmented SRIs with quetiapine, no advantage over 
placebo was found. This data has, however, recently been combined with similar data in 
meta-analyses and demonstrated a benefit over placebo. Finally, we found that patients 
who have failed fewer SRI trials, have more severe illness, and clinical dimensions with 
a putative dopaminergic underpinning, may derive preferential benefit from 
serotonin/dopamine antagonist augmentation of SRIs.  
 
 Through this series of clinical treatment and functional brain imaging studies in 
OCD, I have contributed to the neurobiological understanding of OCD, and its treatment 
in refractory populations. In addition I have explored the intersection of these two 
domains using novel as well as conventional treatment across other anxiety disorders. 
Treatment and pharmacological challenges used, either directly or indirectly impacted 
the monoamine systems serotonin and dopamine and advanced our understanding of 
their involvement in symptom generation.  
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 Future work should focus on the functional intersection of brain function, 
treatment response, and functional genetic polymorphisms within the monoamine 
systems of the brain.   
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OPSOMMING 
 
 Ondersoek na die neurobiologie van obsessief-kompulsiewe steuring (OKS) het 
in die afgelope dekades sinvolle bydraes gelewer tot die begrip van hierdie algemene en 
verminkende steuring. Bemoedigende vordering is ook in die farmakologiese 
behandeling van OKS gemaak. Dit het tot ’n verbetering in kwalitiet van lewe van 
meeste pasiënte gelei wat normaalweg kronies en onophoudelike simptome moet 
verduur. Ten spyte van die uiteenlopende gebruik van eerste-linie behandeling wat 
spesifiek inwerk op die serotonien sisteem in OKS, is relatief min bekend oor die 
neurobiologie van respons op behandeling. So ook is min bekend oor; eerstens die 
spesifieke komponente van die serotonien sisteem wat betrokke is by simptoom 
modulasie, en tweedens die gedeeltelik samevallende en afsonderlike brein streke wat 
deur alternatiewe farmakologiese behandelings beïnvloed word. Ten spyte van die 
vooruitgang wat die selektiewe serotonien heropname inhibeerders tot gevolg gehad 
het, is daar nog altyd ‘n betekenisvolle proporsie van pasiënte wat nie voldoende 
respondeer op hierdie behandelings opsie nie. Dus word alternatiewe opsies benodig. 
Een so ‘n opsie is die klas dopamien reseptor blokkeerders wat tot onlangs min 
ondersteunende data gehad het. So ook, is min bekend oor die subgroepe van pasiënte 
wat die meeste voordeel uit hierdie alternatief sal trek.    
 
 In hierdie proefskrif sal ek ‘n reeks van ses studies wat farmakologiese middels 
en enkel foton emissie rekenaar tomografie (EFERT) gebruik om ‘n bydra tot kennis in 
drie primêre areas van OKS te maak. By name; neurobiologie, behandeling, en die 
kruispunt van die twee. Eerstens spreek ek neurobiologie aan deur middel van ’n studie 
wat rustende brein bloed vloei (rBBV) in OKS ondersoek. Hierna ondersoek ek 
veranderings op rBBV en simptome na eenmalige toediening van ‘n serotonien 1B 
reseptor agonis, sumatriptan. Tweedens ondersoek ek die kruispunt van neurobiologie 
en behandeling deur die effek van behandeling met inositol, ‘n voorloper van die 
fosfoinositol tweedeboodskapper sisteem, op rBBV. Ek ondersoek dan die rBBV patroon 
van veranderinge in brein streke wat deur twaalf weke van behandeling met die 
selektiewe serotonien heropname inhibeerder citalopram in verskeie angversteurings 
bewerkstellig word. Laastens, spreek ek behandeling van OKS aan deur middel van ‘n 
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gekontroleerde studie wat ondersoek instel na die effektiwiteit van die byvoeging van 
quetiapien, ‘n dopamien reseptor antagonis, tot serotonien heropname inhibeerders in 
behandelingsweerstandige OKS. Ek kombineer dan hierdie data met ’n soortgelyke 
datastel om ‘n model af te lei wat kliniese uitkoms vir hierdie behandelings opsie 
voorspel.  
 
 Ek het gedemonstreer dat rBBV in OKS betekenisvol verskil van gesonde 
vergelykbare kontroles. Hierdie verskille het gekorreleer met ernstigheid van OKS in 
frontale brein streke. Dus bly hierdie tipe studies ’n belangrike rigting van ondersoek in 
OKS patofisiologie wat tot op hede nie tenvolle uitgewerk is nie. Eenmalige toediening 
van sumatriptan, het heterogene gedrags en rBBV veranderings in OKS tot gevolg 
gehad. Pre-frontale verhogings in rBBV voor behandeling is met 5HT1B sumatriptan 
toediening verminder, ’n effek wat in lyn staan met die effek van selektiewe serotonien 
heropname inhibeerders. Hierdie werk stel voor dat direkte of indirekte effekte van 
selektiewe serotonien heropname inhibeerders op die 5HT1B reseptore betrokke mag 
wees by die meganisme van behandelingsrespons in OKS.  
 
  In die afdeling waarin ek die kruispunt van neurobiologie en behandeling 
ondersoek, demonstreer ek dat rBBV veranderings gedeeltelik oorvleuel met dié wat 
deur selektiewe serotonien heropname inhibeerders veroorsaak word in verskeie 
angsversteurings. Hierdie data stel voor dat oorvleueling in die neurbiologie van beide 
behandelingsrespons en kern neurobiologie van hierdie angversteurings ’n 
waarskynlikheid is. Ek wys ook dat effektiewe behandeling met inositol in OKS ook 
veranderings in rBBV bewerkstellig wat gedeeltelik in lyn staan met dié van die 
selektiewe serotonien heropname inhibeerders. Hierdie data ondersteun dus hipoteses 
van ‘n gemeenskaplike meganisme, wat tweede boodskapper sisteme insluit, wat in die 
behandelings respons van effektiewe anti-obsessionale middels betrokke is.  
 
 Die finale deel van hierdie proefskrif handel oor behandeling van OKS. Ten spyte 
van die onvermoë om ‘n verskil tussen quetiapien en plasebo te demonstreer, het ons 
onlangs met hierdie data in ‘n reeks meta-analises wel ‘n voordeel vir hierdie intervensie 
getoon. Ten slote, het ons gevind dat (1) pasiënte wat minder kursusse selektiewe 
serotonien heropname inhibeerders gefaal het; (2) voor behandeling ‘n erger vorm van 
OKS gehad het, en (3) ook voordoen met simptoom dimensies wat oënskynlik ‘n 
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dopaminerge basis het, die grootste waarskynlikheid toon om met quetiapien byvoeging 
tot selektiewe serotonien heropname inhibeerders te respondeer.  
  
Met hierdie reeks behandelings en funksionele breinbeeldings ondersoeke, lewer 
ek ‘n bydra tot die begrip van OKS. Spesifiek dra ek by tot die begrip van die 
neurobiologie, hantering van behandelingsweerstandige OKS asook die kruispunt van 
die twee. Farmakologiese middels wat ons óf eenmalig óf vir ‘n volle 
behandelingskursus toegedien het, het direkte of indirekte uitwerkings op die serotonien 
and dopamien sisteme gehad, en dus dra hierdie werk ook by tot kennis oor dié se 
betrokkenheid al dan nie in simptoom modulasie in OKS. 
 
 Toekomstige werk in die area sal in die breë fokus op die kruispunt van 
breinfunksie, behandelingsrespons en funksionele genetiese polimorfismes van die 
monoamien sisteem. 
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 PREAMBLE 
 
 It is “without doubt” that our post-modern world can assert it has made 
considerable advances in understanding and treating complex psychiatric disorders. 
Equally, it is “with doubt” that many questions in relation to underlying biology and 
treatments remain unanswered. Uncertainty and doubt arguably remain critical 
ingredients to continued evolution in thinking and understanding. However, in a minority 
of people, this uncertainty and doubt can pervade thinking, influence actions, and 
occasionally result in paralysing ineffectiveness.  
 
 Pervasive uncertainty and doubt were first described as “délire du doute” 
(obsessive doubt) and “folies du toucher” (contamination fears) by Falret in the late 
nineteenth century [1]. His and shortly thereafter others’ recognition of an imbalance of 
certainty and doubt began a journey that has lead to the current understanding of the 
complex neuropsychiatric disorder we now refer to as obsessive-compulsive disorder 
(OCD).  
 
 The first half of the twentieth century witnessed a dramatic shift in thinking from 
pre-modernism with a spiritual understanding of illness, to a post-modern view that 
integrates biological, emotional and spiritual components into disease conceptualisation. 
The shift to post-modern approaches in scientific investigation of mental illness required 
a fundamental shift in thinking in relation to disease and also disability. Needless to say, 
this kind of transition brought with it considerable conceptual and methodological 
challenges embodied in comments by CP Emerson in his Wesley M. Carpenter Lecture 
(1929):  
 
“This new field of medical research where hithertofore quacks and fanatics had blindly, 
though profitably, ranged, promises to be most important, but certainly would seem to be 
far more difficult than those through which we have worked.” 
 
1 
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  Undoubtedly buoyed by a transitioning thinking of his day, Emerson could not 
have known the resonance his prophetic words would continue to have early in the 21st 
century. Though not without considerable success since this statement was made, 
clinicians and neuroscientists a century later continue the struggle to uncover the 
fundamental changes that underlie disorders such as obsessive-compulsive disorder 
and by implication how best to treat it.   
 
 Epidemiological data suggesting OCD is highly prevalent transnationally has 
been accompanied by increasing awareness among clinicians of the considerable 
burden OCD places on many patients. This in turn is translating to increased recognition 
of OCD in primary care. Neurobiological research in OCD was fuelled by the discovery 
of the selective treatment benefit of the serotonergic agent, clomipramine. Together 
these advances mean that many patients now enjoy relief from symptoms and the 
burden of OCD. 
 
 Despite these advances, a significant proportion of OCD sufferers still continue to 
have an inadequate response to available treatments. This reflects our incomplete 
understanding of OCD psychobiology. Specifically, our understanding of the effects of 
treatment on brain function remains poorly understood. In addition, we know relatively 
little about the specific effects of modulation of specific neurotransmitter components on 
symptoms of OCD. Developing an understanding of the points of intersection of OCD 
neurobiology and the effects of a variety of treatments will potentially contribute to the 
development of more effective treatment for OCD.    
 
 This thesis explores the psychobiology of treatment in OCD using a variety of 
brain imaging and treatment studies. I have used these to demonstrate both distinct and 
overlapping effects of disparate treatments on brain function as well as specific 
symptoms in OCD. These studies demonstrate that technological advances in the 
assessment of brain function can be usefully applied to advance our understanding of 
the biology of OCD.     
 
2 
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 3 
 As a clinician I am privileged to have shared in part of the journey of the 
exploration of OCD with many like-minded clinicians around the world. I have come to 
appreciate the hope of relief from OCD through more effective treatment my patients 
have. I have also come to appreciate that a universally effective treatment for OCD is 
likely to remain elusive as this disorder impacts every person it afflicts in profoundly 
different biological and psychological ways. The latter suggests that subtle differences in 
neurobiology underlie variable phenomenology and treatment response in OCD. From 
work in this thesis and a number of other ongoing lines of investigation in this field, I am 
confident that better tolerated, more effective, and accessible treatment options for 
obsessive-compulsive disorder will be forthcoming. 
 
 
1. Falret JP: De la folie raisonnante ou folie morale. Annals of Medical Psychology 1866, 7: 382-    
431. 
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 CHAPTER 1 
 
 
Introduction and Background 
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 1.1 General Introduction 
 
 Obsessive-compulsive disorder (OCD) is a disorder characterized by 
obsessions (recurrent or persistent unwanted thoughts, images or impulses) and 
compulsions (repetitive behaviours or mental acts performed to relieve tension or 
anxiety induced by obsessions) [1]. Thought at one time to be relatively rare, it is now 
recognized to affect 2-3% of the general population [2]. In the majority of cases OCD 
tends to run a chronic, fluctuating, unremitting and highly co-morbid course [3,4]. As 
such it is one of the most costly and disabling of psychiatric disorders [5]. 
Encouragingly, significant advances have been made in our understanding of the 
neurobiological underpinnings of OCD in recent decades. Equally significant advances 
in effective treatment strategies have also been seen. Despite this, however, 
considerable work is still required to address the precise intersection of treatment and 
neurobiology.  
 
 The selective efficacy of compounds that inhibit the re-uptake of serotonin has 
underpinned a serotonergic hypothesis in OCD for some time [6,7]. While it is worth 
noting that evidence for the effectiveness of these treatments does not specifically 
implicate the serotonin system in the pathophysiology of OCD, effects on this system 
would seem to be an essential ingredient to treatment response in most patients. 
Peripheral receptor binding studies, a possible marker of CNS serotonergic status, 
have failed to reliably implicate this system in OCD [7]. Somewhat more promising are 
indications that mutations within the serotonin transporter are involved in numerous 
neuropsychiatric disorders including OCD [8]. Genetic association studies have 
implicated the 5HT1B receptor [30] (see detail in section 1.2.2) in some but not all 
studies. Also, an association with female gender and the promoter region of the 5HT2a 
encoding gene has also been found, but not replicated [9-11].  5HT2A receptor density 
has been shown to be increased in brain receptor binding studies, an effect that is 
attenuated with effective treatment response to SRIs [9]. While not directly implicating 
5HT2A receptors in the pathophysiology of OCD, at the very least, these data lend 
support to their involvement in mediating treatment response.  
 
5 
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  Numerous studies have explored the neurochemistry of OCD, but as yet have 
not demonstrated a consistent pattern of difference from controls. Specifically, 
concentrations of cerebrospinal fluid serotonin metabolites have suggested that 5HIAA 
may predict treatment response, but these too have been inconsistent [12]. Animal 
models of OCD also strongly suggest that the serotonin system is involved in 
mediating symptoms and the response to treatment [13].  
 
 The administration of pharmacological compounds directed at the serotonergic 
system has also been explored [14]. This work has included agents with varying 
specificity for the serotonin system, often making clear dissection of the specific 
serotonergic effects difficult to delineate. Behavioural and neuroendocrine responses 
to serotonergic challenges using agents including MK212, m-CPP, sumatriptan, and 
zolmitriptan, have been demonstrated [44-54] (see section 1.2.2). These however 
have not shown consistent effects on OCD symptoms even when the same compound 
is used. While pharmacological challenge studies and genetic association studies 
certainly lend some indirect support to the serotonin hypothesis in OCD, their precise 
interactions remain poorly understood.  
 
 The most obvious explanation for the inability of the serotonergic hypothesis to 
fully delineate the neurobiology of OCD is that it is not the only viable hypothesis. From 
treatment studies we know that a substantial proportion of patients either fail treatment 
with an SRI or respond inadequately to these first-line interventions. Clinicians have 
known for some time that the addition of drugs that modulate the dopamine system 
through D2 receptor antagonism brings some clinical benefit to patients who have 
failed to respond to first-line SRI treatment [15]. Combining this knowledge with the 
hypothesized role of striatal and orbitofrontal brain regions in mediating repetitive 
behaviours [12], a dopaminergic hypothesis in OCD has become increasingly 
defendable [16].  
 
 Animal studies have suggested that potentiation of specific sub-populations of 
D1 receptors in the prefrontal cortex and amygdala results in compulsive behaviours 
akin to human OCD [17]. Similarly chronic pharmacological challenge of D2/3 
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 receptors with the agonist quinoprole, results in compulsive behaviour in rats [18]. 
Post-mortem, these animals were found to have increased levels of dopamine rich 
tissue in limbic (accumbens) and prefrontal cortex [19]. These findings lead to 
development of the deficient response feedback mechanism theory in which reward 
seeking with repetitive behaviours is not sought despite the discontinuation of external 
feedback [20]. D1 receptor agonist administration in these animals, in turn reduces 
repetitive lever-pressing [13]. Together, as summarized by Denys et al [16], this work 
suggests a role for D1/2 receptors in mediating compulsive behaviours in animal 
models of OCD.   
  
 Neurochemical investigations of dopaminergic metabolites such as 
homovanillic acid (HVA) in CSF have for the most part yielded very limited evidence of 
differences compared to normal controls [16,21-23]. Recently a small patient series 
suggested reduced HVA levels correlated with treatment response, however, this did 
not hold for MHPG levels [24]. Marazziti et al [25] have previously investigated 
sulfotransferase activity as an indirect measure of catecholamine catabolism including 
dopamine. They found increased levels in OCD patients compared to controls, again 
suggesting higher levels of dopamine turnover in OCD. Taken together, however, only 
very limited neurochemical evidence supports the notion of dopaminergic changes in 
OCD.  
 
 A wide range of genetic association studies have now been reported in OCD, 
with some evidence to suggests an association with components of the dopamine 
system. Increased allele frequency of DRD4 in OCD [26,27] has been shown, but a 
range of negative studies have also been reported [9,28]. Interestingly, in a 
homogenous population of Afrikaners, an association with early onset OCD and DRD4 
has been demonstrated [29]. Only negative studies have been reported for DRD3 
[30,31] and DRD2 [30,32].  
  
 Arguably the most interesting findings in relation to the dopamine system in 
OCD genetics have been the reports of the association with catechol-O-methyl-
transferase (COMT). Associations with the presence of the low-activity COMT allele in 
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 males [33] and females [34] have been separately reported. The former was replicated 
recently by Denys et al [35]. Other positive studies, however, have not replicated the 
gender findings [36], but found an association with homozygosity at the COMT locus 
[37].  Negative studies in smaller samples have been reported [38,39]. Despite these 
positive indications, a recent meta-analysis of COMT association studies was negative 
[40]. 
 
 Numerous brain imaging studies using a variety of ligands for different aspects 
of the dopamine system have been investigated in OCD. PET studies using 18F-6-
Fluorodopa have found lower striatal uptake suggesting reduced numbers of 
dopaminergic neurons [41]. Increased binding of dopamine transporters (DAT) has 
been reported with 123I IPT SPECT [42]. A similarly designed, but negative study has 
also been reported [43]. A similar, but different line of investigation has explored D2 
receptor binding in OCD using 123I IBZM SPECT. Denys et al [44] reported lower 
caudate binding of D2 receptors. Together DAT and D2 findings suggest an up 
regulation of dopamine neurotransmission [16]. Emerging evidence for the functional 
differences in DAT allele function may suggest that while functional polymorphisms 
may not be easily recognizable, differential functioning DAT alleles may mediate 
symptoms and treatment responsivity despite negative genetic association studies.                
   
 Together the serotonin and dopamine hypotheses in OCD, while not the only 
recognized neurotransmitter systems involved in OCD, remain the most compelling. 
Furthermore, it seems evident that an integrated view of the phenomenology, genetic 
underpinnings and treatment response in OCD in relation to each of these systems, is 
likely to remain the most widely applicable.     
 
 Despite the availability of numerous tools with which to investigate crucial 
questions related to the psychobiology of OCD, many remain unanswered. For 
instance, the precise pattern of resting brain function in OCD is not yet full delineated. 
Equally, the resting brain perfusion response to pharmacological challenge of specific 
components of the serotonin system such the serotonin 1B autoreceptor has enjoyed 
only very limited attention to date. At the time of planning this work, no published data 
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 existed for the use of the dopamine antagonist quetiapine in treatment refractory OCD. 
Also, very little is known about the ability to predict treatment response to 
augmentation agents in OCD. At the intersection of treatment and neurobiology, very 
little is known about the effects of novel treatments on brain function. Also it is not 
known to what extent effective treatment for anxiety disorders including OCD has 
overlapping or distinct effects on brain function.   
 
 Single photon emission computed tomography (SPECT), is arguably the most 
widely available functional brain imaging modality in nuclear medicine departments 
across the world. SPECT perfusion imaging uses radio-active tracers with moderately 
long half lives that when combined with lipophylic compounds readily traverse the 
blood-brain barrier [45]. Thereafter the tracer is distributed and through incompletely 
understood cellular processes, becomes “trapped” in the brain. The image of the 
distribution of this “trapping” indirectly represents the magnitude of regional brain 
perfusion at the time of cellular interaction. In the studies reported here, I have used 
technetium-99m labeled hexamethylpropylene amine oxime (Tc-99m HMPAO) which 
is taken up by astrocytes. Thereafter the ligand undergoes a conformational change 
through a redox reaction to become hydrophilic. These molecules are now unable to 
traverse cellular membranes and are retained within the cellular cytoplasm [45].  
SPECT perfusion studies using HMPAO to define differences between varied clinical 
populations are accepted to reflect differences (albeit an indirect measure) in 
underlying cellular metabolic function.  
 
Imaging itself is performed using a gamma camera. It comprises a gantry 
designed to detect emitted photons with an energy window between 100 and 400keV. 
Spatial localisation is possible with the use of collimators that direct photons onto 
scintillation crystal detectors. Photocathode detection in photomultiplier tubes convert 
the light into an anode current which after a digital conversion is sampled together with 
full emission data using computer algorithms to derive a final image series [46].  
  
Reconstruction techniques vary, but in the studies we undertook are simplified 
as they form a stack of 2D images. These are then combined to calculate a 3D map of 
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 activity distribution across the brain. We used one of a variety of standard analytical 
reconstruction models, filtered backprojection [47], in which it is assumed that data can 
be modelled mathematically through a series of transformations. This method is both 
simple to use and efficient, but has some inherent limitations. These include a limited 
accounting for noise in acquisitions as well as the possible introduction of minor 
artefact. Despite this, the method remains widely applied in many settings.  
 
Analytical reconstruction processes inevitably lead to some degree of image 
degradation. The effect on the energy of photons moving through tissue (attenuation) 
as well as the possible mispositioning of photons in the final image due to scattering 
effects both need to be controlled for. Attenuation correction methods used in our 
SPECT studies use whole brain uniform correction methods as described by Chang 
[48]. After these steps have been completed with an individual patient data set, images 
can then be reliably combined with similar acquisitions in a study group.   
 
Being reliably able to combine data following reconstruction to determine tracer 
distribution requires a number of steps to improve the reliability of the observations. 
The specific methods used to some extent depend on the study question at hand. 
Semi-quantitative analysis methods such as voxel-wise statistical parametric mapping 
(SPM) have been possible for some time [49] and provide an option for reliable 
comparison of subject groups. These methods begin by spatially re-orientating and 
standardising images in 3D space. This important step ensures that similar voxels 
across a series of acquisitions reliably represent the same brain region. The co-
ordinates of these brain regions can then be reliably located on standard brain atlases. 
In the studies presented here we used the Montreal Neurological Institute (MNI) 
standards.  
 
In general, rigid transformations in three dimensions (affine) with rotations, 
translations and scaling are performed. Depending on the situation, non-linear 
transformations or warps can be applied to improve image registration. This step, 
however, can mask image effects, and will vary according to the study and the effect of 
interest. Finally, similarity tests or tests of normalisation need to be performed in order 
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 to determine the degree of fit of images. This process uses data from all voxels to 
compute an image dependent normalisation factor. Each voxel count is then divided by 
this factor to standardise voxel intensity across the volume and render a voxel-wise 
semi-quantitative map.  
 
Previously, volume of interest (VOI) or region of interest (ROI) analyses 
provided for relatively accurate “by volume” analysis of rCBF. These techniques are 
constrained in part by limited anatomical definition in SPECT imaging. Also, the 
reliance on predominantly operator dependent determination and placement of 
volumes may be considered a limitation. Brain regions not falling within the VOI are not 
examined. Newer voxel-based approaches obviate the need for VOI placement, but in 
turn introduce a range of challenges including that of multiple comparisons. Gaussian 
smoothing of images is thus required. The latter reduces anatomical differences 
between subjects, increases signal to noise ratio based on the normalised data 
derived as described above. The resulting group maps are amenable to statistical 
comparison on a voxel-wise basis. Specific tests will depend on the questions being 
addressed.  
 
Modern SPECT images now have spatial resolution that is comparable to 
positron emission tomography (PET). The wide range of paradigms lend themselves to 
SPECT examination and in some cases “real-life” testing situations are more easily 
mimicked than with PET or indeed functional magnetic resonance imaging. It can 
however be constrained by its lower temporal resolution compared to PET. In this 
thesis however, I have confined investigations to resting paradigms. While I will argue 
that this is not without its challengers, this method is robust and easily replicable 
across imaging sessions and crucially also across different studies. 
 
In the remainder of this chapter I will provide a brief background and rationale 
for each of the studies undertaken. I use this section on the one hand to introduce the 
reader to the specific questions addressed in each of the studies, and on the other to 
point out how each of these studies contributes to an integrated understanding of the 
psychobiology of OCD. It should come as no surprise that no single study can be 
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 12 
considered definitive in this area. Nevertheless, this body of work makes a meaningful 
contribution to our understanding of the impact of treatments in mediating or 
ameliorating symptoms of OCD through both direct and indirect effects on the 
serotonergic and dopaminergic systems.  
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 1.2 Introduction to Part I 
 
1.2.1 Regional brain perfusion in OCD compared to normal controls – a basis 
for establishing the impact of treatments on functional status 
 
 Resting brain perfusion studies have repeatedly demonstrated a capacity to 
distinguish OCD from normal controls. As such they have the potential to provide 
useful information on the brain function of patients with symptomatic OCD. One 
advantage of resting studies is that they are theoretically more easily comparable 
with similar studies and across disorders compared to activation studies. A series of 
resting perfusion studies have however, produced often inconsistent results that have 
served to highlight the complexity of OCD, in part related to a high degree of 
symptom heterogeneity.   
 
 Functional brain imaging tools continue to grow in sophistication with passing 
years. So too do the methods with which this data is analyzed. Current capacity to 
examine the entire brain without the constraints of limited computing power, has 
transformed this field. With VOI approaches the need to specify a priori all regions of 
interest may have limited the completeness of information derived from previous 
studies in this area. In OCD for example, modern approaches enable investigators to 
examine a range of brain regions that until recently were largely ignored. As such 
most literature to date has focused on brain regions believed to be the primary 
mediators of OCD symptoms. Even in these brain regions, recent meta-analyses 
have shown that the strength of evidence supporting their involvement is relatively 
limited [50]. As such resting brain perfusion in OCD represents one area of 
investigation where the full value of contribution using these methods may not have 
been fully exhausted.  
 
 The apparently robust construct of OCD delineated in DSM-IV belies the 
clinical heterogeneity that exists across clinical populations. Symptoms of OCD are 
held by some to exist on a spectrum of disorders [51]. Disorders putatively 
represented on this spectrum share aspects of symptomatology, responsivity to 
treatment, neurogenetic and neurochemical underpinnings [52]. Within this spectrum, 
significant overlap of symptoms occurs, that presumably reflects an overlapping 
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 psychobiology. As such, in recent years we have witnessed an emergence of a 
literature that seeks to define homogenous clinical sub-groups in OCD and OC 
spectrum disorders [53] in the hope that this will lead to a clearer understanding of 
both the shared and distinct aspects of psychobiology underlying them. Numerous 
methods have been employed to define sub-groups with specific symptom 
dimensions in OCD. Factor analysis of symptoms derived from the YBOCS symptom 
checklist [54], and more recently the Dimensional YBOCS [55], have been 
associated with specific brain changes [56,57]. These in turn have been associated 
in some studies with predicting treatment outcome [58,59]. 
  
  Work on OC spectrum of disorders has also implicated a wider range of brain 
regions than were initially described in the cortico-striatal-thalamic-cortical loop 
model of OCD. These include extra-striate regions [56] as well as the amygdala [60]. 
The role that studies of this kind are poised to play in delineating the underlying 
biology of specific symptoms cannot be underestimated. Particularly as these 
techniques now permit reliable dissection of specific sub-regions within the prefrontal 
and limbic cortices that are believed to mediate specific symptoms. In time, these 
lines of investigation will be useful when used in conjunction with studies that 
correlate specific receptor binding profiles and allelic variants with these functional 
brain changes.  
 
 Despite the heuristic appeal of a dimensional approach, some fundamental 
characteristics of OCD are likely to mean that this cannot be considered the only 
valid line of investigation of brain function in OCD. Importantly, the typically waxing 
and waning course of symptoms implies that within an individual, brain functional 
patterns may vary considerably over time [61]. By implication, biological 
investigations of symptom dimensions, whether brain functional (imaging, 
neuropsychological), genetic or neurochemical, are likely to reflect a symptom “state” 
rather than an underlying pattern of the enduring neurobiological effects of OCD as 
currently defined in DSM-IV.  
 
 This line of thinking has two primary implications for investigating functional 
brain imaging patterns in OCD. First, studies that explore resting brain function are 
likely to continue to be useful in examining the biology of OCD. It is already clear that 
a range of different brain regions may be implicated when compared to symptom 
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 provocation studies. Second; evidence that more symptomatic disease is associated 
with higher brain activation may suggest that studies using symptom provocation or 
activation are likely to reflect brain changes of an order of magnitude greater than 
might be expected in the resting state. With this later point in mind, resting state 
studies should be designed to detect very much smaller changes overall. One 
explanation for the inconsistency across studies using this approach is that they are 
essentially underpowered. In fact there are indications that disorder severity does 
influence brain imaging findings at rest [62,63], However, this question has not been 
consistently explored across studies using similar methodologies.  
 
 As such, I question whether, in the face of inconsistency of results in previous 
resting brain perfusion studies, this approach still help inform our understanding of 
the underlying neurobiology of OCD?  In what now constitutes a reasonably large 
body of literature, Whiteside et al recently conducted a meta-analysis which included 
data from 13 studies comparing OCD with controls at rest  [50]. Significant 
challenges were noted by the authors in combining these data and may well have 
had a significant impact on study outcome. Despite the reasonable sample size in the 
combined analysis, only the findings within the area of the caudate head achieved 
levels of significance set by the authors. Furthermore, this finding was derived from 
only 3 of the 13 studies included in the analysis and as such should also be 
considered preliminary. While the authors acknowledge the existence of a range of 
data that support the involvement of the frontal-sub-cortical (striatal)-thalamic circuit 
in OCD, the findings of their meta-analysis suggest that data from rCBF studies do 
not, as has been strongly contended in the past  [64,65], reinforce the involvement of 
these brain regions OCD. As such, I belive that with increasingly consistent analysis 
methods now being employed across studies, this line of investigation will benefit 
from the addition of studies that use whole brain methods to examine brain function 
in the resting state of patients with OCD.   
 
 In the context of this thesis then it is worth questioning to what extent a 
resting perfusion SPECT study can contribute to our understanding of the 
serotonergic and dopaminergic systems’ contribution to OCD psychobiology? I have 
already mentioned that these monoamine systems are very widely distributed 
throughout the central nervous system (CNS). In studies that involve 
pharmacological challenge of these systems at rest, it seems is important to provide 
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 a foundation for understanding the basis of changes resulting from modulation of 
either or both of these systems.  
 
 In this section (Chapter 2) I explore the resting brain perfusion patterns of 
participants with OCD using whole-brain voxel wise analysis and compare them to 
matched healthy controls. In addition, I examine the impact of disorder severity, a 
putative predictor of treatment response to serotonergic and dopaminergic 
treatments, on brain perfusion patterns.  
 
 What follows then, is a series of three studies in which the symptomatic 
resting state of patients with OCD is interrogated with (1) chemical challenge of the 
serotonin 1B (5HT1B) autoreceptor (Chapter 3), (2) serotonergic treatment across 
anxiety disorders to examine the overlapping and distinct effects on brain function 
(see Chapter 4), and (3) direct activation of the putative final common pathway of 
effective treatments for anxiety disorders, namely the second messenger systems 
using inositol (Chapter 5).  
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 1.2.2  Acute effects of the Serotonin 1B auto-receptor agonist Sumatriptan 
on Regional Brain Perfusion SPECT in OCD 
 
 We have noted that the selective response of OCD symptoms to first-line 
treatments with specific effects on the serotonin system is arguably the most 
consistent, albeit indirect, evidence for the involvement of the serotonin system in 
OCD [66]. Despite this, it is also clear that this advance in the treatment of OCD does 
not implicate specific components of the serotonin system. It does however implicate 
the serotonin system in mediating the symptom response to serotonergic treatment. 
Guided by increasingly sophisticated genetic, molecular and brain imaging tools, it 
has become possible to examine specific aspects of neurotransmitter systems in a 
variety of clinical conditions.  
 
 The identification of the 5HT1B receptor on chromosome 6 in humans in the 
early nineties [67-69], has lead to considerable interest in these genes and their 
potential role in many disorders including OCD. The 5HT1B receptor was first 
identified in rats and pigs [69], and then the 5HT1D receptor in humans and rabbits 
[70] was reported. Subsequent receptor amino-acid sequencing has confirmed high 
degrees of similarity between rat and human receptors which lead to the 
classification of these receptors as the human (h) 5HT1B (formally 5HT1Dβ and the 
rat (r) 5HT1B [71]. Despite this, there is still some evidence of variable 
pharmacological effects following interaction with these receptors [72]. More recently, 
evidence that the formally rat 5HT1B receptor has been detected in humans 
suggests that an accurate sub-classification of this receptor is still some way off [73]. 
5HT1B receptors have now been mapped using autoradiography. These studies 
have found a predominance of 5HT1B receptors in the basal ganglia and the frontal 
cortex, however, receptors in varying concentrations are detected throughout the 
brain [74,75]. 
 
 Three primary lines of evidence provide partial insights and an ongoing 
rationale to explore the role of the serotonin 1B receptor in the psychobiology of 
OCD. These include genetic association studies, pharmacological challenge studies 
and finally clinical treatment response to 5HT1B agonists. Gene association studies 
have found positive associations with the preferential transmission of the G-allele of 
the gene encoding for 5HT1D on chromosome 6q13 in some [76,77], but not all 
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 [11,78] studies in OCD. The difference from the C-allele of the gene is conferred by a 
single base-pair difference, and is believed to have functional significance. In a single 
study presence of the G-allele was associated with higher YBOCS scores [78].  
 
 Drug challenge studies have for some time provided the ideal setting in which 
to explore the functional role specific receptor-drug (ligand) interactions have in 
mediating symptoms of a particular disorder. In OCD, this approach has been used 
for some time to explore the role of the serotonin system. Initially the use of less 
specific compounds such as m-Chlorophenylpiperizine (m-CPP), a compound with 
non-specific agonist action on 5HT2c, 5HT1b, and 5HT2a receptors lead to mixed 
results [79]. For instance, acute administration results in OC symptom exacerbation 
in some [80-83], but not all studies [84,85]. The more specific 5HT1a and b receptor 
agonist, MK-212, appeared to have little impact on OCD symptoms when 
administered acutely [86]. The results of these studies, suggest that while some 
impact on symptoms may be mediated through acute manipulation of serotonin 
receptors, the specific receptors involved could not be accurately deduced. 
 
 The introduction of the 5HT1B auto-receptor agonist sumatriptan, and 
subsequently the wider family of triptans [87] for the treatment of migraine, has 
afforded investigators the opportunity to explore the role of this receptor in OCD 
symptomatology. Initially studies used acute administration of sumatriptan to patients 
with OCD to explore immediate changes in OC symptomatology. This line of 
investigation produced mixed clinical results with a transient exacerbation of 
symptoms [81,88,89] before a moderate reduction with more chronic treatment 
[88,89] was reported. The relatively low bio-availability and low lipophylicity lead 
some to speculate that a central action for sumatriptan seems unlikely. Subsequent 
studies with newer triptans including zolmitriptan, a compound which more readily 
crosses the blood-brain barrier, also found no significant difference in measures of 
behavioural change in OC and anxiety symptoms [90]. I will discuss a number of 
lines of evidence that now support a central action for the triptans including 
sumatriptan. Together they suggest that alternative explanations should be sought to 
clarify the reasons for the mixed response to acute challenge with 5HT1B agonists. 
In a recent review of this work, Zohar et al [66] encourage the use of functional brain 
imaging tools, and in time to combine this with genotyping data to elucidate the 
specific functional response of the 5HT1B receptor in OCD. 
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 Taken together, clinical, genetic, and functional brain imaging data can be 
usefully combined to provide a rationale for exploring the impact of acute 
pharmacological challenge with a specific 5HT1B receptor agonist on functional brain 
perfusion patterns in OCD. We have previously reported on a preliminary study with 
14 subjects to whom a single dose of sumatriptan was administered in a double-
blind, placebo-controlled, cross-over design [91]. We found heterogeneous OC 
symptom responses to sumatriptan challenge, with nearly a third of patients 
experiencing a worsening of OC symptoms. In the analysis of the SPECT perfusion 
data, we used manually placed regions of interest in areas putatively involved in the 
functional neurocircuitry of OCD. We found increased thalamic perfusion in 
sumatriptan relative to placebo challenge using cross-over design. Worsening of OC 
symptoms was associated with decreased perfusion in inferior and medial frontal 
brain regions while symptom exacerbation correlated with reduced inferior frontal and 
putaminal perfusion. We did not detect any significant differences in this study 
between responders and non-responders to acute sumatriptan challenge.  
 
 In this section, I build on the strengthening hypothesis for the involvement of 
the 5HT1B receptor in OCD and extend the study mentioned above to examine the 
effects of sumatriptan challenge and OC symptom responses uaing a whole-brain 
voxel wise approach to image analysis. This approach will potentially yield 
information on brain changes outside of the putative functional OCD circuit.  
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 1.2.3 Functional brain changes in response to citalopram serotonergic 
 treatment across anxiety disorders:  Similarities and distinctions 
 
 The introduction of the selective serotonin re-uptake inhibitors into routine 
practice and their subsequent adoption as first line agents in all of the major anxiety 
disorders in addition to OCD [92], including posttraumatic stress disorder (PTSD) [93] 
and social anxiety disorder (SAD) [94], still represents one of the major advances in 
the treatment of this highly prevalent and costly group of disorders. Numerous lines 
of investigation suggest distinct genetic, neurochemical and brain functional patterns 
exist for all the major anxiety disorders. Despite this, the response of these 
apparently different anxiety disorders to the same treatment raises a number of 
questions regarding the overlapping and distinct effects of these drugs on the 
underlying brain dysfunction across the anxiety disorders.  
 
 In obsessive-compulsive disorder, the superior response to serotonergic 
compounds such a clomipramine is now well known. Available evidence would 
suggest that the same cannot be said for some of the other anxiety disorders 
including social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD) 
where a consistent advantage of SRIs over drugs that also incorporate noradrenergic 
re-uptake and monoamine oxidase inhibiting effects has not been clearly shown. In 
SAD strong effects also exist for the monoamine oxidase inhibitors [94], a fact that 
has not been convincingly shown in OCD [95,96]. Overall, the superior tolerability of 
SRIs along with its similar efficacy to other drug classes continues to support their 
use as first-line agents in these disorders.  
 
 In OCD, attenuation of pre-treatment regional activation has been shown to 
correlate with treatment response in the anterolateral orbitofrontal cortex (OFC), 
caudate nucleus, thalamus, and temporal regions [97-102]. Results for studies 
assessing pre-treatment cerebral perfusion as a predictor of response, have, 
however, yielded mixed results. In some, an inverse relationship appears to exist with 
pre-treatment regional activation of the OFC [103], anterior cingulate, caudate [6] and 
subsequent responses to treatment. Conversely findings of higher prefrontal, 
cingulate and basal ganglia activation correlating with subsequent treatment 
response have also been reported [104,105]. In OCD co-morbid with depression, 
substrates of response to the SSRI, paroxetine, appear to differ based on 
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 pretreatment [106] activation patterns. Also, differences in rCBF are seen in 
response to SSRI treatment in both depression and OCD when each condition exists 
on its own [107].  
  
 In SAD, prefrontal and insula activation in response to public speaking as well 
as with anticipation anxiety related to public speaking [108,109] have been 
demonstrated. In response to treatment, attenuation of frontal, anterior and lateral 
temporal cortex, cingulate, and thalamic activity has been demonstrated by our own 
and other groups [110,111]. There are also additional indications that higher anterior 
and lateral temporal cortical perfusion at baseline correlated with subsequent 
treatment response in the former study. Unpublished data from our group also 
demonstrates evidence of functional connectivity of brain regions impacted by SRI 
treatment (Warwick et al, unpublished). In an interesting paper in SAD, the SSRI 
citalopram and cognitive behavioural therapy resulted in overlapping changes in 
regional brain metabolism. This finding suggests that different (pharmacological and 
non-pharmacological) interventions result in similar regional attenuation of activity 
despite employing apparently different underlying mechanisms of action [111]. 
  
 In PTSD, a single study by our group has demonstrated attenuated medial 
temporal lobe perfusion in response to treatments irrespective of observed clinical 
response. Further, attenuation of medial prefrontal cortex activation did correlate with 
treatment response [112]. Also, in a case series of female rape survivors with PTSD, 
I have recently found that similar medial and superior prefrontal attenuation in 
perfusion was associated with improvement in PTSD symptoms following 12 weeks 
of exposure therapy (Carey et al, unpublished data). Taken together, it is 
hypothesized that symptomatic pretreatment prefrontal and medial prefrontal 
increased perfusion, is attenuated as the effective treatment aids in restoring “top-
down” control of temporo-limbic hyperperfusion when compared to controls.  
 
 Modern brain imaging techniques have been sparingly employed in exploring 
the possible overlap in the functional neurocircuitry that underlies individual anxiety 
disorders [113,114]. These studies do suggest that while there is overlap among 
anxiety disorders, particularly in respect of fear-processing, there are distinct effects 
on regional brain perfusion related to each. The evidence suggests that there are 
similar overlapping and distinct brain regions impacted by effective treatments. 
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 Indeed, higher resolution of modern imaging techniques used to examine brain 
function such as f-MRI, now allow us to recognise different effects within relatively 
small sub-regions of the brain including the amygdala, accumbens and cingulate 
cortex. In these brain regions it is becoming increasingly clear that distinct 
neuropsychological function and emotional processing is mediated by specific sub-
regions.  
 
 In this section I report on a study undertaken to examine the response to 
SSRI treatment in a combined group of subjects with OCD, PTSD, and SAD. On the 
basis of previous findings, I hypothesized that changes in rCBF affecting primarily 
limbic and related prefrontal regions would be shared by all of the disorders. I also 
hypothesized that pretreatment regional brain perfusion would differentiate 
responders to subsequent treatment with citalopram across the anxiety disorders.  
 
1.2.4 Functional brain perfusion SPECT in OCD: Changes in Response to 
 treatment with Inositol 
 
 The crucial contribution of the SRIs to the treatment armamentarium of 
modern psychopharmacologist is in no doubt. In general it is held that increased 
transmission of serotonin through desensitization of 5HT2 and 5HT1B auto-receptors 
in prefrontal and limbic brain regions is responsible for the therapeutic effects of SRIs 
[115] It was shown some time ago that SSRIs enhance 5HT release in the 
orbitofrontal cortex of guinea pigs after 8 weeks of treatment, an effect not seen at 
week three of treatment [116]. The time delay required for this desensitization is 
consistent with the longer lag in therapeutic response in OCD compared to 
depression [117].  
 
 The primary action of the SRIs on the pre-synaptic re-uptake pump inhibits 
the clearance of serotonin from the synaptic cleft, an effect that in time leads to the 
desensitization of post-synaptic receptors [118]. Interestingly, in the same sample of 
guinea pigs, altered serotonergic transmission was not noted in the caudate nucleus 
[116]. It therefore seems that receptor desensitization in response to treatment may 
occur either through direct effects in the region of interest, or in a remote brain region 
that is linked through functionally connected neuronal circuitry [119]. It is also 
22 
Stellenbosch University  http://scholar.sun.ac.za
 noteworthy that the effectiveness of SSRIs in OCD is only produced at higher doses 
than are conventionally required for depression. In the prefrontal cortex, it has been 
shown that similar doses of different SSRIs produce significantly different levels of 
reuptake pump inhibition [116]. Blier et al [119] have shown that higher doses are 
necessary in most cases to produce a treatment effect. As such, not only do regional 
differences in serotonin autoreceptor desensitization exist, but different affinity of 
various SSRIs for re-uptake pumps. This implies a quite distinct mechanism of action 
of these agents in depression and OCD [120]  
 
 The serotonin (5HT2) and dopamine systems (D1, D2) are involved in 
mediating action in the the GABA-ergic system in the regulation of motor behaviour 
through the cortico-striatal-thalamo-cortical circuit [121]. Within this circuit, 5HT2 
receptor stimulation results in attenuated DA release with downstream consequences 
on motor function mediated by the GABA system [122]. Work from our group has 
previously found that administration of inositol, a precursor in the phosphstidylinositol 
(PI) second messenger system, resulted in reduced D2 receptor density with a much 
smaller effect on 5HT2 receptors [123]. These findings suggested that the effect of 
inositol is less likely to be mediated by serotonergic than dopamine action.  
 
 Despite this, there is widespread support for involvement of second 
messenger system activation in the action of effective antidepressants. Action follows 
specific drug-receptor interactions on the neuronal membrane. Conformational 
changes of transmembrane G-proteins then activate a variety of second messenger 
systems including inositol triphosphate (IP3), calcium, diacylgliserol (DAG) and 
protein kinase C (PKC). The subsequent effects of these intracellular signaling 
pathways on gene transcription and translation in turn impacts protein receptor 
expression.  
 The PI cycle acts as the second messenger system to a variety of 
neurotransmitter systems including monoamines [124]. More specifically, myo-
inositol (MI) serves as a precursor to receptor-activated phosphatidyl 
inositolbisphosphate (PIP2) hydrolysis by phospholipase-C (PLC) [124]. This 
interaction produces inositol triphosphate (IP3) and diacylglycerol (DAG) (Fig 1.1). In 
addition to the direct effect on these systems, phosphoinositides (PI) are seemingly 
involved in regulating the interaction of signalling proteins [125], neurotransmitters 
and membrane receptors [124]. The specific contribution of each of these effects of 
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 inositol to the mechanism of action in exerting behavioural effects, however, remains 
unknown.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PA
Inositol
   PI 
synthase PI 
I – 1,4,5P3 1,2 DAG
I – 1,4,P2
IPPase 
I – 4P 
IMPase 
5HT2a receptor 
PL-C activation 
PI – 4P 
PI – 4,5P2
Fig 1.1. Representation of the inositol cycle. The figure depicts metabotropic receptor (e.g., 
5HT2) activation of PLC, the subsequent hydrolysis of membrane PIP2 leading to the 
formation of IP3 and DAG, and the cycle concluding with the replenishment of PIP2 via the 
linkage between MI and DAG degradative pathways through the action of PI synthase. 
Abbreviations: PLC: phospholipase C; PI-4,5P2: phosphatidylinositol bisphosphate (PIP2); I-
1,4,5P3: inositol trisphosphate (IP3); I-1,4P2: inositol bisphosphate (IP2); I-4P: inositol 
monophosphate (IP); IMPase, inositol-1-monophosphatase; IPPase: inositol polyphosphate 1-
phosphatase; 1,2-DAG: 1,2 diacylglycerol (DAG); phosphatidylinositol (PI); PI-4P: 
phosphatidylinositol 4-phosphate (PIP).  
       Revised from Harvey BH et al, 2002 
The behavioural effects of inositol have been known for some time [126]. Controlled 
evidence of its effective use in treating obsessive-compulsive disorder (OCD) [127], 
panic disorder [128,129] and depression [130] has been shown. Inositol was, 
however, found to be ineffective as an augmentation strategy to SSRI non-
responsive OCD [131]. In addition, disorders such as premenstrual dysphoric 
disorder [132], schizophrenia [133], autism [134], Alzheimer’s disease [135] and 
attention deficit hyperactivity disorder (ADHD) [136] have not responded to inositol.  
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  These data may suggest that the clinical efficacy of inositol is limited largely 
to disorders that respond preferentially to drugs that modulate the serotonergic 
system [126]. This is interesting in the light of the animal data from Harvey et al cited 
above. As such, it remains unclear what the reasons for the preferential effect of SRI 
responsive disorders is. Evidence from genetic studies has emerged in which genes 
encoding for inositol-mono-phosphatase have been identified on chromosome 
8q21.13-21.3 (IMPA1) as well as 18p11.2 (IMPA2). The latter is located close to or 
on the same site as a susceptibility locus for bipolar disorder [137]. While no specific 
genetic evidence implicates this gene in OCD, there is evidence of altered activity in 
the PLC pathway in OCD [138]. 
 
 Functional brain imaging data has demonstrated an attenuation of activity in 
regions within the cortico-striatal-thalamo-cortical (CSTC) following a response to 
treatment with SRIs [65,104,139,140]. Given the limitations of some of this data, and 
the capacity to examine the whole brain using voxel-wise analysis methods, 
investigating the effects of inositol on regional brain perfusion before and after a 
course of therapy with orally administered inositol is warranted. Given the suggestion 
that there may be an overlapping mechanism of action between inositol and 
downstream effects of the SSRIs, we hypothesized that clinical efficacy of inositol 
would translate to similar attenuation of perfusion that has been demonstrated with 
SSRI’s.  
 
 In this section I report on a study in which we used SPECT (as a measure of 
cerebral perfusion and examined the effects of inositol treatment on regional cerebral 
perfusion before and after 12 weeks of open-label treatment in subjects with OCD.  
1.3 Introduction to Part II 
  
1.3.1 Treatment effects of combined dopamine and serotonin receptor 
blockade in OCD 
 
Recognition that the tricyclic antidepressant clomipramine has predominantly 
serotonergic modulating properties, and demonstrates preferential benefit for patients 
with OCD, constituted a major advance in the pharmacological treatment of OCD 
[96]. Prior to this, OCD had been considered to be relatively difficult to treat 
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 contributing to the conceptualisation that it typically runs a chronic and fluctuating 
and predominantly unremitting course [141,142]. Subsequently, the introduction of 
the selective serotonin re-uptake inhibitors rapidly established this class as the first-
line treatment  in OCD [15,143-145]. 
 
Despite the considerable benefit brought by the widespread use of SRIs, this 
class of agents has unfortunately not brought the desired degree of relief from 
symptoms that was originally envisaged or hoped for. While the majority of patients 
will experience some relief of symptoms of OCD [141], currently some 40-80% still 
fail to respond adequately to an initial trial of therapy with an SRI  [141,142,146,147]. 
Still fewer will experience complete remission from their symptoms [148]. Recent 
systematic reviews suggest that there is some support for switching to an alternative 
SRI [96], however some 30% of patients will still fail to respond adequately to this 
strategy [149]. In addition, alternative augmentation strategies that may enhance the 
serotonin system have in the main been disappointing [150]. These include lithium, 
and buspirone [151,152]. 
 
Brain imaging, genetic and clinical evidence now provides relatively robust 
support for the involvement of the dopamine system in the pathophysiology of OCD 
[16]. In line with this, augmentation of SRI treatment with dopamine receptor 
antagonists has enjoyed considerable attention in recent years. A wide variety of 
open-label studies have suggested that augmenting SRI’s with atypical 
antipsychotics is likely to be a promising strategy for treatment-refractory OCD. 
These include support for risperidone [153-155], olanzapine [156-161], and more 
recently amisulpride [162] and quetiapine [163-166]. A single open-label study using 
quetiapine as augmentation showed lack of effect in a small sample using low doses 
[167].  
 
 The outcome of the first controlled studies in this area with the antipsychotic 
haloperidol demonstrated preferential benefit for refractory OCD subjects with co-
morbid tic disorder [168]. Haloperidol is a potent a reasonably selective antagonist of 
the dopamine 2 receptor with negligible binding of the post-synaptic serotonin 2A 
receptor. Most subsequent studies of augmentation with antipsychotics have used a 
variety of second generation antipsychotics, which have amongst others a dual 
action at D2 and 5HT2a receptors. In two of these, efficacy of risperidone in SRI 
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 refractory OCD has been reported [169,170]. Interestingly the former study [169], did 
not replicate the particular advantage for subjects with co-morbid tic disorder. At the 
time this study was conceptualised, no controlled published data for quetiapine 
existed. Subsequently, efficacy has  been shown for quetiapine [171] and olanzapine 
[172] using similar designs, but the effect on co-morbid tic disorders was not 
reported. In contrast a recent controlled study using olanzapine failed to demonstrate 
efficacy over placebo in a six week study [173]. Despite there being mixed evidence 
in this area, in general the available literature appears to support the use of relatively 
short trials of low doses of antipsychotic agents as augmentation to SRIs in refractory 
OCD.  
 
Quetiapine, is a second generation antipsychotic with moderately low affinity 
and highly transient binding to dopamine 2 receptors in addition to moderate 5HT2a 
and 5HT1D/B receptor binding. Combined with the open label evidence supporting its 
use and subsequent to the initiation of this work, the reported efficacy of this strategy 
in a controlled trial suggests this is a reasonable and hypothetically appealing 
treatment alternative that deserves further exploration in augmentation of SRIs in 
refractory OCD. Demonstration of its efficacy would contribute to a growing body of 
literature supporting a role for the serotonin and dopamine systems in OCD.  
 
In this study I report on the effects of flexible dose quetiapine augmentation of 
SSRIs in subjects with OCD who had failed to respond adequately to a minimum 12 
week trial of an SRI using a double-blind placebo controlled study design. 
 
1.3.2 Clinical and demographic determinants of response to treatment with 
combined dopamine and serotonin receptor blockade in OCD 
 
 While OCD is a replicable and robust construct with obsessions and 
compulsions being present in most patients, there is considerable clinical 
heterogeneity in most study populations. This heterogeneity is reflected in the 
variability in response to treatment with evidence-based interventions. Also, genetic, 
functional brain imaging, and neurochemistry studies in OCD have produced 
characteristically heterogeneous findings in many disorders including OCD. For some 
time this heterogeneity in clinical features and consequent variability in biological 
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 investigations has posed a significant challenge to advances in our understanding of 
the underlying neurobiology of OCD.  
 
 Using clinical tools such as the Yale-Brown Obsessive-Compulsive Scale 
(YBOCS) Symptom checklist [54,174] to delineate the considerable 
phenomenological heterogeneity in OCD has lead to investigations that explore the 
variety of symptom dimensions and their possible biological correlates [50,52,175]. 
Useful as these have been, this line of investigation is not without its limitations as I 
argue in the section on resting brain perfusion in OCD (Chapter 4). As such, much 
work remains to gain a full understanding the role symptom dimensions might have in 
increasing the predictive power of response to treatments.  
 
 Numerous studies have attempted to reconcile the presence of 
particular symptoms with prediction of response to predominantly serotonergic 
treatment such as the SRIs in OCD. To date, findings from this line of investigation 
remain incomplete [176,177]. It has, however been shown that behavioural 
dimensions may have different neuronal substrates [57] with different genetic 
variants [178,179]. Further evidence suggests symptom dimensions may be 
associated with differential outcome to treatment [58,180].  
 
 A superior response to treatment has been associated with washing 
symptoms and exposure therapy [181,182], compared to poorer response to SRIs 
[183,184]. Other clinical dimensional predictors of better response to SRIs have 
included checking compulsions [185], and overall greater severity of obsessions 
[186].  Poorer response to treatment has been associated with hoarding [187,188], 
symmetry and hoarding, contamination and cleaning [189], cleaning [190,191], 
somatic obsessions [192], and sexual/religious obsessions [190]. As such it is clear 
that specific symptoms impact significantly on the natural course and outcomes in 
OCD.  
 
In addition, a range of other descriptive variables in the context of SRI 
treatment have been associated with better SRI response rates. These include fewer 
previous courses of SRIs [186], female gender [185,193], later life onset [194], co-
morbid depression [195,196] and, higher YBOCS sub-scores [197,198]. Taken 
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 together, this literature remains variable, and in some cases conflicting. This is likely 
due to a range of issues including heterogeneity of samples and methods.  
 
In one of the few studies to develop a model for predicting treatment 
outcome, Denys et al [199] used key findings from the literature cited above to guide 
the choice of variables they entered into a multivariate regression in a double-blind 
placebo-controlled study of venlafaxine and paroxetine [200]. They found that 
YBOCS scores <23, HAM-D depression ratings >6, and fewer than two previous 
treatments for OCD together predicted treatment response with an ROC-area of 
0.71, a model with reasonable discriminative capacity despite its simplicity.    
 
Data from the controlled studies of antipsychotic augmentation of OCD 
including data from the work presented in Chapter 6 of this thesis have recently been 
combined in several separate meta-analyses. Considering the three most recent of 
these, Bloch et al [150], systematically reviewed data from all available controlled 
studies using a variety of antipsychotics and found an overall positive effect for this 
treatment alternative. Interestingly, this meta-analysis confirmed earlier indications of 
a preferential benefit for patients with co-morbid tic disorders first described my 
McDougle [168]. In a Cochrane analysis by Ipser et al  [201] we looked at the effects 
of antipsychotic augmentation across anxiety disorders. Not unexpectedly, we 
confirmed a positive effect for this strategy. In addition, we found that the largest part 
of this effect was produced by the body of evidence in OCD. Thirdly, in a meta-
analysis by Fineberg et al, we combined data from three placebo-controlled studies 
[171,202,203], including my own, in which quetiapine was used to augment SRI 
therapy in OCD. Using less conservative criteria (≥25% reduction in YBOCS score) 
for treatment response than the Bloch analysis (≥35% reduction in YBOCS score), 
we found a significant treatment effect in favour of quetiapine [204]. In a separate 
analysis of the same dataset, we found somewhat surprisingly that lower doses of 
SRIs were associated with superior clinical response to subsequent augmentation 
with quetiapine [205]. 
 
Data like these are responsive to the need for evidence-based alternatives in 
OCD pharmacotherapy, but as yet there is little indication as to which refractory 
patients are likely to derive the most benefit from these interventions. In the present 
study we pool data for a total of 80 subjects from two studies, including our own 
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 described in Chapter 6 of this thesis that used compatible methods. We then used 
available clinical and demographic variables to derive a model that together provides 
the highest predictive power for treatment outcome for augmentation of SRIs with 
atypical antipsychotics in refractory OCD. 
 
1.4    Hypotheses 
 In conclusion, a summary of the core hypotheses for each of the 
studies to follow is given.  
 
 The overall aim of this thesis is to use available clinical, brain imaging 
and treatment tools to contribute to our understanding of the psychobiology of OCD 
its treatment and intersection with treatment response.  
 
Central Hypotheses: 
• Resting brain perfusion differences exist in OCD compared to normal controls 
and that the difference correlates with symptom severity. I also hypothesise 
that whole-brain voxel-wise analysis will demonstrate differences in brain 
regions located outside the cortico–striatal-thalamo-cortical circuitry (Chapter 
2)  
• Brain perfusion changes in response to a single dose challenge with a 
specific 5HT1B receptor agonist, sumatriptan, in OCD will be present, and (1) 
will attenuate OC symptoms while (2) implicating cortico-striatal brain regions 
in this response (Chapter 3). 
• Brain perfusion changes before and after treatment with a single SSRI will 
primarily involve limbic and related prefrontal brain regions across anxiety 
disorders (OCD, PTSD, and SAD). I also hypothesize that pretreatment 
regional brain perfusion will differentiate responders to subsequent treatment 
with citalopram across the anxiety disorders. (Chapter 4) 
• Brain perfusion changes in prefrontal and striatal regions following treatment 
with inositol in OCD will overlap with those of the SRIs. This might suggest an 
overlap in the mechanism of action and imply a single common pathway in 
the downstream effects of these two treatments (Chapter 5)  
30 
Stellenbosch University  http://scholar.sun.ac.za
 •  The efficacy of controlled augmentation of SRIs in treatment refractory OCD 
with quetiapine will demonstrate a benefit over placebo after 6 weeks of 
treatment (Chapter 6). 
• That clinical and demographic factors can be used to predict treatment 
response following augmentation of SRIs with quetiapine (Chapter 7). 
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Regional Brain perfusion in OCD compared 
to normal controls – a basis for 
establishing the impact of treatments on 
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 2.1 Abstract 
 
Background 
 Considerable evidence suggests that obsessive-compulsive disorder (OCD) 
is mediated by frontal-subcortical circuits. Nevertheless, recent meta-analysis of data 
from functional brain imaging studies at rest suggests considerable inconsistency 
across studies. Also, exploration of the relationship between resting perfusion and 
symptom severity is limited. We therefore examined between group differences 
between OCD and normal controls, and the impact of illness severity on resting 
cerebral blood flow (rCBF) in OCD.  
 
Methods 
 Participants recruited from our anxiety disorders clinic (OCD n=18) and the 
community (normal controls n=19) were free of psychotropics and matched for age 
and gender. Resting Tc-99m HMPAO single photon emission computed tomography 
(SPECT) was completed in all subjects, and Yale-Brown Obsessive-Compulsive 
Scale (YBOCS) severity scores were used for correlation analysis with resting brain 
perfusion in a voxel-wise whole brain statistical parametric (SPM) analysis.  
 
Results 
 Compared with healthy controls, OCD subjects had significantly increased 
resting perfusion in left frontal (pre-central) and right mid orbito-frontal cortices. In the 
left frontal cluster, perfusion correlated with YBOCS severity (p<0.001). Conversely, 
significantly (p<0.001) lower perfusion in OCD compared to controls was evident in 
the lingual gyrus, superior orbito-frontal cortex, cerebellum, hippocampus, anterior 
cingulate, precuneus, and superior parietal cortex. All these clusters, except the 
lingual gyrus and the anterior cingulate clusters, correlated negatively with YBOCS 
scores. 
 
Conclusions 
 Our study demonstrates that: (1) there are significant differences in resting 
brain perfusion between participants with OCD compared to healthy controls, and (2) 
that differences correlate both positively and negatively with disease severity across 
a range of brain regions which are inconsistently implicated in mediating OCD. 
Further studies using resting perfusion SPECT and PET using consistent image 
acquisition and analysis methods are likely to provide valuable information on the 
neurobiology of OCD that is distinct from the information gained by dimensional 
approaches which target symptoms that are changeable over the course of the 
illness.  
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2.2 Background 
 
 Obsessive-compulsive disorder (OCD) is a chronic and disabling psychiatric 
disorder characterized by obsessions and compulsions [1]. Despite this apparently 
simple definition of OCD, there is a considerable degree of clinical heterogeneity in 
relation to its phenomenology, severity, and course [2]. Inconsistent and non-
replicable findings in brain imaging and genetic studies of OCD, may be accounted 
for in part by this underlying clinical heterogeneity [3]. The recent emergence of 
studies that delineate distinct biological substrates of specific symptoms dimensions 
in OCD may give us some indication as to the reasons for the frequently divergent 
findings [4]. However, a number of other possible explanations including differences 
in imaging technology used, and patient related factors probably act in concert to 
render the available data as variable as it is.   
 
 In the particular context of functional brain imaging, many have argued that 
the available literature supports the involvement of frontal-sub-cortical (striatal)-
thalamic circuit in mediating OCD symptoms [5,6].  In a recent meta-analysis of the 
functional brain imaging data in single photon emission computed tomography 
(SPECT) and positron emission tomography (PET) in OCD, however, the authors 
question whether available data in fact supports a number of the conclusions that 
have previously been assumed to have been well substantiated [3].  
 
 In particular, meta-analytic findings suggest that a wide range of brain regions 
are probably involved in mediating OCD, and concur that there is a lack of 
consistency across studies, making conclusions difficult to draw at this time.  A wide 
range of brain regions are to greater or lesser degrees specifically involved in OCD, 
including frontal (orbital, anterior, superior; and cingulate), striatal; and thalamic 
areas. However, in the analysis of the 13 studies included in the meta-analysis 
mentioned above, only a single finding in the head of caudate region (drawn from 
only 3/13 studies) reached the specified level of significance in studies of resting 
perfusion. In line with the conclusions of this meta-analysis, this extensive and 
important literature has not delivered the levels of insight that may previously have 
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 been hoped for. Consequently, the question arises as to when and if this data can be 
expected to be meaningfully combined to advance out understanding of OCD.   
 
 Combining studies in meta-analyses that use different imaging platforms, 
subtly different patient cohorts and varied methods of analysis makes comparisons 
challenging. Dividing the literature into smaller groups of studies has the effect of 
reducing the power to detect and explain perfusion abnormalities present in OCD at 
rest. Many investigators have reasoned that symptom activation paradigms are likely 
to yield more robust and specific findings in a particular disorder.  However, given 
that activation of a single symptom/dimension occurs in the context of significant 
symptom heterogeneity across any given sample, the specificity of the resulting 
imaging findings may also be sub-optimal.  
 
 As mentioned above, attempts to minimize clinical variance within samples 
have emerged in recent years in both clinical (phenomenological) and functional 
brain imaging studies with symptoms being classified on a dimensional and not a 
purely categorical basis [4,7-9]. While intuitively appealing, the value of this approach 
in OCD is only partly helpful for two primary reasons. First, many of these dimensions 
are also present to some degree in healthy volunteers though clearly to a less severe 
degree [4]. As such the findings may be fallaciously assumed to occur on a 
continuum of symptom severity between those with behavioral traits and those 
severely impacted by the presence of the symptom in question. Second, while 
dimensional investigations do demonstrate clear brain functional changes related to 
the presence of a particular symptom dimension, there is evidence for limited 
temporal stability and indeed interchangeability of symptoms over the course of the 
disorder. As such, findings cannot be assumed to represent a core neurobiological 
“substrate” for OCD, but merely a specific functional state within the broader 
definition of OCD. Resting brain perfusion studies thus seem likely to reflect a 
different measure of brain function in OCD that is broadly symptomatic and 
temporally relatively more stable then the “provoked” state of OCD. Thus relatively 
small changes anticipated in resting brain perfusion in OCD compared to normal 
controls, would translate to a need for relatively larger samples before firm 
conclusions can be drawn from the findings. As such, it seems important that resting 
and activation studies using both a dimensional and categorical approaches to define 
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 participant cohorts should remain parallel yet complementary lines of investigation in 
the functional imaging of OCD.  
 
 The present study presents a moderately large cohort of subjects with OCD in 
whom we compare resting brain perfusion using SPECT with those of normal 
controls and correlate differences with disorder severity using whole brain voxel-
based analysis.   
 
2.3 Methods 
 
 Study population 
 Study participants were recruited from our teaching hospital anxiety disorders 
clinic. Eligible participants were required to have a primary diagnosis of Obsessive-
compulsive disorder (OCD) (n=18, 13 males, 5 females), and be between the ages of 
18-65 years. A group of age and gender matched participants (n=19, 14 males, 5 
females) without current DSM-IV Axis I disorders were recruited to act as normal 
controls. Data for educational status is not available, however, on clinical 
examination no participants in either group demonstrated a history of showed current 
signs of cognitive impairment. Controls were originally recruited for a separate 
SPECT perfusion study in our group. Recruitment for this study occurred at a similar 
time to the OCD participants in this study, and criteria to define normals were similar 
across studies. Structured diagnostic psychiatric interviews to determine current 
psychiatric status were conducted by a board certified psychiatrist using the 
Structured Clinical Interview for the Diagnosis of Axis-I Disorders (SCID-I [10] on all 
prospective participants (OCD and normal control ). Any other current primary Axis-I 
disorder, current use of psychotropic medicine, medical illness deemed to be 
significant according to the clinical judgment of the investigating clinician, previous 
head injury with loss of consciousness exceeding 10 minutes, history of seizure 
disorder, refusal to consent to procedure or any other condition that might have 
rendered a participant unable to undergo or complete a SPECT study, were grounds 
for exclusion from participation. Previous use of psychotropics was not an exclusion, 
but all participants had psychotropics washed out for a minimum of two weeks before 
the study. Patients on fluoxetine were the only exception where this time was 
extended to four weeks. 
49 
Stellenbosch University  http://scholar.sun.ac.za
  
 Approval for the study was obtained from the relevant Institutional Review 
Board of the University of Stellenbosch. All participants were provided with a patient 
information and consent form prior to inclusion in the study. Inclusion followed 
detailed explanation from the investigating clinician and signed informed consent 
from the participant. The study was conducted in line with international guidelines 
guiding ethical conduct in research on human participants.  
 
 Clinical measures 
 The Yale Brown Obsessive-Compulsive Scale (YBOCS) [11,12] was 
administered to all participants with OCD on the day of SPECT imaging to determine 
illness severity.     
 
 SPECT Imaging 
 Single photon emission computed tomography (SPECT) was performed in the 
resting state for all participants in the study. Participants were required to lie supine 
in a quiet dimly lit room for 30 minutes prior to injection of the radiopharmaceutical.  
Apart from administration of the injection by a physician, they remained alone in the 
room during this period. Subjects were asked to remain at rest for 10 minutes after 
the injection of the radiopharmaceutical to allow uptake of the radiopharmaceutical in 
the brain. 
 
 An injection of 555 MBq (15 mCi) of technetium-99m hexamethylpropylene 
amine oxime (Tc-99m HMPAO) was given into an arm vein through an intravenous 
cannula positioned in an ante-cubital fossa prior to the initiation of the rest period. 
After completion of the minimum 10 minute rest period following the 
radiopharmaceutical injection, SPECT imaging of the brain was performed. We 
supported the subject's head with a standard headrest lined with sponge to maximize 
comfort. SPECT imaging was performed using a dual detector gamma camera 
(Elscint Helix, GE Medical Systems, USA) equipped with fan beam collimators. 
 
 Data were acquired in the step-and-shoot mode using a 360° circular orbit, 
with the detectors of the gamma camera positioned as close as possible to the 
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 subject's head.  Data were acquired using a 128 x 128 image matrix in 3 degree 
steps of 15 seconds per step. 
 
 Data were reconstructed by filtered back-projection, using a Metz filter 
(power=5, FWHM=14mm). The Chang method (µ = 0.11/cm) was used for 
attenuation correction [13]. The final reconstructed voxel size was 1.7x1.7x3.9 mm3. 
Image files were converted from interfile to analyze format using conversion software 
(Medcon, Erik Nolf, UZ Ghent, Belgium). 
 
 Image Spatial Pre-processing 
 Statistical analyses were conducted on a voxel-by-voxel basis using 
Statistical Parametric Mapping (SPM2, Wellcome Department of Cognitive 
Neurology, UK) [14]. The images of each subject were normalized to the Montreal 
Neurological Institute (MNI) standard anatomical space with 4x4x4 mm3 voxels, and 
to a value of 50 using proportional scaling. This was achieved using 12 affine 
transformations and 7x8x7 non-linear basis functions. The normalized images were 
then smoothed using a 3D Gaussian kernel with a FWHM of 12mm. 
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  SPECT Image Analysis 
 1) A multi-group study design was first selected using 2 groups (OCD and 
control group).  Contrasts were designed to detect in the first instance areas of 
significantly increased resting perfusion in OCD participants compared to controls, 
and in the second instance areas of significantly decreased resting perfusion in OCD 
participants compared to control participants.  
 
 2) In a second analysis we performed a correlation analysis between YBOCS 
scores as a measure of OCD severity and resting brain perfusion as measured with 
SPECT. Areas of significant (i) positive and (ii) negative correlation were sought.  
  
 3) In a third and final analysis, we took clusters reaching our significance 
threshold specified in the positive and negative correlation analyses (2) above and 
fitted these to group contrasts (1) above for resting perfusion in OCD > controls and 
OCD < controls respectively. Here we report only on clusters from the correlation 
analyses that were spatially located within 20mm of the clusters from the group-wise 
contrasts using a threshold of p< 0.05 uncorrected. This was done to increase the 
reliability of the assertion that cluster from the two analyses were located in the same 
brain regions.   
 
 We only report here on clusters of five or more (4X4X4mm) voxels in extent, 
as clusters smaller than this in extent are more likely to yield spurious results on the 
basis of the spatial resolution limitations of SPECT. Unless specified, a threshold p-
value of p<0.001 uncorrected was used to denote statistical significance in all 
analyses. The precise anatomical location of significant clusters is described using 
the anatomical regions using MRIcro software (Chris Rorden, Nottingham University, 
UK). 
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 2.4 Results 
 
 Our study sample comprised participants with OCD (n=18, 14 male, 5 
female), with a mean age of 33.1yrs (SD11.0), and controls (n=19, 15 male, 5 
female), mean age 36.9yrs (SD 7.9) (p=0.231). YBOCS scores for the OCD group 
were in the moderate to severe range with a mean of 27 (SD 3.7). No specific 
measure of symptom dimensions with which symptom heterogeneity could be better 
understood was available in this sample.  
 
 In the first contrast of OCD>controls, two small clusters met predefined 
threshold criteria.  The first of these, 5 voxels in extent, was located in the left frontal 
cortex (L-pre-central, x,y,z = -56,4,36) (Fig 2.1a). The second was located in the 
orbito-frontal cortex (Mid-orbito-frontal x,y,z = 0,28,-8) (Fig 2.1b). 
 
  
a 
b 
 
 
Fig 2.1 Resting perfusion in OCD > controls. Two clusters were identified in the left 
frontal cortex (x,y,z = -56,4,36) (a), and the orbito-frontal cortex (x,y,z = 0,28,-8) (b) 
 
In the reverse contrast (OCD<controls), 7 clusters emerged with the two most 
significant of these being in the lingual gyrus and the orbito-frontal cortex. Other 
clusters were found in the cerebellum, hippocampus, cingulate and precuneus. (See 
Table 2.1 for full results) 
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Cluster extent (n-
voxels) = n (4x4x4mm) 
Z-score x,y,z  co-ordinates MNI anatomical 
localization 
33 4.2 -8,-36,0 L – lingual 
11 3.75 -8,44,-32 sup orbito-frontal 
17 3.72 -4,-56,-40 cerebellum 
13 3.61 -12,-8,-16 L- med to hippocampus 
7 3.56 -8,8,28 L anterior cingulate 
6 3.29 12,-52,36 R-precuneus 
6 3.27 -24,-56,52 L superior parietal 
 
Table 2.1: Whole brain group-wise contrast with OCD<controls 
 Height threshold T=3.34, P=0.001, extent threshold 5 voxels 
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a b 
 
 
Fig 2.2: OCD participants displayed lower resting brain perfusion in left lingula (a), 
superior orbito-frontal cortex (b) 
 
 
 
 
c d 
Fig 2.2 OCD participants displayed lower resting brain perfusion in the cerebellum 
(c), and left medial hippocampus (d) 
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e f 
 
Fig 2.2 OCD participants displayed lower resting brain perfusion in the, left anterior 
cingulate (e), right precuneus (f), and left superior parietal cortex (g) 
56 
Stellenbosch University  http://scholar.sun.ac.za
  In the correlation analyses of resting cerebral perfusion with YBOCS scores in 
the OCD group alone, we found no positive correlations at the p=0.001 level. In the 
reverse contrast, significant clusters for negative correlations of perfusion with 
YBOCS scores emerged as follows. These were located in the right mid temporal 
cortex (19 voxels, located at 48, -72,8) (Fig 2.3a), and the left pre-central region (15 
voxels located at -52, -16,48) (Fig 2.3b).  
 
 
a b 
Fig 2.3: For the OCD group alone, total YBOCS scores were inversely correlated with 
regional perfusion in the mid-temporal region (a), and the left pre-central region (b) 
 
Given that with the group-wise contrast we had defined “regions of interest” for use in 
the comparison of regions with the correlation analysis, we used a lower threshold for 
height equivalent to p=0.05. For the contrast of OCD>controls we found one cluster 
in the left frontal region (-64,8,32, distance 9mm) correlated positively with YBOCS 
scores. (Fig 2.1)   
 
 
Fig 2.4: OCD demonstrated higher rCBF  
compared to controls, which correlated  
with OCD severity in the Left pre-frontal  
region 
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             In a similar analysis for the reverse contrast of OCD<controls we found 5 
clusters that correlated negatively with YBOCS scores in the OCD group. These 
were located within the superior orbito-frontal (16,36,-20 within 17mm), left 
cerebellum (-8,-44,-36 within 13mm), medial to hippocampus (90,-16,-8 within 
17mm), right precuneus (12,-60,48 within 14mm), and left superior parietal region(-
28,-56,56 within 6mm). 
 
2.5 Discussion 
 
 In this study we compared SPECT resting brain perfusion in a moderately 
large cohort of participants with OCD compared to normal controls. Our main findings 
included (1) higher perfusion in OCD relative to controls in right mid orbito-frontal and 
left pre-central frontal brain regions, and a positive correlation with a left pre-central 
frontal cluster and illness severity, 2) lower perfusion in OCD versus normal controls 
in more widespread brain regions including left lingual, superior orbito-frontal, 
cerebellar, right precuneus, anterior cingulate, left superior parietal cortex, and left 
hippocampus. 3) an inverse correlation with disorder severity in all the 
aforementioned brain regions with the exception of the left lingual and the anterior 
cingulate cortex clusters.   
 
  In line with our hypothesis, these data confirm that differences in brain 
perfusion are present when comparing OCD and normal controls at rest. The 
opposite direction of the observed differences in some brain regions when compared 
to normal controls adds to the complexity of understanding these data. Symptom 
heterogeneity has long been suggested to represent underlying biological variability. 
We show that some frontal regions (left pre-central) demonstrate increased perfusion 
that correlates with disorder severity, while others (superior orbito-frontal) showed the 
reverse. The mixed findings here, however, are consistent with the variability seen in 
much of the resting SPECT literature to date in OCD [15-19]. Reasons for this 
plausibly include clinical heterogeneity [20,21], sub-regional changes that are not 
equally well explored across studies that use variably sensitive analysis methods, 
imaging methodology, and disorder severity. Many of these hypotheses are difficult 
to test.  
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  Our finding of lower perfusion in a number of brain regions is however in line 
with some previous work. An overlap exists with findings incorporating temporal and 
parietal brain regions such as the right precuneus and left superior parietal regions 
[22-24]. Our findings however differ from others in respect of the direction of change 
in these temporal [16,17,25-27] and parietal regions [16,17,25,27]. Emerging 
evidence has suggested a role for parietal (precuneus) involvement in OCD through 
its connections with striatal, thalamic and frontal brain regions. Parietal regions 
mediate a range of functions including memory processing, and self awareness 
among others [18,28,29]. Particularly interesting in this context is a reported 
association of fronto-parietal deactivation in the conscious resting state possibly 
accounting for the finding here [30]. How this explains the difference between OCD 
and controls however remains unclear.  
 
 In our study involvement in the lingual gyrus did not correlate with symptom 
severity. This region of the occipital cortex is involved in mediating response to 
unpleasant stimuli [31-33] and selective attention [33]. It is possible that despite and 
apparent resting state, participant’s anticipation of injection of a radiopharmaceutical 
and subsequent SPECT scanning may have an impact on brain perfusion and 
consequently brain regions that mediate processing of unpleasant stimuli. If this is 
worse in OCD than in normal controls, this may account for greater deactivation in 
OCD compared to controls.  
 
 The impact of symptom dimensions on the “ability to rest” prior to injection of 
the radiopharmaceutical may be affected by underlying symptoms. A period of 30 
minutes rest in an environment devoid of bright light, noise, pain or otherwise 
uncomfortable sensory stimuli may not induce comparable resting states across 
subjects and studies. Depending on the nature and severity of OC symptoms of 
OCD, participants could plausibly respond with some variability to the instruction to 
rest. Nevertheless, differences in resting state are likely to be of some significance 
and should be considered as possible reasons for discrepant findings across studies 
[17,19].  
 
 Another possible explanation for the variability we see might be explained in 
the findings from the recent meta-analysis by Whiteside et al [3]. Data from 13 
studies were combined which included comparisons of OCD versus normal controls.  
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 By computing the effect size of differences between OCD and normal controls they 
found that only the left and right head of caudate and the left orbital gyrus differed 
significantly from no effect. They also note that very few of the studies actually 
examined these regions. The head of caudate findings are derived from 3/13 studies 
[34-36] and the orbito-frontal findings from 2/13 studies [34,35]. As alluded to in their 
paper, Whiteside et al express concern at the assertions made in previous 
comprehensive narrative reviews [5,6], that current data strongly support the 
involvement of the orbito-frontal cortex and the caudate in the pathophysiology of 
OCD [3]. Meta-analyses have the advantage of accurately quantifying data acquired 
in comparable ways, and in so doing increase the power to detect meaningful 
differences between study groups. While this approach has some appeal in imaging 
literature, caution should be exercised when interpreting pooled data that combines 
studies acquired under different resting conditions. In addition, the effect of different 
imaging equipment and indeed different imaging modalities such as PET and SPECT 
may introduce significant confounds to interpreting these data.  
 
 Whiteside et al [3] do argue that based on their findings, a more specific focus 
on smaller brain regions may be more fruitful. The authors cite the need to create so-
called “super-groups” of brain regional findings in order to generate sufficient power 
for meta-analysis as a potential confound to their results. In so doing they needed to 
some extent to disregard emerging evidence suggesting that sub-regional functional 
differences are likely to exist in orbito-frontal and cingulate cortices in OCD. 
Increasingly sophisticated whole brain, voxel-wise analysis may have an advantage 
over some region of interest (ROI) approaches in that a priori knowledge on expected 
change is not an absolute requirement. As such studies using ROI analyses with 
larger regions of interest may have been set up so that areas believed to be central 
to OCD were prioritized over less well studies area. Also, larger regions of interest, 
as suggested, may entirely overlook changes in opposite directions that occur within 
an ROI, effectively canceling each other out.    
 
 We turn now to the question of the potential of underlying differences in core 
symptom dimensions to influence variability of imaging findings. An emerging 
literature has focused on defining increasingly specific symptom dimensions within 
OCD cohorts [2,4,9] It is anticipated that in time this approach will contribute to 
analyses that combine clinical correlates of symptom dimensions with more sensitive 
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 neuro-cognitive and functional neuroimaging patterns. Barriers to this approach, 
however, lie in the natural course of OCD. Symptoms in OCD typically run a waxing 
and waning course. This approach seeks to classify participants on the basis of the 
presence and severity of specific symptom dimensions. To do this they rely on the 
categorization of symptoms of obsessions and compulsions as (1) present or not, 
and (2) whether a symptom is regarded as primary or not at the time of assessment. 
The typical course of OCD thus suggests that core symptoms without temporal 
stability may be absent at a future assessment and be superseded by other 
symptoms entirely. It is therefore conceivable that a particular individual may at 
another time display a considerably different if not quite distinct pattern of brain 
function as a result of the primacy of a distinct obsession or compulsion. Dimensional 
descriptions, while undoubtedly valuable for a number of other reasons, probably 
capture a specific symptom “state” when using activation techniques as imaging 
paradigms. Theses data may thus represent a distinct and possibly more replicable 
brain functional state that is OCD. While theoretically appealing, however, this 
remains to be shown in studies using a similar methodology.  
 
 Finally, the correlation we found with differences in disorder severity (YBOCS) 
and changes in prefrontal regional brain perfusions in line with a number of previous 
studies. In this area to, it has been argued that variability across studies may be 
accounted for at least in part, by variability in symptom severity both in respect of 
general anxiety at rest as well as specific OC symptoms [17]. For instance, frontal 
abnormalities are frequently seen [3,6] and are likely to mediate a range of cognitive 
and affective dysfunction in part impacted by severity in OCD. Sub-regional 
differences in the direction of that change, whether primary or compensatory may 
account for variability and requires further clarification [19]. 
 
 Limitations of the present study should be noted.  First, we did not objectively 
measure anxiety at the time of the HMPAO injection, and as such we acknowledge 
that anxiety levels may have differed to some degree across subjects and accounted 
for some of the regional differences we see compared to other studies. However, we 
believe that the effect of moderate to severe symptoms of OCD, as was the case in 
our cohort, is likely to be the major determinant of the between-group differences we 
observe. Despite some of the limitations of SPECT examination, the advent of 
increasingly reliable and comparable analysis methods will in time aid in meaningful 
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 comparisons across studies. For this accessible technology such as SPECT can still 
be expected to make a meaningful contribution to this literature. Larger, more easily 
comparable samples will in time move us closer to addressing crucial questions in 
OCD neurobiology.  
 
 We have argued that both categorical and dimensional approaches as well as 
activated and resting state investigations to pursue the biological underpinnings of 
OCD seem justified. In future studies, consistency in analysis methods should be 
pursued. In particular, the advantage that whole brain voxel wise analysis, allows 
examination of smaller sub-regional volumes that in time may provide us with a 
clearer indication of the brain functional changes that underlie OCD.  
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 CHAPTER 3 
 
 
 
Clinical and regional brain perfusion 
changes in response to acute challenge 
with a serotonin 1B receptor agonist in 
OCD  
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 3.1 Abstract 
Background 
 Treatment data, genetic findings, and some previous pharmacological 
challenge data suggest a potential role for the serotonin 1B autoreceptor in mediating 
symptoms in obsessive-compulsive disorder (OCD). A previous acute sumatriptan 
challenge found heterogeneous clinical responses. Frontal brain perfusion 
attenuation correlated with exacerbation of OCD symptoms when measured with 
single photon emission computed tomography (SPECT). Here we expand this 
previous sample and examine brain perfusion effects of acute sumatriptan challenge 
in OCD using whole-brain voxel-wise SPM analysis. 
 
Methods 
 Sumatriptan or matching placebo was administered in a double-blind, 
cross-over, counterbalanced design on separate days to 25 consenting, treatment 
free participants with primary diagnosis of OCD. Participants had no other primary 
psychiatric co-morbidity including depression. SPECT imaging followed a 
standardized rest period and injection with Technetium-99m HMPAO. Repeated 
measures of OC and general anxiety symptoms were performed by trained clinicians 
to assess changes in response to sumatriptan.  
 
Results 
 Behavioural responses of OC and anxiety symptoms did not differ 
significantly between placebo and sumatriptan. This however, masked considerable 
heterogeneity of OC symptom responses. The majority (n=14) of participants had an 
improvement in symptoms of anxiety. Five subjects each reported either worsening 
or improvement in OCD symptoms while the rest were unchanged. Improvement in 
OC symptoms was associated with attenuated regional perfusion in the right mid-
cingulate, and left superior medial frontal cortex. Increased perfusion was also noted 
in the occipital region. Improved anxiety symptoms correlated inversely with 
perfusion in the left fusiform gyrus, right precuneus, and left lingual gyrus.  
 
Conclusions 
  Drug challenge of the 5HT1D/B autoreceptor complex in OCD in the 
present study produced mixed responses in obsessive-compulsive symptoms and 
anxiety in OCD. In general, brain regional perfusion responses to sumatriptan 
challenge were seen in brain regions implicated in the functional neurocircuitry of 
OCD. In addition, whole brain voxel-wise analysis has enabled us to detect and 
speculate on the involvement of regions outside of this circuit. Our data also suggest 
that the change in frontal regional perfusion may be specific to OC symptoms 
following sumatriptan challenge.  
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 3.2 Background  
 
 A range of investigations into the neurobiology that mediates symptoms of 
obsessive-compulsive disorder (OCD) have been undertaken in recent decades. 
Much of this work has focussed on the involvement of neurotransmitter systems 
which are implicated in the pathophysiology of OCD. The selective response to 
treatment with drugs that target the serotonin system have underpinned a 
serotonergic hypothesis in OCD for some time.  
  
 The identification of the 5HT1B receptor on chromosome 6 in humans in the 
early nineties [1-3], lead to positive associations with preferential transmission of the 
G-allele of the gene encoding for 5HT1B in some [4,5], but not all [6,7] studies in 
OCD. Along with a number of other lines of evidence, the 5HT1B hypothesis in OCD 
began to develop [8]. This hypothesis has been particularly strengthened by the 
contribution of pharmacological challenge studies. 
 
 Challenge studies with drugs acting on specific components of receptor 
systems have been informative regarding the involvement of the serotonin system in 
OCD. These began with studies using m-Chlorophenylpiperizine (m-CPP), a ligand 
with non-specific agonist action on 5HT2c, 5HT1b, and 5HT2a receptors. Acute 
administration results in OC symptom exacerbation in some [9-12], but not all studies 
using m-CPP [13,14]. MK-212,  a specific agonist of 5HT1a and b receptors does not 
seem to have an impact on OCD symptoms when administered acutely [15]. 
Together with the neuroendocrine blunting of cortisol and prolactin responses to MK-
212 in OCD, these data may suggest a degree of hypo-responsivity of components of 
the serotonin system [15]. Due, however to the relative lack of specificity of these 
agents, the involvement of particular receptor subtypes in OCD is still not deducible 
from these data.  
 
 The use of triptans such a sumatriptan in clinical practice, introduced a 
potential to investigate the role of the 5HT1B auto-receptor in challenge studies using 
the selective auto-receptor agonist, sumatriptan [16]. Acute administration of 
sumatriptan to patients with OCD has produced mixed clinical responses. In some, a 
transient exacerbation of symptoms [10,17,18] before a moderate reduction with 
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 more chronic exposure [17,18] has been reported. In another study, similar 
exacerbation was found with sumatriptan, but this did not differ significantly from 
placebo [14].  In a study using zolmitriptan, a derivative which traverses the blood 
brain barrier more effectively than sumatriptan, no behavioural effects on measures 
of OCD and anxiety were found [19].  In collating this work, Zohar et al [8] note the 
difficulty in interpreting inconsistent challenge data and call for further clinical studies 
in this area.     
 
 Functional brain imaging tools such as single photon emission computed 
tomography (SPECT) along with specific drug challenges provide the ideal 
opportunity to examine regional brain perfusion and drug interactions. Hollander et al 
[20] using an m-CPP challenge found increased whole brain cortical blood flow 
correlated with increased symptoms of OCD.  Ho Pian et al [21] compared responses 
to m-CPP challenge in OCD with SPECT and found reduced rCBF in frontal, 
caudate, putamen and thalamic reigions. These changes were, however, did not 
accompany changes in OCD symptoms compared to healthy controls. As mentioned, 
both of these studies used the non-specific serotonin receptor agonist m-CPP, 
leaving some doubt as to the specific involvement of the 5HT1B receptor in this 
context.    
 
 Our group have previously reported on a small SPECT study with a sample of 
patients (n=14) with OCD to whom a single dose of sumatriptan was administered in 
a double-blind, placebo-controlled, cross-over design [22]. We found heterogeneous 
OC symptom responses to sumatriptan challenge, with nearly a third of patients 
(n=4) experiencing a worsening of OC symptoms. Using an ROI approach to the 
analysis, we demonstrated perfusion increases in the thalamus and putamen with 
sumatriptan relative to placebo challenge. A worsening of symptoms was associated 
with decreased activity in inferior and medial frontal brain regions. We also found that 
symptom exacerbation correlated with reduced inferior frontal and increased 
putaminal perfusion. Post-hoc analysis of those with and without symptom 
exacerbation did not demonstrate significant rCBF differences.  
 
 In the present study, we extend our previous work in his area and now report 
on a moderately large OCD sample in which we examine the behavioural correlations 
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 of acute sumatriptan challenge with SPECT findings using whole brain voxel-wise 
analysis methods.               
 
3.3 Methods 
 
Study Participants 
 Potentially eligible study participants were screened in our teaching hospital 
anxiety disorders clinic. Suitable participants had a primary DSM-IV diagnosis of 
Obsessive-compulsive disorder (OCD) [23]. The sample (n=25) comprised 19 males 
and 6 females between the ages of 18-65 years. Structured psychiatric diagnostic 
interviews to determine current psychiatric status were conducted by a board certified 
psychiatrist using the Structured Clinical Interview for the Diagnosis of Axis-I 
Disorders (SCID-I [24]. Any other current primary Axis-I disorder, medical illness 
deemed to be significant according to the clinical judgment of the investigating 
clinician, previous head injury with loss of consciousness exceeding 10 minutes, 
history of seizure disorder, refusal to consent to procedure or any other condition that 
might have rendered a participant unable to undergo or complete a SPECT study, 
were grounds for exclusion from participation. All patients had been free of any 
psychotropic medication for a minimum of two weeks (or as appropriate for drugs 
with longer washout times) at the time of the first scan.   
 
 Approval for the study was obtained from the relevant Institutional Review 
Board of the University of Stellenbosch. All participants were provided with a patient 
information and consent form prior to inclusion in the study. Inclusion followed 
detailed explanation by the investigating clinician and signing of the informed consent 
document. The study was conducted in line with international guidelines guiding 
ethical conduct in research on human participants.  
 
Study design and clinical measures 
 Matching sumatriptan/placebo tablets (100mg) were administered to patients 
in a double-blind, placebo-controlled, counterbalanced, cross-over design. On each 
of two scan days (72 hours apart), medication was administered at 08:30, with a 
standardized period of rest beginning at t=60. Radiopharmaceutical injection 30 
minutes later at t=90 (see imaging methods below for detail). We used clinically 
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 trained raters with good inter-rater reliability, to assess obsessive-compulsive and 
general anxiety symptoms at regular intervals throughout the 4-hour period of the 
clinic visit. We used the Clinician Challenge Obsessive-Compulsive scale (CC-OCS) 
[12] to measure obsessive-compulsive symptoms at all protocol specified time 
intervals. The CC-OCS is derived from the Yale-Brown Obsessive-Compulsive scale 
(YBOCS) [25,26]. This 9 item scale assesses both obsessions (time spent, anxiety, 
control, overall severity) and compulsions (time, anxiety, control, indecisiveness, 
overall severity), and was designed with the drug challenge environment in mind. 
Measures of state anxiety were also taken using the Acute Panic Inventory [27], a 
27-item version of the scale designed to measure the effects on general anxiety and 
panic in the context of drug challenge studies.  Behavioral measures were taken at 
t=-30min, time of drug administration (t=0), and again at t=30, t=, 90, 150, and 210. 
To derive a baseline measure of anxiety, we summed the scores of t-30, 0, 30. 
Similarly, to derive a measure of anxiety over the period of maximal uptake of the 
sumatriptan, we summed behavioral scores from t=90, 150, and 210. 
 
 Overall measures of OCD severity included the YBOCS which was measured 
on each of the scan days. While no participant met criteria for depression at the time 
of the study, we used the Montgomery Äsberg Depression Rating Scale (MADRS) 
[28] to assess symptoms of depression.  
 
SPECT Imaging 
 Single photon emission computed tomography (SPECT) was performed in the 
resting state for all participants on two separate days with a minimum of 72 hours 
separating examinations of an individual participant. Randomization of medication 
was counterbalanced across the two imaging sessions to ensure blinding of symptom 
raters. For the rest period beginning at t=60, participants were required to lie supine 
in a quiet, dimly lit room for 30 minutes prior to injection of the radiopharmaceutical. 
Apart from administration of the injection by a physician, they remained alone in the 
room during this period. Subjects were asked to remain at rest for 10 minutes after 
the injection of the radiopharmaceutical to allow uptake of the radiopharmaceutical in 
the brain. 
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  An injection of 555 MBq (15 mCi) of technetium-99m hexamethylpropylene 
amine oxime (Tc-99m HMPAO) was given into an arm vein through an intravenous 
cannula positioned in the right ante-cubital fossa prior to the initiation of the rest 
period. After completion of the minimum 10 minute rest period following the 
radiopharmaceutical injection, SPECT imaging of the brain was performed. While on 
the scanner bed, the participant’s head was supported with a standard headrest lined 
with sponge to maximize comfort. SPECT imaging was performed using a dual 
detector gamma camera (Elscint Helix, GE Medical Systems, USA) equipped with 
fan beam collimators. 
 
 Data were acquired in the step-and-shoot mode using a 360° circular orbit, 
with the detectors of the gamma camera positioned as close as possible to the 
subject's head.  Data were acquired using a 128 x 128 image matrix in 3 degree 
steps of 15 seconds per step. 
 
 Data were reconstructed by filtered back-projection, using a Metz filter 
(power=5, FWHM=14mm). The Chang method (µ = 0.11/cm) was used for 
attenuation correction [29]. The final reconstructed voxel size was 1.7x1.7x3.9 mm3. 
Image files were converted from interfile to analyze format using conversion software 
(Medcon, Erik Nolf, UZ Ghent, Belgium). 
 
Image Spatial Pre-processing 
 Statistical analyses were conducted on a whole brain voxel-by-voxel basis 
using Statistical Parametric Mapping (SPM2, Wellcome Department of Cognitive 
Neurology, UK) [30]. The images of each subject were normalized to the Montreal 
Neurological Institute (MNI) standard anatomical space with 4x4x4 mm3 voxels, and 
to a value of 50 using proportional scaling. This was achieved using 12 affine 
transformations and 7x8x7 non-linear basis functions. The normalized images were 
then smoothed using a 3D Gaussian kernel with a FWHM of 12mm. 
 
Behavioural symptom analysis  
 Clinical behavioural data were collated and analysed using the Statistical 
Package for Social Sciences (SPSS Version 14). To assess within subjects change 
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 in response to placebo and medication, we used paired sample t-tests to assess 
change in API scores from baseline (t -30+0+30) to the end point defined as the sum 
of scores from t = 90+150+210 for both the sumatriptan and the placebo scan days. 
To assess differences between treatments within subjects we used general linear 
model and a repeated measures analysis of variance (RMANOVA) using the 
baseline and endpoint API, and CC-OCS respectively as factors, and treatment 
(sumatriptan/placebo) as the between subjects factor.   
    
SPECT Image Analysis 
1)  A single group, within subjects design was employed to compare placebo 
versus sumatriptan scans. Contrasts were designed to examine in the first instance 
areas of significantly increased resting perfusion in sumatriptan scans compared to 
placebo, and in the second instance areas of significantly decreased resting 
perfusion in OCD participants compared to control participants.  
 
2) In a second analysis we examined areas with significant (i) positive and (ii) 
negative correlations between a) the change in API score , and b) the CC-OCS in 
response to sumatriptan/placebo and resting brain perfusion as measured with 
SPECT. 
 
 3) In a third and final analysis, using only the sumatriptan scans, we used a 
simple between subjects design to examine the resting SPECT perfusion differences 
between participants who had symptom improvement versus participants who did not 
on the API measure of anxiety, and the CC-OCS. Contrasts for (i) responders>non-
responders, and (ii) responders<non-responders were designed.  
 
We only report here on clusters of four or more voxels (4X4X4mm) in extent, 
as clusters smaller than this in extent are more likely to yield spurious results on the 
basis of the spatial resolution limitations of SPECT. We used a threshold p-value of 
p<0.001 uncorrected to denote statistical significance in all analyses. The precise 
anatomical location of significant clusters is described using the anatomical regions 
using MRIcro software (Chris Rorden, Nottingham University, UK). 
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 3.4 Results  
 
Study sample characteristics 
Our study cohort comprised 25 subjects (19 male, 6 female). Of those who 
were eligible and consented to participate, all completed both imaging sessions. No 
adverse effects from either the sumatriptan or placebo were reported. The mean age 
of participants was 33.5 years (SD 12.21). The mean YBOCS score was 23.15 (SD 
5.06) suggesting participants were moderately ill overall. As co-morbid depression 
was an exclusion criterion and MADRS mean scores were predictably low (11.03, SD 
4).    
 
Behavioural outcomes  
Results of paired sample t-tests assessing within-group (placebo and 
sumatriptan) changes in 1) obsessive-compulsive symptoms (CC-OCS), and 2) 
overall anxiety (API) (see Table 3.1) suggest that overall, participants did not 
demonstrate significant changes. Within subject treatment differences of OC 
symptoms were also not significant (p=0.48). This however masks what was 
essentially a heterogeneous response to sumatriptan. Five subjects reported 
improved symptoms of OCD while 5 reported a worsening, and the rest remaining 
unchanged. On overall measures of anxiety, however, both sumatriptan (p=0.04) and 
placebo (p=0.03) challenges were accompanied by reduced symptoms. Here 14 
participants improved, 10 were worse and 1 was unchanged in response to the 
sumatriptan challenge. The magnitude of the differences, however, did not differ 
significantly between sumatriptan and placebo (p=0.77). 
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Behavioral 
Measure 
Sumatriptan 
(mean, SD) 
Paired t-
test 
Mean 
(df,(SD), 
p) 
Placebo 
(mean, SD) 
Paired t  
Mean df 
(df,(SD), p) 
RMANOVA 
Sumatriptan 
vs placebo 
(F, p) 
API Baseline  25.28 
(25.58) 
24.08 
(22.53) 
API Peak  21.36 
(21.17) 
3.92 
(9.07)  
p=0.04 20.78 
(20.67) 
3.30,(10.68) 
p=0.03 
0.089, 
p=0.77,  
CC-OCS 
Baseline 
11.06 (5.87) 11.92 (5.74) 
CC-OCS 
Peak 
11.00 (7.25) 
0.06 
(4.30) 
p=0.95 12.66 (7.62) 
-0.74 (5.49) 
p=0.507 
0.516, 
p=0.48 
 
  Table 3.1: paired t-tests for changes in scale scores for sumatriptan and placebo 
and RMANOVA for within subject treatment comparisons.  
API – Acute Panic Inventory, CC-OCS – Clinician Challenge Obsessive-Compulsive Scale 
 
SPECT imaging results  
In the first analysis which contrasted sumatriptan and placebo in a paired 
design, there were no differences in brain regional perfusion that cleared the height 
and extent threshold set a priori in either the sumatriptan>placebo or 
sumatriptan<placebo contrasts. As we may have anticipated from the absence of 
meaningful overall change in OC behavioral findings, we found neither positive nor 
negative regional correlations of perfusion with change in CC-OCS scores.  
Despite the small overall change in OC symptoms, the heterogeneous clinical 
response to sumatriptan warranted further exploration of this group for possible 
differences in brain perfusion between participants in whom symptoms improved and 
those in whom symptoms worsened. We found a cluster within the right mid-cingulate 
region (7 voxels, x=4,y=24,z=36, Z=3.97, p=0.001)(Fig 3.1a)  in which those with 
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 symptom improvement had lower regional perfusion than non-responders following 
sumatriptan challenge.  Another small cluster (4 voxels) was noted in the left superior 
medial frontal cortex (x=-8, y=56, z=28, Z=3.81, p=0.001) (Fig 3.1b).  
 
 
a b 
 
Fig 3.1: Reduced right mid cingulate (a) and left superior medial frontal (b) perfusion 
in participants with improved OC symptoms in response to sumatriptan challenge 
 
For the reverse contrast (Responders>non-responders) we found a single 
large cluster (42 voxels) located within the right mid-occipital cortex at MNI co-
ordinates x=32, y=-84, z=12 (Z=5.3, p<0.001) (Fig 3.2). 
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Fig 3.2: Right mid-occipital region in 
which participants who responded to 
sumatriptan challenge demonstrated 
higher perfusion relative to those 
who did not.   
 
In line with the overall improvement in anxiety, improved anxiety correlated positively 
with reduced brain perfusion in two small clusters; these were 1) the left fusiform 
gyrus (6-voxels; x=-36, y=-12, z=-32 [Z=3.87, p<0.001) (Fig 3.3a), and 2) the right 
precuneus (4 voxels; x=16,y=-44, z=8 [Z=4.59, p<0.001]) (Fig 3.3b).  
 
 
a b 
Fig 3.3: Lower anxiety symptoms in response to sumatriptan challenge correlates 
with lower regional perfusion in the left fusiform (a) and the right precuneus region 
(b). 
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  We found no negative correlations with perfusion and changes in 
anxiety. A single small cluster (4 voxels)  in the left lingual gyrus using one-way 
ANOVA (x=-16, y=-72, z=-8 [Z=3.91, p<0.001]) (Fig 3.4) demonstrated a significant 
increase in perfusion in participants who had improved anxiety symptoms relative to 
those who did not respond or worsened in response to sumatriptan.   
 
 
Fig 3.4: Left lingual perfusion was 
increased in participants in whom 
anxiety symptoms improved 
compared to those who did not 
improve in response to sumatriptan  
 
 
3.5 Discussion  
  
 We found that overall, behavioural responses to sumatriptan did not differ 
significantly from placebo. The main clinical imaging findings of the present study are 
that those with OC symptom improvement in response to a single dose challenge 
with sumatriptan had significantly lower right mid-cingulate, superior medial frontal, 
and higher right mid-occipital rCBF than those who had no change in OC symptoms. 
We found that more than half the participants experienced improvements in anxiety 
in response to sumatriptan challenge and that these changes (lower symptom 
scores) correlated with reduced brain perfusion in the left fusiform gyrus and the right 
precuneus. When we contrasted those in the sumatriptan group with improved 
anxiety symptoms had lower left lingual perfusion than non-responders.  Finally, we 
found that response to sumatriptan on measures of both OCD and anxiety symptoms 
were variable. A sizeable minority of participants (n=10) had a measurable response 
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 to sumatriptan, and that numbers showing improvement (n=5) and exacerbation 
(n=5) were evenly divided.  
 
Our findings are in line with other functional imaging data in OCD [31], 
including our own unpublished data, in which resting perfusion is higher in frontal 
brain regions in more symptomatic OCD patients compared to controls (See Chapter 
2). Our main finding that participants who experienced a response to sumatriptan 
challenge differs from the findings in our previous work in which lower putaminal 
perfusion was noted in the same group. These data did not replicate this finding. 
Also, in our previous data we found that frontal inferior-anterior perfusion increased 
with symptom response to sumatriptan. Here we see that right inferior frontal 
perfusion was attenuated in response to a reduction on OC symptoms following 
sumatriptan challenge. At the time we hypothesized that the lower frontal perfusion 
with increased symptoms may have resulted from decreased compensatory frontal 
activity in this subgroup of patients. In general, brain perfusion data in OCD suggests 
pre-treatment increases in frontal perfusion relative to controls [32] and that with 
treatment this effect is attenuated [33,34]. Our findings suggest therefore that 
serotonergic modulation of clinical symptoms through either an SRI or more 
specifically with the acute administration of a 5HT1B autoreceptor agonist results in 
partial attenuation of frontal perfusion. Agonist activity at the autoreceptor has the 
effect of acutely reducing serotonin levels within the synapse. This might be seen to 
be akin to the effect of receptor desensitization that occurs with chronic treatment 
[9,12,17]. While this explanation has some appeal it does not account for the 
heterogeneity of the clinical response in our study.  
 
We speculate that different clinical responses may be the result of a number 
of factors. Those at a receptor level may include receptor density, distribution, 
function or allelic composition.  A limitation of the present study is the absence of 
allele data. At present the lack of available SPECT ligands for the 5HT1B receptor 
limits our ability to address the questions of receptor density, distribution and 
function. We did note however that for changes in general anxiety, we found no 
specific frontal area in which perfusion was attenuated. As such the specificity of 
these frontal findings with respect to change in OC symptoms and lends weight to the 
distinctiveness of OCD and general symptoms of anxiety.  
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 The response to sumatriptan challenge of overall anxiety symptoms in our 
cohort is less heterogeneous than is seen for specific OC symptoms. While we found 
an overall reduction in symptoms in both the sumatriptan and placebo conditions, 
these did not differ significantly from one another. Nevertheless, the effects are 
interesting due to the differences in regional brain perfusion that we demonstrated 
between those with differing anxiety responses. We found a correlation with 
improved anxiety and reduced brain perfusion in the left fusiform gyrus and the right 
precuneus, when comparing sumatriptan and placebo.  
 
The fusiform gyrus within the inferior temporal cortex extending to the base of 
the occipital cortex has primarily been implicated in higher order visual object 
processing. More recently though, this area has also been implicated in the amount 
of retrieved information related to visually perceived objects [35]. Also, this region 
has been implicated in processing of OC dimensions of aversion, hoarding and 
aggression/checking [36]. In the case of aggression/checking, and aversion 
symptoms, controls demonstrated greater activation than OCD subjects. In hoarding 
the reverse was true. These data suggest that not only do different symptoms when 
provoked results in distinct patterns of rCBF, but that brain regions outside of the 
putative CSTC circuit may be important determinants of OCD symptoms and 
treatment response.  
 
Lower perfusion in the right precuneus correlated with reduced levels of 
anxiety in response to sumatriptan challenge in our study. Preliminary evidence has 
previously suggested that the precuneus within the tempero-parietal region may also 
be involved in OCD [36] . This region is richly connected with sub-cortical and frontal 
brain regions to mediate memory processing (spatial working memory), and self 
awareness among a range of other functions [37-39]. In the light of the association 
with the precuneus and fusiform regions in relation to anxiety in our data, we 
speculate that higher levels of anxiety are generally associated with higher regional 
brain perfusion most notably in frontal and temporal cortices. However, the precise 
regional specificity of these changes still needs to be worked out.   
 
In addition to receptor effects accounting for heterogeneity, is the is the 
likelihood that heterogeneity could plausibly reflect different responses in the “resting” 
state to radiopharmaceutical administration. Entry of the investigator to administer 
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 the HMPAO after a period of 30 minutes rest, may have effects on brain activity. 
Variability in the “ability” of participants to rest when instructed to do so has been 
cited as an additional confound of resting brain imaging studies. Also, less anxious 
subjects would probably be less likely to respond with increased activation as they 
use all available recalled information/recognition of investigator to “reassure” 
themselves in the face of a subtle change in their environment [14,31]. Depending on 
the specific symptoms of OCD, it would thus seem reasonable to believe this may 
translate to differential effects on attention, self awareness and memory.  
 
While we recognize that the effects cited above may be significant in 
conventional resting perfusion studies, they would seem to be less of a significant 
factor in the present study for reasons of the design we used. A blinded cross-over 
study design (ie within subjects) counterbalanced for sumatriptan and placebo 
between imaging sessions would seemingly minimize these differences. Thus, the 
heterogeneity in clinical response we see here is more likely to be mediated by the 
impact of underlying differences in core symptoms and response to sumatriptan.  
 
A number of limitations of our study preclude more definitive conclusions 
being drawn from our findings. First, the absence of a clinical response to 
sumatriptan in a proportion of our cohort might reflect relatively low or even 
insignificant effects of sumatriptan in the CNS. Our finding, however is in line with the 
clinical findings of Ho Pian et al [14] where minimal clinical response to sumatriptan 
challenge was reported. The authors speculated that sumatriptan’s low potential to 
cross the blood brain barrier, may have accounted for this lack of effect. While it is 
known that bio-availability and blood brain barrier penetration of sumatriptan is 
generally low [40], there are several sets of data indicating that sumatriptan does 
indeed have central actions. First, centrally mediated effects on growth hormone [14], 
2) our own data on clinical responses in patient subgroups to sumatriptan challenge 
[22] , 3) evidence of disruption of the blood brain barrier (BBB) in OCD with 
consequently higher levels of BBB penetration by sumatriptan [41,42], and 4) the 
demonstration of an overall effect to reduce SPECT rCBF in non-human primates 
[43] all support this notion. These data challenge the argument that no response 
reflects a failure by sumatriptan to cross the blood-brain barrier. In addition, 
sumatriptan also has direct effects on brain tissue by acutely affecting diffusion 
coefficients in the cat brain after intra-peritoneal administration measured with 
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 diffusion weighted magnetic resonance imaging [44]. Further clinical evidence for a 
direct and central action of sumatriptan comes from a small case series in which it 
was chronically administered to patients with severe treatment refractory OCD. 
Moderate OC symptom improvement was demonstrated, and the effect was lost 
when sumatriptan was withdrawn [17].   
 
 Second, the fact that we did not measure peak plasma sumatriptan levels. 
This would have enabled us to control for the effect of differences in drug levels in 
the context of response heterogeneity. While this may have accounted for some of 
the effects, we have already alluded to the equally variable response to treatment in 
OCD for a variety of reasons including genetic determinants that stand aside of 
variability in drug levels [45]. Third, data on allelic status of the 5HT1B receptors in 
our cohort was not collected precluding findings on the impact of allelic variations in 
5HT1B on differential responses to sumatriptan challenge. 
 
 In conclusion, the present study confirms that the 5HT1B auto-receptor 
complex in OCD is variably responsive to acute challenge with OCD. In general, 
brain regional perfusion responses to sumatriptan challenge are seen in brain 
regions implicated in the functional neurocircuitry of OCD. In addition, whole brain 
voxel-wise analysis has enabled us to detect and speculate on the involvement of 
regions outside of this putative circuit that deserve further investigation [32]. Our data 
also suggest that regions likely to mediate aspects of the anxiety response may differ 
from those that are impacted with direct 5HT1B challenge to mediate changes in OC 
symptom severity. Future studies in this area could make further contributions to our 
understanding whether OC dimensions combine with differences in 5HT1B 
autoreceptor alleles to produce clinical heterogeneity in response to sumatriptan.     
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 CHAPTER 4 
 
 
Functional brain changes in response to 
serotonergic treatment across anxiety 
disorders:  Similarities and distinctions 
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 4.1 ABSTRACT  
 
Background 
 Several studies have now examined the effects of selective serotonin reuptake 
inhibitor (SSRI) treatment on brain function in a variety of anxiety disorders 
including obsessive-compulsive disorder (OCD), posttraumatic stress disorder 
(PTSD), and social anxiety disorder (social phobia) (SAD). Regional changes in 
cerebral perfusion following SSRI treatment have been shown for all three 
disorders. The orbitofrontal cortex (OFC) (OCD), caudate (OCD), medial pre-
frontal/cingulate (OCD, SAD, PTSD), temporal (OCD, SAD, PTSD) and, thalamic 
regions (OCD, SAD) are some of those implicated. Some data also suggests that 
higher perfusion pre-treatment in the anterior cingulate (PTSD), OFC, caudate 
(OCD) and, antero-lateral temporal region (SAD) predicts subsequent treatment 
response. This paper further examines the notion of overlap in the neurocircuitry of 
treatment and indeed treatment response across anxiety disorders with SSRI 
treatment.   
 
Methods 
 Single photon emission computed tomography (SPECT) using Tc-99m HMPAO to 
assess brain perfusion was performed on subjects with OCD, PTSD, and SAD 
before and after 8 weeks (SAD) and 12 weeks (OCD and PTSD) treatment with the 
SSRI citalopram.  Statistical parametric mapping (SPM) was used to compare 
scans (pre- vs post-medication, and responders vs non-responders) in the 
combined group of subjects. 
 
Results 
 Citalopram treatment resulted in significant deactivation (p=0.001) for the entire 
group in the superior (t=4.78) and anterior (t=4.04) cingulate, right thalamus 
(t=4.66) and left hippocampus (t=3.96). Deactivation (p=0.001) within the left 
precentral (t=4.26), right mid-frontal (t=4.03), right inferior frontal (t=3.99), left 
prefrontal (3.81) and right precuneus (t= 3.85) was more marked in treatment 
responders.  No pattern of baseline activation distinguished responders from non-
responders to subsequent pharmacotherapy. 
 
Conclusions 
 Although each of the anxiety disorders may be mediated by different 
neurocircuits, there is some overlap in the functional neuro-anatomy of their 
response to SSRI treatment.  The current data are consistent with previous work 
demonstrating the importance of limbic circuits in this spectrum of disorders.  
These play a crucial role in cognitive-affective processing, are innervated by 
serotonergic neurons, and changes in their activity during serotonergic 
pharmacotherapy seem crucial. 
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 4.2 Background 
 
  Significant advances in our understanding of the mediating psychobiology 
and the development of effective treatments for anxiety disorders have been made 
in recent years. Modern brain imaging techniques have proved useful in exposing 
specific albeit overlapping neurocircuitry that underlies individual anxiety disorders 
[1,2]. However, relatively little work has focused on the extent to which the anxiety 
disorders overlap with respect to changes in brain perfusion that accompany 
response to first-line treatment that is after all pharmacologically similar for different 
disorders.  
 
  The selective serotonin reuptake inhibitors (SSRIs) are currently 
recommended as first line medications for most anxiety disorders, including 
obsessive-compulsive disorder (OCD) [3], posttraumatic stress disorder [4] and 
social anxiety disorder [5]. A number of imaging studies have now examined the 
effects of SSRI’s on brain perfusion in individual anxiety disorders. In OCD, 
attenuation of pre-treatment regional activation has been shown to correlate with 
treatment response in the anterolateral orbitofrontal cortex (OFC), caudate 
nucleus, thalamus, and temporal regions [6-11]. Results for studies assessing pre-
treatment cerebral perfusion as a predictor of response, have, however, yielded 
mixed results. In some, an inverse relationship appears to exist with pre-treatment 
regional activation of the OFC [12], anterior cingulate, caudate [6] and subsequent 
responses to treatment. Conversely findings of higher prefrontal, cingulate and 
basal ganglia activation correlating with subsequent treatment response have also 
been reported [13,14]. In OCD co-morbid with depression, substrates of response 
to the SSRI, paroxetine, appear to differ based on pretreatment [15] activation 
patterns as well as changes that accompany treatment response when an SSRI is 
given in identical doses for either of the two conditions separately [16].   
 
  In social anxiety disorder SSRI treatment response accompanies 
attenuation of frontal, anterior and lateral temporal cortex, cingulate, and thalamic 
activity [17,18]. Higher anterior and lateral temporal cortical perfusion at baseline 
correlated with subsequent treatment response in the former study. The latter 
study also demonstrated some overlap of regions demonstrating attenuation of 
activity for both cognitive and pharmacotherapy interventions. 
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  In PTSD, a single study by our group demonstrated medial temporal lobe 
deactivation with treatment irrespective of clinical response and medial prefrontal 
cortex activation correlated with treatment response. In addition, no baseline 
differences distinguished responders and non-responders to subsequent SSRI 
treatment [19]. 
 
  In this present study, we hypothesised firstly, that response to SSRI 
treatment in this combined group of subjects with anxiety disorders (OCD, PTSD, 
SAD) would effect shared changes in rCBF affecting primarily limbic and related 
prefrontal regions and thus suggest some overlap between disorders in the 
mechanism of their response to effective treatment with SSRI’s. Secondly, pre-
treatment differences in regional perfusion would likely differentiate responders to 
subsequent treatment with citalopram across the anxiety disorders.   
 
4.3 Methods 
 
  Subjects 
  Adult subjects with a primary diagnosis of OCD (n=11), PTSD (n=11) or 
SAD (n=15) were recruited from the Anxiety Disorders Clinic of our tertiary 
hospital.  All subjects were interviewed with the Structured Clinical Interview for the 
Diagnosis of Axis-I Disorders [20]  to ascertain diagnosis according to DSM-IV 
criteria. Results for the PTSD group have been reported previously [19].  
 
  Comorbid major depression was an exclusion criterion in the OCD and 
SAD, but not in the PTSD subjects. Nevertheless, in all cases comorbid disorders 
were considered secondary in terms of temporal course, symptom severity, and 
associated distress. Patients previously treated with SSRI’s had been free of 
medication for a minimum of four weeks for fluoxetine and two weeks for other 
SSRI’s. In total 30 (81%) of the group were SSRI naïve. Subjects with other central 
nervous system disorders including previous head injury or epilepsy were 
excluded.  The Institutional Review Board of our University approved the protocol 
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 and all patients gave informed written consent after a full explanation of the 
possible risks and benefits. 
 
  Pharmacotherapy and measures 
  All patients underwent treatment with citalopram, the most selective of the 
currently available selective serotonin reuptake inhibitors (SSRIs).  The duration of 
the trial of treatment was 12 weeks for OCD and PTSD, and 8 weeks for SAD. 
 
  Dosage was initiated at 20mg daily for the first two weeks and then 
maintained at 40mg daily for the remainder of the study.  Measures of symptom 
improvement were made bi-weekly by clinicians using the Clinical Global 
Impressions (CGI) scale [21]. Subjects with a CGI change score of 2 or less post-
treatment were defined as responders, while those with scores greater than 2 were 
defined as non-responders. 
 
  Anxiety symptoms were also rated using disorder specific scales  including 
the Liebowitz Social Anxiety Scale(LSAS) [22], the Yale Brown Obsessive-
Compulsive Scale (YBOCS) [23] and the Clinician Administered Scale for PTSD 
[24].  Depressive symptoms were rated using the Montgomery-Asberg Depression 
Rating Scale (MADRS) [25]. 
 
  SPECT Imaging 
  Single photon emission computed tomography (SPECT) was conducted 
before and after pharmacotherapy.  Subjects lay supine in a quiet dimly lit room for 
30 minutes prior to injection of the radiopharmaceutical.  Apart from administration 
of the injection by a physician, they remained alone in the room during this period. 
Subjects were asked to remain at rest during the 30 minute period and for 10 
minutes after injection of the radiopharmaceutical. 
 
  An injection of 555 MBq (15 mCi) of technetium-99m hexamethylpropylene 
amine oxime (Tc-99m HMPAO) was given into an arm vein through a previously 
placed intravenous cannula.  After completion of the rest period, SPECT imaging of 
the brain was performed, with the subject's head supported by a headrest, using a 
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 dual detector gamma camera (Elscint, Helix, GE Medical Systems, USA) equipped 
with fan beam collimators. 
 
  Data were acquired in the step-and-shoot mode, using a 360 degree 
circular orbit, with the detectors of the gamma camera as close as possible to the 
subject's head.  The height of the imaging table and radius of rotation were noted 
for each subject and the same measurements were used for the follow-up study.  
Data were acquired using a 128 x 128 image matrix in 3 degree steps of 15 
seconds per step. 
 
  Data were reconstructed by filtered backprojection, using a Metz filter 
(power=5, FWHM=14mm) and a zoom factor of 2.29.  The Chang (1978) method 
was used for attenuation correction. Scatter correction was not performed. The 
final reconstructed pixel size was 3.87mm by 3.87mm.  Image files were converted 
from interfile to analyze format using conversion software (Medcon, Erik Nolf, UZ 
Ghent). 
 
  Statistical analyses were conducted on a voxel-by-voxel basis using the 
Statistical Parametric Mapping  (SPM99, Wellcome Department of Cognitive 
Neurology, UK)[26]. The realign function was used to co-register baseline and 
post-treatment SPECT images for each subject and to generate a mean image for 
each subject. Realigned images were then normalised to the Montreal Neurological 
Institute (MNI) standard anatomical space to a value of 50 using proportional 
scaling. For this the transform function from the mean image for each subject to the 
normalised image with 4mm3 voxels using 12 affine transformations and 7x8x7 
non-linear basis functions was used. Standardised images were then smoothed 
using a Gaussian kernel with a FWHM of 12mm3. 
 
  A multi-group study design was performed using 2 groups (responders and 
non-responders) with 2 conditions each (pre- and post-treatment).  Contrasts were 
applied to look for areas of significant change post-treatment compared to pre-
treatment.  Contrasts were also used to search for areas of relative change in 
treatment responders compared to non-responders.  A second design was 
employed to compare the baseline scans of responders to SSRI pharmacotherapy 
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 with those of non-responders.  Contrasts were used to search for regions of 
significant differences on the baseline scans of responders compared to non-
responders. 
   
  In view of a priori knowledge suggesting involvement of the cingulate, 
hippocampus, inferior frontal cortex, and striatum in the anxiety disorders, an 
uncorrected p-value of p<0.001 corresponding to a t value of 3.34, was chosen for 
the analysis of these regions in order to minimize type I errors. Given the relative 
paucity of data in this area, we chose this uncorrected p-value, based on work 
using a similar methodology [19].  In order to minimize type I errors a significance 
level of p<0.05 corrected for Gaussian Random Field Theory was used for the 
remainder of the brain.  A spatial extent threshold of 5 voxels was also used at all 
times.  Masking using a threshold proportional to 0.4 times the mean voxel value 
was used to minimize the analysis of voxels not located in grey matter. 
Furthermore, clusters were ignored if co-registration with a SPECT template 
demonstrated that they were located outside of grey matter. 
 
4.4 Results 
 
  Twenty-two males and fifteen females with a mean age of 33.5 years (SD 
9.8) completed the study. Clinical changes with pharmacotherapy for each disorder 
are provided in Table 4.1 This shows that for each of the anxiety disorders being 
studied, citalopram was effective in significantly reducing clinical measures of 
severity as determined by a CGI change score of 2 or less (much or very much 
improved). As such, 20 of 37 patients (54%) were responders to citalopram. 
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  Baseline Endpoint p 
YBOCS  26.6 ± 4.7 23.7 ± 5.8 0.001 
MADRS 13.64 ± 9.6 9.9 ± 6.4 0.119 
CGI-severity 4.7 ± 0.647 4.18 ± 1.1 0.025 
OCD (n=11) 
CGI-
improvement  3.1 ± 0.7  
LSAS 79.2 ± 30.2 63.1 ± 28.5 0.003 
MADRS 15 ± 4.9 9.1 ± 5.9 0.004 
CG -severity 4.6 ± 0.8 3.3 ± 1.1 0.001 
SAD (n=15) 
CGI-
improvement  2.7± 1.2  
CAPS 78.1 ± 16.9 45.5 ± 23.9 <0.01 
MADRS 25 ± 6.7 15.9 ± 8.0 <0.01 
CGI -severity 4.5 ± 0.5 2.5 ±0.7 <0.01 
PTSD 
(n=11) 
CGI-
improvement  1.9 ± 0.7  
 
Table 4.1: Clinical parameters for all the groups (mean ± SD), (paired t-test) 
Legend: YBOCS, Yale Brow Obsessive-compulsive scale; MADRS, Montgomery Asberg 
Depression Rating scale; CGI-s, Clinical global impressions severity; CGI-I, Clinical global 
impressions – improvement; LSAS, Liebowitz Social Anxiety Scale; CAPS, Clinician 
Administered PTSD scale. 
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   Comparison of pre- and post-treatment scans for the whole group showed 
decreased activity in 4 significant clusters in grey matter (Figure 6.1):  These 
included the superior cingulate, right thalamus, anterior cingulate, and the left 
hippocampus (Table 6.2).  Comparison of pre- and post-medication scans showed 
no significant areas of activation. 
 
 
Cluster size 
(voxels) 
 
t 
 
MNI co-ordinates 
(x,y,z) 
 
Brain region 
44 
19 
10 
7 
4.78 
4.66 
4.04 
3.96 
-4,12,36 
24,-28,12 
0,48,8 
-24,-12,-20 
Superior cingulate 
Right thalamus 
Anterior cingualate 
Left hippocampus 
 
Table 4.2: Localisation of significant clusters of deactivation following treatment for 
the combined group of OCD,SAD, PTSD. Zmax  set to threshold of t=3.34 
corresponding to p<0.001 
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a b 
  
c d 
 
 
 
Figure 4.1: Regions of deactivation for the combined group of OCD + SAD + PTSD 
following treatment with citalopram. Significant grey matter clusters are seen in the 
left superior cingulate (a), right thalamus (b), anterior cingulate (c), left medial 
temporal region (hippocampus) (d).   
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Cluster size 
(voxels) 
 
t 
MNI co-
ordinates 
(x,y,z) 
 
Brain region 
21 
33 
17 
 
5 
18 
4.26 
4.03 
3.99 
 
3.85 
3.81 
-24,-20,56 
12.64,-8 
36,32,-20 
 
8,-48,16 
28,60,-8 
Left precentral 
Right mid-frontal 
Right inferior frontal 
cortex 
Left prefrontal 
Right precuneus 
 
Table 4.3: Clusters in which responders had significantly lower perfusion following 
treatment 
 
 
 
 
  Comparison of responders with non-responders demonstrated that 
responders had a significantly greater decrease of activity in 4 clusters (Figure 
4.2).  These clusters were localised to the left precentral, right middle frontal, right 
inferior frontal and, left prefrontal and right precuneus regions (Table 4.3). 
Comparison of baseline scans of responders and non-responders did not reveal 
any significant differences. 
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a b 
c 
d 
 
Figure 4.2: Regional 
deactivation (responders > non-
responders) in left precentral 
(a), right mid-frontal (b), right 
inferior frontal (c, left prefrontal 
(d), and right precuneus (e) 
 
 
e 
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 4.5 Discussion 
 
  The main finding in this study is that citalopram pharmacotherapy resulted 
in significant deactivation within anterior and superior cingulate cortex, the left 
hippocampus and the right thalamus in a combined group of patients with different 
anxiety disorders (OCD, PTSD, and SAD).  Furthermore, deactivation was 
significantly more apparent in responders than in non-responders to SSRI 
treatment within precentral, right inferior, middle frontal and left prefrontal regions. 
Interestingly, no pre-treatment differences in regional perfusion between 
subsequent treatment responders vs non-responders were found.  
 
 Although there are important differences in the symptomatology of the anxiety 
disorders, these conditions do share certain aspects of their phenomenology, 
including heightened anxiety and avoidance behaviour.  Furthermore, previous 
functional brain imaging work has demonstrated overlapping neurocircuitry across 
different anxiety disorders with activation of paralimbic circuitry and right inferior 
frontal cortex in a combined group comprising subjects with OCD, PTSD, and 
specific phobia [1]. Results in the present study now also point to an overlap in the 
functional neuroanatomy, primarily implicating paralimbic neurocircuitry, in 
treatment response to the same SSRI, citalopram, across anxiety disorders. In 
citalopram responders, effects across disorders were most pronounced in the mid, 
inferior and prefrontal cortex.  In other regions, such as the striatum, data on 
treatment response and symptom provocation seems to indicate less overlap 
across anxiety disorders, which may suggest only partial and regionally specific 
overlap between disorders [1,2]. 
 
 Specific limbic regions are well-known to play a role in broadly mediating anxiety.  
Early observations of epileptogenic cingulate lesions support its role in regulating 
affect [27]. Furthermore, recent work has suggested a role for the anterior cingulate 
in integrating cognitive and motivational processes. These include evaluating 
environmental cues and monitoring performance [28]. On the other hand, a central 
role for the hippocampus in contextual aspects of fear conditioning has been 
demonstrated [29,30]. 
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  The findings here complement previous studies of OCD, PTSD, and SAD that 
have demonstrated a specific role for the cingulate and hippocampus in these 
conditions.  Studies in OCD have shown increased anterior cingulate activity at 
baseline, or deactivation during pharmacotherapy with serotonergic agents [31]. In 
PTSD, anterior cingulate activity is also increased in some, although not all, studies 
of PTSD [32,33].  Further, the anterior cingulate is deactivated during citalopram 
treatment of SAD patients [17].  Dysfunction of the hippocampus, as indicated by 
smaller hippocampal volume and declarative memory deficits, may play an 
important role in PTSD [34]. 
 
 The medial prefrontal cortex comprises several related areas including anterior 
cingulate cortex.  Lesions of this area are associated with suboptimal responses to 
stress, and the area has important inhibitory inputs to the amygdala which mediate 
extinction of fear conditioning [29].  The middle and inferior frontal cortex, on the 
other hand, is involved in encoding and retrieval of verbal memories.  Our finding 
that the right inferior frontal cortex was more deactivated in responders is perhaps 
consistent with previous findings showing increased activity pre-treatment in this 
region across different anxiety disorders [2] and in some, but not all, studies of 
PTSD [35]. 
 
 Serotonergic circuits innervate the medial prefrontal cortex and other limbic 
structures, and chronic administration of a serotonin reuptake inhibitor may lead to 
an increase in their neurotransmission. It is possible that the medial prefrontal 
cortex deactivation during serotonergic pharmacotherapy indicates that a 
compensatory increase of activity in this region is no longer needed after symptom 
improvement.  Along these lines, a number of functional and electrophysiological 
imaging studies of depression have found that anterior cingulate hyperactivity 
predicts a positive response to pharmacotherapy, a finding that has also been 
interpreted as indicating the baseline presence of an adaptive compensatory 
response [36].  In addition changes in cognitive processing of frontal cortex may be 
secondary to symptom reduction caused by primary drug-induced changes within 
the limbic system. We have previously demonstrated similarly higher pre-treatment 
prefrontal perfusion in subsequent responders relative to non-responders using 
inositol in OCD [37]. Interestingly, inositol responsive disorders overlap with those 
responsive to SSRI’s which may suggest that it is serotonergic components of 
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 these disorders that account for at least some of the overlap in perfusion patterns 
demonstrated here. 
 
 In contrast, however, increased activity in anterior cingulate or orbitofrontal 
region in OCD has also been shown to predict a poorer response to 
pharmacotherapy [9]. Perhaps increased activity in particular limbic circuits plays a 
different functional role in different psychiatric disorders. Only limited functional 
imaging studies of pharmacotherapy effects have involved provocation paradigms 
[38] and such differences in design may account for certain inconsistencies across 
studies. Alternatively, it is feasible that different effects in different disorders may 
also help explain inconsistencies. In the current dataset, however, we were unable 
to demonstrate any associations between baseline activity and pharmacotherapy 
response for the combined group. 
 
 This study is limited by the slightly different inclusion criteria (inclusion of 
secondary depression in PTSD group) and pharmacotherapy duration for different 
disorders. While the absence of untreated controls may to some extent limit the 
conclusions we can draw, comparing non-responders to responders we believe 
serves as a reasonable evaluation of changes that result from treatment response. 
The lower spatial resolution of SPECT may be considered a limitation nevertheless 
this study usefully emphasizes the importance of limbic regions (amygdala, 
hippocampus) in mediating anxiety. Furthermore, deactivation within these regions 
as well as richly connected frontal regions following SSRI treatment, particularly in 
responders, is clearly demonstrated.  Further research combining pharmacological 
interventions and functional methodologies, and using tracers tailored to specific 
neurotransmitter receptors, will undoubtedly lead to increased understanding of the 
pathogenesis of the anxiety disorders and the mechanisms of response to 
treatment in the future. 
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 CHAPTER 5 
 
Functional brain perfusion measured with 
single photon emission computed 
tomography (SPECT) in obsessive 
compulsive disorder: Changes in response 
to treatment with Inositol 
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 5.1  Abstract 
 
Background 
  Inositol, a glucose isomer and second messenger precursor, regulates 
numerous cellular functions and has demonstrated efficacy in obsessive-
compulsive disorder (OCD) through mechanisms that remain unclear. The effect of 
inositol treatment on brain function in OCD has not been studied to date. 
 
Methods 
  Fourteen OCD subjects underwent single photon emission computed 
tomography (SPECT) with Tc-99m HMPAO before and after 12 weeks of treatment 
with inositol. Whole brain voxel-wise SPM was used to assess differences in 
perfusion between responders and non-responders before and after treatment as 
well as the effect of treatment for the group as a whole. 
 
Results 
 There was; 1) deactivation in OCD responders relative to non-responders 
following treatment with inositol in the left superior temporal gyrus, middle frontal 
gyrus and precuneus and the right paramedian post-central gyrus, 2) no significant 
regions of deactivation for the group as a whole post treatment, and 3) a single 
cluster of higher perfusion in the left medial prefrontal region in responders 
compared to non-responders at baseline. Significant reductions in the YBOCS and 
CGI – severity scores followed treatment.  
 
Conclusions 
 These data are only partly consistent with previous functional imaging work on 
OCD. They may support the idea that inositol effects a clinical response through 
alternate neuronal circuitry to the SSRI’s and may complement animal work 
proposing an overlapping but distinct mechanism of action. 
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 5.2  Introduction  
 
  Selective serotonin re-uptake inhibitors (SSRI’s) are currently accepted 
first-line therapies for obsessive compulsive disorder (OCD) [1,2]. However 40-
50% of patients fail to respond to a first trial of an SSRI [3]. There is therefore 
strong interest in developing novel pharmacological approaches. Inositol, a single 
isomer of glucose has proved effective in treating obsessive-compulsive disorder 
(OCD) [4] panic disorder [5,6] and depression [7] in small controlled studies. 
Inositol was, however, found to be ineffective as an augmentation strategy to SSRI 
non-responsive OCD [8,9]. In addition, disorders such as premenstrual dysphoric 
disorder [10], schizophrenia [11], autism [12], Alzheimer’s disease [13] and 
attention deficit hyperactivity disorder (ADHD) [14] have not responded to inositol.  
 
 The mechanism of action of inositol remains an interesting question. Previous 
work suggests that the efficacy of inositol is limited to the most SSRI responsive 
disorders [15] with medium to high effect size (ES) of 0.73 [15]. Similarly, effect 
size for inositol (0.97) in OCD seems to indicate at least comparable efficacy to 
SSRI’s (0.69-0.35) [3]. The selective responsivity of OCD to serotonergic 
compounds makes it a useful exemplar for examining the mechanisms of action of 
inositol. Perhaps a common mechanism is able to account for the efficacy of both 
SSRI’s and inositol in this disorder, and may shed more light on the sub-cellular 
neurobiology of the disorder.  
 
 Myo-inositol (MI) serves as a precursor to receptor-activated phosphatidyl 
inositolbisphosphate (PIP2) hydrolysis by phospholipase-C (PLC) [16] that 
produces inositol triphosphate (IP3) and diacylglyserol (DAG). Monoamine ligands 
for postsynaptic receptors, including serotonin, couple with G-proteins and trigger 
post-synaptic signal transduction pathways through activation and synthesis of the 
second messenger, IP3. While this may suggest some overlap in functioning of 
treatments, animal work has demonstrated that phosphoinositides (PI) are also 
involved in regulating the interaction of signalling proteins [17], neurotransmitters 
and membrane receptors [16] some of which suggests a contribution from other 
mechanisms to the action of inositol. 
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  The cortico-striatal-thalamo-cortical (CSTC) functional neuro-circuit is believed to 
be central to the cerebral changes that characterise OCD . Hyperactivity within this 
circuit is attenuated following administration of SSRI’s [18-20]. The use of inositol 
as a treatment strategy in OCD is novel in that most other precursor strategies 
have employed neurotransmitters as precursors. The question arises as to whether 
the clinical efficacy of inositol is reflected in similar patterns of attenuation of 
activation that have been demonstrated with SSRI’s.  
 
 We report on a single photon emission computed tomography (SPECT) study 
undertaken to examine the effects of inositol treatment on regional cerebral 
perfusion before and after treatment in subjects with OCD. We hypothesised that: 
1) attenuation of activation on SPECT in responders would differentiate them from 
non-responders following 12 weeks of treatment with inositol, 2) that attenuation of 
activation from baseline to endpoint would be most pronounced within the CSTC 
functional circuitry known to mediate OCD, 3) lower activation pre-treatment of the 
orbito-frontal cortex would predict poorer treatment response. 
 
5.3  Methods 
 
Subjects 
  Fourteen patients (7 male, 7 female) were recruited from the outpatient 
clinic of our research unit which is attached to a tertiary referral hospital. The 
diagnosis of OCD was made using the Structured Clinical Interview for DSM IV 
(SCID-I) [21]. Subjects were excluded if they met criteria for alcohol/substance 
abuse/dependence currently or in the six months preceding the study. One subject 
had a single previous depressive episode and another subject had a recurrent 
major depressive disorder, neither subject was depressed when the study started. 
All subjects were treatment free having completed adequate washout periods for 
psychotropic medications prior to commencing inositol. Subjects were required to 
provide written informed consent prior to the commencement of any study related 
procedures. The study protocol was approved by the Pharmaceutical Advisory 
Committee of the University of Stellenbosch Institutional Review Board (IRB) 
(Cape Town, South Africa).  
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   Treatment and measures 
  Inositol was administered to subjects as a powder dissolved in water or tea 
in a fixed dose of 18 grams per day in three divided doses for twelve weeks. 
Subjects were assessed at two weekly intervals for efficacy, safety and tolerability. 
Clinical measures were performed at two weekly intervals for the duration of the 
study and included the Yale-Brown-Obsessive-Compulsive Scale (YBOCS) 
[22,23], the Montgomery-Asberg Depression Rating Scale (MADRS) [24] and the 
Clinical Global Impression Scale - severity and improvement (CGI) [25]. The Y-
BOCS was used as the primary outcome measure with treatment response defined 
as a 50% or greater decrease in the YBOCS. Adverse events were also 
documented at the 2-weekly study visits. 
 
  SPECT Acquisition 
  Prior to administering the radiopharmaceutical an intravenous cannula was 
placed in an arm vein and a solution containing 200mg of sodium perchlorate was 
administered orally to minimise uptake of free pertechnetate by the salivary glands. 
Subjects then remained supine with their eyes open in a quiet, dimly lit room for 30 
minutes. At this point 555MBq (15mCi) of technetium-99m hexamethylpropylene 
amine oxime (Tc-99m HMPAO) was injected via the indwelling cannula. Subjects 
remained basal for a further 10-minute period post-injection. SPECT images of the 
brain were acquired with the subject's head supported by a headrest and bandage 
using a dual detector gamma camera (Elscint Helix, General Electric Medical 
Systems, USA) equipped with fanbeam collimators. Acquisition of data was done in 
step-and-shoot mode using a 360 degree circular orbit with the detectors of the 
gamma camera as close as possible to the subject's head. Data was acquired 
using a 128 by 128 matrix with 3 degree steps of 15 seconds per step. For quality 
control raw images were inspected using a cine display to ensure that no subject 
movement had occurred. If patient movement was noted, the imaging was 
repeated. The height of the imaging table and radius of rotation were noted for 
each subject and also used for the post-treatment SPECT study.  
 
  SPECT reconstruction 
  Data was reconstructed by filtered backprojection, using an Xpert 
workstation (General Electric Medical Systems, USA). A Metz filter (power=5, 
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 FWHM=14mm) and a zoom factor of 2.29 were used. The image reconstruction 
matrix was 64 by 64. The Chang method [26] was used for attenuation correction. 
The final reconstructed pixel size was 3.87mm2. Reconstructed images were 
converted from interfile to ANALYZE format using Medcon (Erik Nolf, UZ Ghent, 
Belgium). 
  
 SPECT Pre-processing 
  Spatial pre-processing and statistical analysis of the images was performed 
using Statistical Parametric Mapping (SPM99, Wellcome Department of Cognitive 
Neurology, UK) [27]. The realign function was used to co-register the baseline and 
post therapy SPECT images for each patient.  A single mean image was then 
created from these two realigned images for each patient.  All of the SPECT scans 
were normalised to a standard brain of the Montreal Neurological Institute, using 
the ICBM152 template.  Due to its improved statistical quality, the mean image of 
each patient was first normalised to the standard space. Transformation was 
performed to 4mm3 voxels using 12 affine transformations and 7x8x7 non-linear 
basis functions.  The normalised SPECT images were then smoothed using a 
Gaussian kernel with a FWHM of 12mm3. The intensity of all SPECT scans was 
scaled to a global value of 50.  An analysis threshold of 0.8 was used.  
 
  Statistical analysis 
  Paired t-tests were used to define the mean change scores for the clinical 
measures. Responders were defined using a conservative YBOCS change score 
of greater than or equal to 50% reduction from baseline. Two study designs were 
utilised. The first with two groups (treatment responders and non-responders) and 
two conditions (baseline and post therapy) used contrasts to search for regions of 
deactivation post therapy across all subjects, and to search for regions of 
deactivation that was more marked in treatment responders compared to non-
responders. The second design compared the baseline perfusion of treatment 
responders to that of non-responders using an unpaired t-test. Only clusters 
achieving an uncorrected height threshold of p<0.001 and an extent threshold of at 
least 5 voxels are discussed. 
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 5.4  Results 
  Fourteen subjects with a mean age of 32.4 years (SD 12.3), mean age of 
onset of OCD symptoms of 17.3 years (SD 9.3), and mean illness duration of 14.6 
years (SD12.6) completed the study. The lag time to initial treatment was long 
(mean 10.1 years, SD 12.9). Five patients (35%) in the sample reported having 
had at least one previous trial with an SSRI.  
 
Clinical measures 
  Inositol treatment over twelve weeks yielded a response (YBOCS ≤ 50% of 
baseline score) in 8/14 (57%) of subjects. The overall reduction in the YBOCS 
score for the group as a whole was significant (paired t-test t=5.75, p<0.0001). 
Similarly the CGI-severity scores were significantly different between baseline and 
endpoint (t=6.27, p<0.0001) (Table 5.1). Notably no significant differences were 
found between responders and non-responders with respect to current age, 
duration of illness, gender, lag time to treatment initiation, and previous history of 
treatment. Furthermore no significant differences in clinical measures of illness 
severity (YBOCS, CGI) were noted between responders and non-responders at 
baseline.  
 
 
 
 
 
 
 
 
 
 
 
 
110 
Stellenbosch University  http://scholar.sun.ac.za
  
 
Table 5.1: Clinical measures for group as a whole 
Clinical measure 
Mean 
score 
t (two-tailed)(p value) 
 
YBOCS (Week 0) 
YBOCS (Week 12) 
MADRS (Week 1) 
MADRS (Week 12) 
CGI – severity (Week 1) 
CGI – severity (Week 12) 
 
  
24.5 
13.78 
12.42 
 4.5 
 4.35 
 2.78 
 
 
5.75 (p<0.0001) 
 
3.95 (p<0.001) 
 
2.785 (p<0.0001) 
 
SPECT Imaging 
  In our first design a comparison of baseline and post-treatment SPECT 
scans for the group as a whole demonstrated no statistically significant 
deactivation. Responders however demonstrated significantly greater deactivation 
in a number of clusters compared to non-responders (Fig 5.1). These include 
primarily the left antero-lateral temporal cortex (x=-40, y=12,z=-32), two clusters in 
the antero-lateral prefrontal cortex on the left side (x=-36, y=60,z=8 and x=-24, 
y=40,z=36) and finally two small clusters in the left superior parietal region (x=40, 
y=-20,z=52) and left paramedian occipital cortex (x=-4, y=-60,z=32) (Table 5.2) 
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Cluster 
size 
(voxels) 
Zmax MNI co-ordinates 
(x,y,z) 
Brodmann 
Area 
Brain Region 
25 
 
5 
 
 
11 
 
6 
5 
4.40 
 
3.55 
 
 
4.30 
 
3.65 
3.52 
-24, 40, 36 
 
-36, 60, 8   
 
 
-40, 12,-32 
 
-4,-60,32 
40,-20,52 
9 
 
10 
 
 
38 
 
7 
3 
Left antero–lateral  
 
prefrontal cortex 
(middle frontal gyrus) 
 
Left superior temporal 
gyrus 
Left Parietal (precuneus) 
Right post-central gyrus 
 
Table 5.2: Localisation of significant clusters for deactivation in responders > than 
non-responders after treatment 
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b a
 
c d 
 
e
Figure 5.1: Areas of deactivation in responders compared to non-responders. 
Clusters of significance are noted in the left antero-lateral temporal cortex (a), 
antero-lateral prefrontal cortex (mid-frontal gyrus) (b), left superior temporal region 
(c), left parietal (precuneus), and right post-central gyrus (e) 
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 In our second design, responders demonstrated significantly greater baseline 
activity in the left anterior frontal cortex (superior frontal gyrus) (x=8, y=44, z=48, 
Zmax , 3.67) (Figure 5.2).  
 
 
 
 
Figure 5.2: Baseline perfusion showing significantly greater perfusion in the left 
anterior superior frontal gyrus region for responders compared to non-responders 
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 Safety and tolerability 
  Inositol was generally well tolerated. All patients enrolled completed the 12 
week study. No serious adverse events were reported. Side-effects were generally 
mild and resolved within two weeks of initiation of treatment (Table 5.3). 
 
 
 
Side-effect N (%) 
Diarrhoea  
Flatulence  
Bloating 
Nausea 
Abdominal cramps 
Fatigue/Lethargy 
Dizziness 
Headache 
Increased appetite 
8 (57%) 
5 (36%) 
4 (28.5%) 
3 (21%) 
2 (14%) 
2 (14%) 
2 (14%) 
1 (7%) 
1 (7%) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3:  Side-effects reported for entire cohort 
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 5.5  Discussion 
 
 In summary we report: 1) deactivation in OCD responders relative to non-
responders following treatment with inositol in the left antero-lateral temporal cortex 
(superior temporal gyrus), antero-lateral prefrontal cortex (middle frontal gyrus), left 
superior parietal cortex (precuneus) and right paramedian post-central gyrus, 2) no 
significant regions of deactivation for the group as a whole post treatment, and 3) a 
single cluster of higher perfusion in the left medial prefrontal region in responders 
compared to non-responders at baseline. To our knowledge this is the first study to 
assess the effects of inositol treatment on brain perfusion SPECT in OCD and 
findings are preliminary, but interesting. 
 
 The cortico-striatal-thalamic cortical (CSTC) functional loop is now widely 
accepted to mediate the symptoms of OCD [18]. Within this loop regions most 
consistently activated at rest and accentuated on symptom provocation, include the 
orbitofrontal cortex, anterior cingulate cortex and the sub-cortical caudate nucleus. 
In addition attenuation of activation in similar regions follows effective treatment 
with fluoxetine [28], clomipramine [29], paroxetine [30], and behaviour therapy 
[31,32]. This suggests that response specific patterns are likely in disorders 
irrespective of treatment type.  
 
 We hypothesised that inositol would be similar to SSRI’s in attenuating 
activation in regions specific to OCD incorporating the CSTC circuit. The apparent 
deactivation in the anterior dorsolateral prefrontal cortex (middle frontal gyrus) and 
the antero-lateral temporal cortex (superior temporal gyrus) in treatment 
responders, may, however, suggest that inositol has a different mechanism of 
action and ultimately affect different neuronal circuits to SSRI’s in effecting a 
clinical response in OCD.  
 
 The findings are not completely inconsistent with previous work. The frontal 
cortex has been associated with OCD [33] and more recently implicated in 
mediating specific symptom dimensions [34] and neuropsychological dysfunction 
[35]. In addition a recent study using MR spectroscopy [36] in children with OCD 
found evidence for N-acetyl-aspartate increases in the DLPFC of subjects, 
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 suggesting neuronal hypertrophy/hyperplasia possibly indicative of abnormal 
development and or neuronal pruning in children with OCD. Similarly the temporal 
lobe has previously been implicated in OCD [37,38]. Furthermore, animal work has 
shown that temporal structures play an important role in anxiety, and that inositol is 
anxiolytic [39]. The precuneus of the parietal lobe, in which our data demonstrates 
attenuation of regional perfusion following treatment response, has also been 
implicated in OCD with regional activation appearing to correlate with symptom 
severity [35,40] . 
 
 Demand for inositol and substrates amenable to its effects are widespread in 
the brain. Our data demonstrate a pattern of brain perfusion following a clinical 
response to inositol that is different from that of SSRI’s and apparently links 
regions that have been previously implicated in OCD. As such it is conceivable that 
specific neuronal circuitry may mediate the clinical response to inositol that 
incorporates the prefrontal cortex, the superior temporal, gyrus and the precuneus 
of the parietal lobe. Furthermore, our data found no significant effect of treatment 
alone on brain perfusion SPECT for the group as a whole. 
 
 The current data demonstrate a small cluster in the anterior medial prefrontal 
cortex with significantly higher perfusion pre-treatment correlating with subsequent 
treatment response in OCD. Saxena et al [41] recently demonstrated disorder 
related changes in activation in response to SSRI treatment. Relationships have 
been found between pre-treatment regional brain activation and subsequent 
response to SSRI’s ([42] 2002) and behaviour therapy [43]. However, the direction 
and localisation of the change is neither consistent between studies nor treatment 
types within the same disorder. This may lend support to the idea that the neuronal 
circuitry involved in response may differ between treatments. In this regard, we 
have recently found that inositol acts by decreasing the receptor signaling capacity 
through G proteins, and is thus able to modify serotonergic 5HT2a and muscarinic 
receptor signaling ([44]. Since cholinergic dysfunction has been described in 
anxiety states [45,46], this may represent a novel site of action for inositol. 
Moreover, that this property was shared by fluoxetine, but not imipramine, possibly 
explains why inositol is effective exclusively in SSRI sensitive disorders. Further 
exploration of the value of functional brain imaging to predict response to treatment 
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 is necessary and may in future allow tailoring of treatment options to particular 
patients.  
 
 Our present study may have been limited by the high (10.72 or 44%, p<0.0001) 
mean change in YBOCS score for the whole group coupled with the small sample 
size to reduce the power to detect additional group differences. Furthermore the 
inclusion of a control group treated with an SSRI would have served to strengthen 
the debate on the differential effects of disparate, but effective treatment options in 
OCD [43]. 
 
5.6  Conclusions 
 
 We have demonstrated reduced brain SPECT perfusion in the prefrontal 
cortex, the temporal lobe, and the parietal cortex correlating with clinical response 
to inositol. Furthermore, higher medial prefrontal activation correlated with 
subsequent treatment response. While this data implicate less well studied regions 
in OCD, all have been previously implicated in the disorder. As such this data may 
support the idea that inositol effects a clinical response through different neuronal 
circuitry to the SSRI’s and may complement animal work that suggests an 
overlapping but distinct mechanism of action. Despite a number of small controlled 
studies supporting the clinical utility of inositol, it deserves further evaluation.  
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 CHAPTER 6 
 
 
Treatment effects of combined dopamine 
and serotonin receptor blockade in 
obsessive-compulsive disorder 
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 6.1 ABSTRACT 
Background 
Although serotonin reuptake inhibitors are effective in the treatment of 
OCD, many patients fail to respond to these agents.  Growing evidence from open-
label and placebo-controlled trials suggests a role for augmentation of SRIs with 
atypical antipsychotics in OCD. Quetiapine is generally well tolerated and previous 
open-label data has produced mixed results in OCD and additional controlled data 
is needed.  
 
Methods 
We undertook a double-blind, randomised, parallel-group, flexible-dose, 
placebo-controlled study of quetiapine augmentation in subjects who had 
responded inadequately to open-label treatment with an SRI for 12 weeks. 
Following informed consent and screening, forty-two subjects were randomised to 
either placebo or quetiapine for six weeks.  
 
Results 
There was significant improvement from baseline to endpoint on the Yale-
Brown Obsessive-Compulsive Scale in both the quetiapine and placebo groups 
(quetiapine, n=20, p<0.0001; placebo, n=21, p=0.001) with 40% (n=8) of 
quetiapine and 47.6% (n=10) of placebo treated subjects being classified as 
responders. Quetiapine did not demonstrate a significant benefit over placebo at 
the end of the six-week treatment period (p=.636). Similarly quetiapine failed to 
separate from placebo in the subgroup of subjects (n=10) with co-morbid tics. 
Quetiapine was generally well tolerated. 
 
Conclusions 
In this study, quetiapine augmentation was no more effective than placebo 
augmentation of SRIs. A number of limitations in study design make comparisons 
with previous studies in this area difficult and probably contributed to our negative 
findings. Future work in this important clinical area should address these 
limitations. 
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 6.2 Background  
 
 Obsessive-compulsive disorder (OCD) is a prevalent, chronic and disabling 
disorder [1]. Controlled pharmacotherapy studies have established superiority of 
serotonin re-uptake inhibitors (SRI’s) over noradrenaline reuptake inhibitors and 
over placebo in OCD and these currently form the cornerstone of pharmacotherapy 
management [2]. Despite the considerable advances made with the introduction of 
the SRI’s into clinical practice, 40-60% of subjects still fail to respond adequately to 
initial therapy [3,4]. 
 
 From this it is clear that a need exists to pursue more effective treatments 
for those with OCD who fail to respond or respond inadequately to SRI’s. To this 
end, preliminary evidence supports a role for the addition of atypical antipsychotics 
to SRIs in OCD. These agents combine serotonin-dopamine antagonism with the 
advantage of being well tolerated including a low potential for inducing motor side-
effects.  
 
 To date a number of open-label studies have suggested that augmenting 
SRI’s with atypical antipsychotics is an effective strategy for treatment-refractory 
OCD. These include support for risperidone [5-7], olanzapine [8-13], and more 
recently amisulpride [14] and quetiapine [15-18]. A single open-label study using 
quetiapine as augmentation showed lack of effect in a small sample using low 
doses [19].  
 
 The outcome of the first controlled study in this area with the antipsychotic 
haloperidol demonstrated preferential benefit for refractory OCD subjects with co-
morbid tic disorder [20]. In two subsequent studies the efficacy of risperidone in 
SRI refractory OCD has also been reported [21,22]. Interestingly the former study 
[21], did not replicate the particular advantage for subjects with co-morbid tic 
disorder. Efficacy has also been shown for quetiapine [23] and olanzapine [24] 
using similar designs, but the effects on co-morbid tic disorders were not reported. 
In contrast a recent controlled study using olanzapine failed to demonstrate 
efficacy over placebo in a six week study [25].  
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  Despite some mixed evidence in this area, in general the available literature 
appears to support the use of relatively short trials with low doses of antipsychotic 
agents as augmentation to SRIs. Quetiapine has a particularly interesting profile in 
that it is the only available antipsychotic with significant 5-HT1D effects and this 
serotonin receptor subtype has been implicated in OCD [26,27]. 
 
Our objective was to examine the effects of quetiapine augmentation in 
subjects with OCD who had failed to respond adequately to a 12 week trial of an 
SRI, employing a double-blind, placebo-controlled, six week study design. 
 
6.3 METHODS 
 
 Patients 
 Forty two subjects aged 18-65 years inclusive were recruited in our multi-
centre study comprising five sites in South Africa and one in Canada. Recruitment 
took place between May 2002 and November 2003. Prior to commencement, all 
sites in the study received approval from their relevant Research Ethics 
committees/Institutional review boards and regulatory authorities. All subjects 
provided written informed consent prior to the commencement of any study-related 
procedures. Diagnosis was confirmed using the MINI Neuropsychiatric Interview 
(Version 5.00, 1998) [28] to ensure compatibility with the Diagnostic and Statistical 
Manual for Mental Disorders, Fourth Edition (DSM-IVTR)[29] criteria for OCD. 
Subjects with any co-existing Axis I disorder were excluded unless the co-morbid 
condition was deemed to be secondary to the OCD. Female subjects of 
childbearing potential were required to use adequate contraception and were not 
permitted to breastfeed while on the study. Subjects were excluded if they suffered 
from unstable medical conditions including renal or hepatic insufficiency, epilepsy 
or had suffered previous brain injury or undergone brain surgery. Taking 
medication that was deemed likely to interact with quetiapine or any other 
psychoactive substance was grounds for exclusion.  
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  Study Design 
 All subjects were treated and monitored by investigators for the minimum 
twelve week duration of SRI-alone treatment phase before inclusion into this study. 
This was to ensure that patients met criteria for duration of SRI treatment which 
included at least 6 weeks on the maximum tolerated dose of the relevant SRI. 
Sample size calculations were based conservatively on similar work in this area 
[20,21]. Accordingly, for the primary outcome variable (YBOCS), clinically 
meaningful differences between treatment groups of 6.67 with a standard deviation 
(SD) of 6 would be detected with a power of 80% at a 5% significance level with a 
sample size of 14 in each of the treatment groups. The larger sample recruited 
reflects the anticipation of a 33% drop-out rate in the double-blind treatment phase.  
 
 A double-blind, randomised, parallel-group six-week augmentation with 
quetiapine or matching placebo of the SRI to which participants had not responded 
adequately, was undertaken. Specific SRI’s, mean doses and dose range are 
provided in Table 1. Non-responsiveness to an SRI was defined as either an 
improvement score on the clinical global impression scale of minimally improved 
(3) or worse (4,5,6), or less than 25% reduction in Yale Brown Obsessive-
compulsive score following twelve weeks of treatment. Inadequate response, as 
defined above, to at least one SRI administered for a minimum of 12 weeks of 
which 6 weeks was either at the maximum tolerated dose or alternatively the 
manufacturer’s recommended maximum daily dose. SRI doses were maintained at 
the same level throughout the double-blind treatment phase. For assignment to 
either quetiapine or placebo groups, we used a computer generated randomization 
schedule supplied by the sponsoring pharmaceutical company which also 
packaged the medication. This procedure ensured blinded, balanced allocation to 
each treatment group across all the study sites. All investigators remained blind to 
this schedule until closure of the study. No incidents requiring investigators to 
break the blind occurred through the course of the study.  
 
 Treatment 
 At baseline participants were randomly allocated to receive treatment with 
either quetiapine or placebo using a computer generated schedule and numbered 
dispensing wallets. A flexible dosing schedule was initiated at 25mg per day for 
one week and then doubled weekly to the start of week 4. Based on Clinical Global 
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 Impression of Improvement (CGI-I) scores of minimally improved or worse, 
clinicians were permitted to increase the dose to a maximum of 300mg per day for 
the final two weeks of the study. In addition to clinical measures of improvement, 
clinicians also considered patient tolerability in their decision to adjust doses. 
Following completion of the treatment phase, subjects were withdrawn from study 
medication while continuing their SRIs. All subjects were then followed up for any 
adverse effects.  
 
 Ratings 
 Patients were assessed by clinicians at baseline and on completion of 
weeks 2, 4 and 6. Telephonic assessments were performed on completion of 
weeks 1 and 3. Symptoms of obsessive-compulsive disorder were measured by 
the same clinician where possible at all study visits using the Yale Brown 
Obsessive Compulsive Scale YBOCS) [30,31]. A global assessment of severity 
and improvement was made by clinicians at all assessment points using the 
Clinical Global Impressions scale of Severity (CGI-S) and Improvement (CGI-I) 
[32]. Depression was rated using the 10-item Montgomery-Asberg Depression 
rating scale (MADRS) [33]. For a measure of patient-rated disability we used the 
Sheehan Disability scale (SDS) [34]. For subjects with tics, frequency and severity 
were rated using the Yale Global Tic Severity Scale (YGTSS) [35].  
 
 Our primary outcome measures for OCD symptoms were (1) the change in 
YBOCS score from baseline to endpoint and (2) the clinical global impression of 
improvement (CGI–I) at endpoint. In the final analysis, treatment response was 
defined as a 25% or greater reduction in YBOCS score and a CGI-I of 1 (very 
much improved) or 2 (much improved) from baseline to endpoint. Secondary 
outcome measures included the MADRS, SDS and YGTSS (in subjects with co-
morbid tics). 
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 Statistical analysis 
 Thirty-nine of the forty-two randomised subjects successfully completed the 
six-week treatment phase. Two subjects withdrew from the study prematurely 
(Week 1 and Week 4) due to severe levels of sedation. In both of these cases at 
least one week of study medication had been taken and at least one post-baseline 
clinical assessment was completed. Both of these subjects were included in the 
final analysis using data from the last observation carried forward (LOCF). The 
single subject not included in the efficacy analysis completed the study, but was 
found not to have correctly fulfilled the study definition of treatment refractoriness 
and was excluded. Twenty subjects were allocated to the quetiapine arm and 
twenty-one to the placebo arm. Student’s t-tests were used to determine any 
baseline differences in the groups for age, gender, number of previous trials of 
SSRI’s, severity of symptoms in relation to OCD, depressive symptoms, and CGI-
S. Analysis of variance was undertaken with group and tics as factors. All tests 
were two-tailed with p-values of less than 0.05 considered significant. 
 
6.4 Results 
 
 Study sample characteristics 
 For the final analysis, our sample comprised 19 men and 22 women. 
Baseline characteristics of two treatment groups did not differ with respect to age 
(years) (quetiapine group 33.8(SD 9.66), placebo group 31.81 (SD 12.14); p=0.57), 
gender (p=0.29), number of previous adequate SRI trials (quetiapine 1.55 (SD 1), 
placebo 1.62 (SD 1.02) (p=0.83), baseline severity of OCD (CGI-severity, p=0.47; 
YBOCS, p=0.33), depressive symptoms (p=0.91), patient-rated disability (p=0.28) 
or the presence  (n=11, p=0.66) and severity (p=0.87) of co-morbid tics.  
  
 Treatment outcomes 
 For the primary outcome measure of severity (YBOCS), quetiapine 
(p<0.0001) and placebo (p=0.001) augmentation of an SRI significantly improved 
symptoms of OCD. However quetiapine did not demonstrate significant benefit 
over placebo at the end of the six-week treatment period (F=.19; p=.636) (Figure 
2.1).  
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Figure 6.1 - YBOCS change for treatment groups 
  
 The mean reduction in YBOCS scores for the combined group was 7.15 
points (quetiapine = 7.10; placebo 7.19). Forty percent (n=8/20) of subjects on 
quetiapine were classified as responders (YBOCS reduction of >25% from 
baseline and CGI-improvement score of 1 or 2) while 47.6% (n=10/21) of subjects 
on placebo were classified as responders. A higher number of previous SRI trials 
for the each treatment group did not correlate with the degree of change on the 
YBOCS or the response status. Table 6.1 provides details of individual subject SRI 
doses, baseline clinical severity ratings and response status.  Table 6.2 provides a 
summary of baseline and change scores for each of the primary and secondary 
outcome variables.  
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Treatment 
Group 
 SRI baseline SRI Dose
baseline 
(mg/day) 
Prev 
SRI 
trials
Total  
YBOCS 
Baseline
Total 
YBOCS 
Week 6 
Endpoint 
dose 
(mg/day) 
% 
CHANGE 
CGI –  
Improve-
ment 
Response 
status 
 
Quetiapine 1 Paroxetine 60 1 33 29 50 -12.00 3 N/R 
 2 Citalopram 60 2 25 23 200 -8.00 4 N/R 
 3 Fluvoxamine 300 1 32 27 300 -16.00 3 N/R 
 4 Citalopram 70 1 27 25 25 (E/W)* -7.00 4 N/R 
 5 Clomipramine 250 2 22 27 100 23.00 5 N/R 
 6 Paroxetine 60 5 35 32 300 -9.00 4 N/R 
 7 Fluoxetine 80 3 25 16 300 -36.00 2 R 
 8 Sertraline 200 1 18 3 50 -83.00 1 R 
 9 Fluoxetine 20 1 21 20 300 -5.00 4 N/R 
 10 Fluoxetine 60 1 22 17 300 -23.00 2 N/R 
 11 Citalopram 60 1 32 17 300 -47.00 1 R 
 12 Fluoxetine 80 1 32 14 300 -56.00 1 R 
 13 Fluvoxamine 300 1 30 12 50 -60.00 1 R 
 14 Fluoxetine 60 1 25 7 50 -72.00 1 R 
 15 Citalopram 60 1 27 24 200 -11.00 4 N/R 
 16 Fluvoxamine 300 1 24 12 150 -50.00 2 R 
 17 Fluvoxamine 200 2 22 22 50 .00 4 N/R 
 18 Fluvoxamine 300 2 25 22 25 -12.00 4 N/R 
 19 Fluoxetine 60 2 24 25 25 (E/W)* 4.00 4 N/R 
 20 Clomipramine 250 2 27 12 300 -56.00 2 R 
           
Placebo  1 Fluvoxamine 300 2 32 25 300 -22.00 3 N/R 
 2 Fluvoxamine 300 1 30 28 300 -7.00 3 N/R 
 3 Fluoxetine 80 2 34 38 300 12.00 4 N/R 
 4 Paroxetine 60 1 22 18 300 -18.00 1 N/R 
 5 Citalopram 60 1 28 26 300 -7.00 4 N/R 
 6 Fluoxetine 60 5 26 24 300 -8.00 3 N/R 
 7 Fluoxetine 60 1 23 23 300 .00 4 N/R 
 8 Fluoxetine 60 1 27 10 300 -63.00 1 R 
 9 Fluoxetine 40 1 32 18 300 -44.00 2 R 
 10 Citalopram 60 2 24 23 300 -4.00 4 N/R 
 11 Citalopram 60 1 35 23 300 -34.00 2 R 
 12 Fluvoxamine 300 3 22 14 300 -36.00 2 R 
 13 Citalopram 60 1 28 10 50 -65.00 2 R 
 14 Fluoxetine 60 1 28 4 50 -86.00 2 R 
 15 Citalopram 60 1 26 19 100 -27.00 2 R 
 16 Fluoxetine 60 1 27 12 100 -56.00 1 R 
 17 Fluoxetine 20 1 26 18 200 -31.00 2 R 
 18 Fluvoxamine 300 2 23 35 200 52.00 6 N/R 
 19 Citalopram 60 2 26 9 100 -65.00 2 R 
 20 Paroxetine 80 1 32 29 300 -9.00 3 N/R 
 21 Fluvoxamine 300 3 31 25 100 -19.00 2 N/R 
Table 6.1: Baseline characteristics of treatment groups  
*E/W = Early withdrawal 
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Quetiapine                              Placebo 
YBOCS (baseline) 
YBOCS (change at week 6) 
YBOCS % change 
 
CGI-Severity (baseline) 
CGI-Severity (week 6) 
 
MADRS (baseline) 
MADRS (change at week 6) 
 
SDS (baseline) 
SDS (change at week 6) 
 
YGTSS (baseline) 
YGTSS (change at week 6) 
YGTSS % change 
26.4 (SD4.6) 
-7.1(SD7.2) 
-26.9% 
 
5.2 (SD0.8) 
4.1 (SD1.4) 
 
10.6 (SD 4.8) 
-2.6 (SD 6.5) 
 
17.9 (SD 5.3) 
-5.3(SD5.6) 
 
24.7 (SD 19.3) 
-4.5( SD 5.1) 
-18.2% 
27.7(SD3.9) 
-7.2( SD8.4) 
-26% 
 
5.3 (SD0.8) 
4.1(SD1.5) 
 
10.71 (SD 9.8) 
-3 (SD 8.3) 
 
19.6(SD4.7) 
-6.1 (SD4.8) 
 
22.6(SD 22.3) 
-9.4 (SD 14.6) 
-41.6% 
Table 6.2 - Summary scores (baseline) and change scores for primary and 
secondary outcome variables. 
 
 Of the 11 subjects with co-morbid tics, six were randomised to quetiapine. 
Endpoint data was missing for one subject on quetiapine. Of the remaining 10 
subjects, 3 (quetiapine n=2 (33%); placebo n=1(20%)) were classified as YBOCS 
responders. The reduction in the YGTSS did not differ significantly between 
treatment groups with tics (quetiapine -4.5, placebo -9.4; F=2.8, p=.46). 
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  Severity ratings for depressive symptoms (MADRS) were low at baseline 
(mean 10.6, SD 4.8), showed little change over the study period, and at week 6 
remained similar for both groups (quetiapine = 8.2, SD 4.8; placebo = 7.7, SD 6.1). 
 
 The mean daily dose at week 6 for the quetiapine group was 168.75mg (SD 
120.82) compared to 228.57mg (SD 99.46) per day for those on placebo. 
Quetiapine responders  (187.5mg, SD 124.6) did not differ significantly from 
quetiapine non-responders (156.25mg, SD 122.1) in their mean daily dose at Week 
6 (p=.585). Furthermore, within the quetiapine group, participants receiving 
≥200mg/day (10/20 at week 6 demonstrated non-significant differences (F=6.837, 
p=.988) and a marginally lower percentage reduction in YBOCS at endpoint 
(26.7%, SD 20.34) compared to those receiving a dose ≤200mg/day (26.9%, SD 
36.24) at endpoint.  
 
 Tolerability  
 Quetiapine was generally well tolerated and no serious adverse events 
(SAE’s) were reported through the course of the study period. Two patients on 
quetiapine withdrew from the study due to severe sedation (Week 1 and Week 4) 
that was judged to be drug related. Otherwise adverse events were in the mild to 
moderate range and were mostly self-limiting. No subjects on placebo withdrew 
from the study. Table 6.3 provides a list of the adverse events and their 
frequencies in the respective study groups. 
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Adverse event Quetiapine (%, n) Placebo (%, n) 
Sedation 
Dry mouth 
Headache 
Fatigue 
Irritability 
Impaired concentration 
Dizziness 
Nausea 
Increased appetite 
Delayed ejaculation 
Weight gain 
Worsening mood 
Memory difficulties 
Muscle aches 
Abdominal tenderness 
Slurred speech 
75% (15) 
15% (3) 
15% (3) 
15% (3) 
10% (2) 
10% (2) 
5% (1) 
5% (1) 
5% (1) 
5% (1) 
5% (1) 
5%(1) 
5%(1) 
5%(1) 
5%(1) 
5%(1) 
33.3%(7) 
0 
38% (8) 
19% (4) 
4.7% (1) 
0 
14.3% (3) 
9.5% (2) 
9.5% (2) 
0 
0 
4.7%(1) 
0 
0 
0 
0 
 
Table 6.3: Percentage of subjects for each treatment group reporting 
adverse events 
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 6.5 Discussion 
 
 Our findings indicate that both quetiapine and placebo significantly reduced 
symptoms in subjects with OCD who had failed to respond adequately to 12 weeks 
of an SSRI and, that the difference between groups was not significant. Similarly in 
the subgroup with co-morbid tics, no preferential benefit was noted for quetiapine. 
Interestingly, the high placebo response was similar to that seen in a recent failed 
controlled trial of olanzapine [25], but stands in contrast to the positive studies in 
this area in which low placebo response rates were seen when demonstrating 
efficacy of quetiapine [23], risperidone [21], and olanzapine [24]. It is likely that 
features of study design or specific study population characteristics may have 
contributed to this finding and these are discussed below.  
 
 First, the duration of a therapeutic trial of an SRI prior to augmentation with 
an antipsychotic should be of adequate dose and duration. In our study the 
majority of participants had failed only the single trial of an SRI on which they 
continued during the study (63.4% mean 1.59). Notably only six weeks of this 
treatment was required at the maximum tolerated dose. Despite the notion that an 
optimum trial of pharmacotherapy in OCD is 12 weeks, it may be argued that 
higher and ultimately effective doses of an SRI had not been maintained for an 
optimum duration prior to randomization. Given that therapeutic doses of SRIs in 
OCD are usually on the upper end of the dose range, it seems feasible that the 
high placebo response rate may reflect a response to SRI’s once they had been 
administered at these higher doses for the additional six weeks of the study. It 
seems possible that the recent study by Shapira et al [25] may have been 
impacted by similar factors.  
 
 In a second and related point; the number of previous SRI trials in the 
subgroup receiving quetiapine did not predict a poorer response to treatment. This 
effect is probably related to the lack of statistical power to detect these differences 
in a group in which the low number of previous SRI trials was a distinguishing 
characteristic. Certainly, previous positive studies in this area have used relatively 
more refractory groups based on the number of previously failed SRI trials. Taken 
together with the first point above, we suggest that future work in this area should 
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 consider longer periods at maximum tolerated doses of SRI’s prior to 
categorisation of subjects as treatment refractory. 
 
 Third, the use of a slow up-titration resulted in a relatively low mean daily 
dose being administered for the majority of the study. For instance, a mean daily 
(week 6) dose of 168mg/day in the quetiapine group (median 175 mg) had only 
been achieved for the final two weeks of the study. These doses are comparably 
low to those used in the negative single-blind study using low dose quetiapine by 
Sevincok et al [19]. In contrast the positive study using quetiapine by Denys et al 
[23] employed a more rapid up-titration and a fixed-dose design. This meant that 
subjects were exposed to 200mg daily doses that were generally well tolerated, 
from the start of week 3. The authors of this study were able to show significant 
YBOCS differences between groups from the end of week 4. Similarly Mc Dougle 
et al [21], using risperidone, began treatment on 1mg per day for one week and 
permitted weekly 1mg incremental increases for 6 weeks. They found that by the 
beginning of week 2, most subjects were on or around the mean daily dose for 
treatment responders (2.2mg). Despite the significant improvement in the 
quetiapine group demonstrated in our study, the apparent lack of benefit of doses 
higher than 200mg per day may seem surprising, however, we cannot rule out the 
possibility that administering these higher doses for an adequate duration would 
have changed the outcome. In addition it must be noted that in our study the 
quetiapine group reported high rates of sedation (n=15, 75%) and a 10% (n=2) rate 
of premature withdrawal was experienced. As such it seems likely that a more 
aggressive up-titration schedule might have resulted in even higher rates of 
withdrawal. By comparison, rates of sedation were equally high, but did not appear 
to restrict use of the more rapid up-titration in the study by Denys et al [23]. 
Certainly  evidence of efficacy using lower doses has been demonstrated in 
studies of 6 and 8 weeks duration [21,23,24], and it seems that therapeutically 
adequate doses should probably be reached earlier than week 4 in a 6 week study.  
 
 Fourth, the impact of repeated clinical assessments and rating of relatively 
small changes in clinical severity combined with regular dose increases, may 
conceivably have increased the placebo response rates resulting from increased 
optimism, a tendency to over-report improvements and belief that higher doses are 
more likely to be more effective than lower doses. This may be particularly true for 
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 the placebo-treated group that were considerably less likely to report sedation as 
an adverse event and as such were more likely to have their treatment dose 
increased at each visit. Our results differ, with respect to placebo response, from a 
considerable literature that suggests a consistently lower placebo response rate in 
treatment trials in OCD than in other mood and anxiety disorders. While we believe 
that the reasons (1-3) discussed above probably provide the main reasons for our 
finding, the impact of repeated assessments and the potential effect thereof cannot 
be entirely discounted.  
 
6.6 Conclusions 
 
 Despite significant improvement in each of the study groups, response to 
quetiapine augmentation in SRI non-responders, failed to separate from placebo 
treated subjects at the end of the six week treatment phase. A number of 
limitations in study design make comparisons with previous studies in this area 
difficult and probably contributed to our negative findings. Future work in this 
important clinical area should address these limitations.  
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 CHAPTER 7 
 
 
Clinical and demographic determinants of 
response to treatment with combined 
dopamine and serotonin receptor blockade 
in obsessive-compulsive disorder. 
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 7.1 Abstract   
Background 
 Treatment response to serotonin re-uptake inhibitors (SRIs) in OCD remains 
unsatisfactory in a high proportion of patients. Recent meta-analyses have 
demonstrated a benefit for the addition of quetiapine to SRIs in treatment refractory 
obsessive-compulsive disorder (OCD). Numerous studies have investigated a range 
of clinical and demographic variables that may predict response to SRI treatment, but 
fewer data are available on the predictors of response in this context. We aimed to 
delineate predictors of response to quetiapine augmentation in refractory OCD.   
 
Methods 
Data for 80 subjects was combined from two previously published placebo-
controlled augmentation studies. In both studies, quetiapine augmentation followed 
inadequate response to a minimum of 12 weeks SRI treatment.  We combined data 
derived from the Yale-Brown Obsessive-Compulsive Scale (YBOCS) checklist with a 
variety of clinical and demographic variables previously shown to predict treatment 
outcome in OCD. We then derived a model to best predict treatment outcome using 
best-subset logistic regression. Clinical and demographic variables were measured 
against YBOCS change and YBOCS endpoint scores as dependent variables for 
outcome.   
 
Results 
 In univariate analyses, a lower number of previous SRI treatment trials was 
associated with YBOCS response. In our model, 45% of the variance for better 
treatment response (YBOCS change) was explained by subjects having failed fewer 
previous SRI treatments, and having higher baseline obsession scores as well as 
ordering and arranging compulsions. In a separate analysis using YBOCS endpoint 
scores we found a lower number of previous SRI trials, higher baseline compulsion 
scores, counting/ordering and arranging compulsions together predicted 50% of the 
variance in treatment outcome.    
 
Conclusions 
Despite the relatively small sample size, the data here provide a number of 
preliminary predictors of clinical response to quetiapine augmentation of SRIs in 
treatment refractory OCD.  These include fewer previously failed SRI trials and 
generally higher overall baseline scores for obsessions and compulsions as well as 
ordering, arranging, and counting compulsions. Together the predictive value of 
these data suggest that other as yet unidentified factors may also contribute to 
predicting treatment outcome to augmentation with antipsychotics in treatment 
refractory OCD.  
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 7.2 Background 
 
Obsessive-compulsive disorders are not only highly prevalent [1,2], but are 
considered one of the most disabling of all medical illnesses [3]. The introduction of 
compounds with selective serotonergic reuptake inhibition represented a major step 
forward in the treatment of obsessive-compulsive disorder (OCD), up to 40% of 
patients still fail to respond adequately to this first-line strategy [4,5]. A further 
sizeable proportion retain significant symptoms even after switching to alternative 
drug treatments [6,7]. The ensuing chronicity contributes to the disease burden of 
OCD so that patients and physicians perceive a need for more effective and better 
tolerated alternatives to the serotonin re-uptake inhibitors (SRIs). 
  
To this end, the most widely used alternative in recent years has become 
adjunctive treatment with typical and atypical antipsychotics. The first evidence to 
support this treatment strategy was published by McDougle using haloperidol [8]. 
Since then the introduction of a range of the second generation antipsychotics, this 
class of drugs has been tested as augmentation to first-line treatments for refractory 
OCD in a number of studies.  
 
Data from these controlled studies of antipsychotic augmentation of OCD 
have recently been combined in several separate meta-analyses and reviews. All 
consistently demonstrate an overall benefit for this strategy. Bloch et al [9], 
systematically reviewed data from all available controlled studies using a variety of 
antipsychotics. Using response criteria of a minimum 35% reduction in Yale Brown 
Obsessive-Compulsive Scale (YBOCS) [10,11], scores from baseline to endpoint, 
they found an overall positive, albeit small, effect with absolute risk difference of 0.22 
(95% CI 0.13, 0.31). Consistent with the favourable effect noted by McDougle in his 
early study [8] for patients with tic disorders, an overall benefit for this strategy was 
also found. A specific benefit in those with tic disorders as well as schizotypal 
personality disorder was also highlighted in review by Keuneman et al [12]. Fineberg 
et al pooled data from three placebo-controlled studies [13-15] that used quetiapine 
to augment SRI therapy.  Using less conservative criteria for treatment response 
(>25% reduction in YBOCS), they found a significant treatment effect in favour of 
quetiapine (p=0.008) with the clinical effect falling in the range of “only limited clinical 
benefit” on a forest plot of overall effect [16]. Ipser et al [17] in a recent Cochrane 
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 analysis of antipsychotic augmentation across anxiety disorders, also demonstrated 
an overall benefit for this strategy, a result conferred largely through the contribution 
of controlled augmentation studies in OCD.   
 
An initial response to the question of which patients respond best, Denys et al 
[18] found that lower doses of SRIs predicted a more robust response to quetiapine 
augmentation. This finding together with the meta-analytical data mentioned above is 
interesting and responsive to the need for evidence-based alternatives in OCD 
pharmacotherapy. As yet, however, there is very little indication as to which 
refractory patients are likely to derive the most benefit from these interventions.  
 
In the context of SRI monotherapy for OCD, an extensive literature now exists 
in which clinical and demographic variables have been combined in a variety of ways 
to derive a series of clinical predictors of treatment outcome [19-27]. In these studies 
a wide range of dimensional symptom factors have been shown to be predictive of 
poorer response to treatment. These include hoarding [25,27] symmetry and 
hoarding [21], cleaning [26,28], somatic obsessions [23], and sexual/religious 
obsessions [26]. Clinical symptom predictors of better response to SRIs have 
included checking compulsions [29], and overall greater severity of obsessions [30].  
 
With respect to other descriptive variables in the context of SRI treatment, 
fewer previous courses of SRIs [30], female gender [29,31], later life onset [19], co-
morbid depression [32,33] and, higher YBOCS sub-scores [20,34] have been 
associated with better treatment outcome. In one of the few studies to develop a 
model for predicting treatment outcome, Denys et al [35] used key findings from the 
literature cited above to guide the choice of variables they entered into a multivariate 
regression in a double-blind placebo-controlled study of venlafaxine and paroxetine 
[36]. They found that YBOCS scores <23, HAM-D depression ratings >6, and fewer 
than two previous treatments for OCD predicted treatment response with an ROC-
area of 0.71. This represents a reasonable discriminative capacity of this simple 
three-variable model.    
 
In the present study we pool data for 80 subjects from two previously 
published studies which used a similar design. We used available clinical and 
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 demographic variables to derive a model that together provides the highest power to 
predict treatment outcome for augmentation of SRIs with atypical antipsychotics in 
refractory OCD.     
 
7.3 Methods 
 
Data from two studies using a double-blind placebo-controlled, parallel group, 
flexible dose, augmentation with quetiapine of continued selective serotonin re-
uptake inhibitors (SRIs) [14,15] was pooled. In the study by Denys et al participants 
had to have failed at least two adequate (12 week) trials of an SRI [15]. Efficacy for 
quetiapine over placebo augmentation in a sample of 40 patients was shown from as 
early as the 4th week of double-blind treatment. Mean YBOCS improvements of 32% 
from baseline compared to 6.8% improvement on placebo were seen at the week 8 
treatment endpoint. In the second study reported in Chapter 6 of this thesis [14], we 
studied a sample of 42 subjects who had responded inadequately to a minimum of 
12 weeks of SRI treatment of which six weeks needed to be at maximum tolerated 
doses. We found quetiapine (YBOCS reduction of 26.9%) and placebo (YBOCS 
reduction 26%) groups improved significantly, but not significantly differently over the 
6 week treatment period.  
 
Here we use data derived form the YBOCS symptom checklist  [10,11] to 
define the primacy and presence or not of each of the symptom domains. Scores 
were assigned as follows: “1’ for being present and ‘0” for being absent. Further to 
this, study participants were asked to specify for each of the broad domains of 
obsessions and compulsions which of the symptom domains was primary or most 
prominent. For symptom domains in this category, a score of 2 was assigned. The 
result is a description of the main obsession and compulsion symptom dimensions in 
OCD, with scores for their presence and primacy now presented in a semi-ordinal 
fashion for use in subsequent analyses [37]. 
 
Clinical symptom dimensions included contamination, sexual, hoarding, 
religious, symmetry, and somatic obsessions and cleaning/washing, checking, 
repeating/ritual, counting, ordering/arranging, hoarding, and mental compulsions. 
These were combined with a range of previously identified clinical and demographic 
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 variables including age, gender, previous number of failed SRI trials,  YBOCS 
obsession and compulsion scores separately and together at baseline, and the 
presence of tics.  Despite previous indications that higher depression scores may 
predict response to SRIs in OCD, the data sets combined in this study used different 
measures of depression (HAM-D and MADRS), making direct comparison difficult.   
 
In the first instance all variables were employed in univariate chi-square 
analyses with YBOCS responder status (>25% reduction in YBOCS), as the 
dependent variable.  Two multivariate best subset regression analyses formed the 
basis of this study. Using all possible combinations of predictor variables in best-
subsets multiple logistic regressions, we derived the best “subset” of variables that 
most strongly predict for; (1) the change in YBOCS score from baseline to endpoint, 
and (2) the YBOCS score at week 6 endpoint [38]. Finally, in both instances we then 
used the best subset combination of derived variables and used them into a “best of 
subsets” logistic regression to determine the overall predictive value of each of these 
dependent variables. From this a measure of the overall predictive value of our 
models was derived.  
 
7.4 Results 
 
 Results of univariate analyses of demographic and symptom dimensional 
characteristics showed that fewer previous failed SRI trials were significantly 
associated (p<0.01) with response status as defined by a 25% reduction in YBOCS 
from baseline to endpoint. No other clinical/demographic variables of interest were 
significantly associated with response status on chi-square (gender, p=0.81, 
presence of tics, p=0.938) or one-way ANOVA (age, p=0.61; YBOCS total at 
baseline, p=0.5); YBOCS baseline obsession score (p=0.17), and YBOCS baseline 
compulsion score (p=0.67). Similarly, univariate analysis of individual symptom 
dimensions showed that no one dimension on its own was significantly associated 
with a treatment response.   
 
 For the combined study dataset, the quetiapine group’s mean YBOCS 
percentage reduction was 25.66% (SE 4.33), while in the placebo group’s the 
reduction was 14.94% (SE 4.22). The “best subsets” regression analysis method 
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 used percentage change in YBOCS as the dependent variable without 
predetermined criteria for treatment response. This revealed that 9 of the 
independent variables provided the best model for predicting the percentage YBOCS 
change over the treatment course.  These were treatment group, number of previous 
failed SRI courses, the presence of tics, YBOCS obsession score at baseline, 
symmetry obsessions, somatic obsessions, checking compulsions, counting 
compulsions, and ordering/arranging compulsions. This group of independent 
variables was then combined in a logistic regression against a dependent variable of 
percentage change in YBOCS score. Of the 9 variables, 3 remained significant. 
These included having failed fewer previous SRI trials (p<0.01), higher baseline 
YBOCS obsession sub-score (p<0.01), and ordering/arranging compulsions 
(p<0.01). Together these predictive variables explain 45% of the variance in respect 
of treatment response (R2= 0.45).  
 
 In a second analysis we also undertook a best-subsets and stepwise linear 
regression using the 9 most significant variables with the week 6 YBOCS score as 
the dependent variable. In this case, treatment group, number of previous failed SRI 
courses, the presence of tics, YBOCS compulsions score at baseline, symmetry 
obsessions, somatic obsessions, checking compulsions, counting compulsions, and 
ordering/arranging compulsions were then entered into the model for the linear 
regression. In this model, fewer failed SRI trials (p<0.01); higher YBOCS baseline 
compulsion score (p<0.01), counting (p=0.03), and ordering/arranging (p<0.01) 
compulsions were the only significant predictors of a lower endpoint YBOCS score 
(better treatment outcome) in our model. This model predicted 50% of the variance 
for the week 6 YBOCS score in our sample (R2= 0.50). A tendency to treatment 
group being a significant predictor of outcome was seen for both YBOCS change 
(p=0.09) and YBOCS endpoint scores (p=0.07).     
 
7.5 Discussion  
 
The main findings of the present study were; (1) that failure of fewer previous 
trials with an SRI, (2) higher baseline obsessions (for YBOCS change), (3) higher 
baseline compulsions (for YBOCS endpoint), (4) higher counting compulsions 
(YBOCS endpoint), and (4) ordering/arranging compulsions (YBOCS change and 
endpoint) predicted a greater likelihood of improved outcome to antipsychotic 
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 augmentation of patients poorly responsive to initial SRI treatment. Together, these 
factors combine in a regression model and account for 45% of the YBOCS change 
score and 50% of the YBOCS endpoint score respectively.  
 
Our findings suggest that previous treatment history and more severe disease 
predict a positive treatment outcome. The levels of variance explained by our model, 
however, suggests one or a number of other as yet unknown factors may also be 
important contributors to treatment outcome. Larger samples and increased attention 
to alternative clinical and biological variables would be required to more accurately 
predict treatment outcome in antipsychotic augmentation studies in OCD.   
 
The results of the present study are nevertheless informative. Our finding that 
fewer previous failed trials of SRIs were associated with superior response rates in 
univariate as well as regression analyses is consistent with data from predictors of 
SRI response. This may suggest that the factors underlying poor response to serial 
SRI trials and antipsychotic augmentation overlap.  
 
We recently published data from an expanded cohort derived in part from the 
same data-set we used here suggesting that lower SRI doses were associated with 
more robust changes in response to quetiapine augmentation [39]. As such, it seems 
possible that treatment responsivity in OCD lies on a continuum. Within OCD 
populations, a biologically distinct sub-group who have failed fewer SRI trials may 
specifically benefit from augmentation with atypical antipsychotics. On the other 
hand, it is possible that this finding simply reflects a reality that in those who fail two 
or more SRI trials, the likelihood of responding to either an alternative SRI trial or 
antipsychotic augmentation is low, irrespective of the mechanism of action. In the 
clinic, our data raises the question as to whether there is not potentially more to be 
gained from augmenting with an atypical antipsychotic prior to switching to an 
alternative SRI after failure of a first trial?     
 
In the meta-analysis by Bloch et al [9], the maximum effect of treatment was 
noted in the first 4-6 weeks of augmentation. This suggests that the time to onset of 
action may be significantly faster than is conventionally, though not universally held 
to be the case for SRIs in OCD [7]. This has implications for the underlying biology of 
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 treatment response, as it suggests that the time-delaying process of receptor 
desensitization is either not necessary or is significantly accelerated with 
antipsychotic augmentation.  At a clinic level, these data suggest that a potential for 
time (faster onset of action), therapeutic (more likely to respond robustly) and 
ultimately cost advantages exists in favor of augmentation earlier in the treatment 
course of refractory OCD. This notion deserves further exploration. This will be 
required before it can be considered reasonable to influence current treatment 
guidelines of first switching to an alternative SRI for 12 weeks prior to antipsychotic 
augmentation being considered as the third-line option [7,40].  
 
In respect of the specific predictive value of individual symptoms, we found 
that higher baseline scores for obsessions predicted lower YBOCS scores. We also 
found that higher baseline compulsion scores predicted total YBOCS scores at week 
6 of treatment. In previous studies, higher baseline scores have been found to predict 
a poorer response to treatment with SRIs [41]. In this study, Shetty et al examined a 
cohort in which non-responders had significantly higher baseline YBOCS scores 
(25.3) than responders (18.96). Denys et al [35] derived a model for SRI response 
prediction in OCD and found that moderately high (<23) total YBOCS scores were 
associated with a superior response to SRI therapy. In functional brain imaging 
studies, higher frontal regional perfusion has been associated with more severe OCD 
[42]. Also higher regional perfusion has been shown to predict response to 
subsequent treatment with an SRI. Our data here would seem to be in line with the 
data that suggests higher pre-treatment YBOCS scores predict better outcome. In 
our data, however, total YBOCS scores were not predictive of outcome. We also 
found no obsessions or compulsions that occurred with significantly higher frequency 
than any other.  
 
We did find that symmetry obsessions, counting and ordering/arranging 
compulsions predicted better response to augmentation with quetiapine. There is 
evidence to suggest partial convergence of these symptoms with aspects of OCPD. 
While we did not collect data from which details of personality disorders could be 
extrapolated, this overlap is interesting in the light of recent arguments for 
understanding OCD with co-morbid OCPD as a subgroup of its own [43,44]. It seems 
that if OCPD is co-morbid with OCD, obsessions and compulsions such as 
symmetry, ordering, repeating, cleaning and hoarding are more likely to occur [44].  
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 In the Baer study, associations were also found with tic disorders and hoarding. Both 
of these dimensions have been linked with dopamine as a possible factor in 
mediating these “behaviours” in OCD. While tic disorders have been associated with 
superior responses to dopamine blocking augmentation in OCD [8,9], hoarding has 
demonstrated a poor response to SRI treatment [25,27], though not all data are 
consistent (Stein et al, unpublished).   
 
The association of ordering with response is interesting in the light of data 
suggesting an overlap with dimensions with an apparent dopaminergic basis. These 
include for instance the association with checking and symmetry/ordering with tics 
[25,37,45]. Aspects of our data, however mitigate the argument for dopamine 
involvement here with the absence of a predictive value of tics and behavioural 
dimensions such as hoarding which are believed to have a dopaminergic basis [46]. 
In the review by Bloch et al, co-morbid tics demonstrated preferential benefit to 
antipsychotic augmentation suggesting that the absence of a finding in the present 
study is possibly the effect of small sample size. The same could be argued for 
symptoms such as hoarding, which in trials of purely serotonergic compounds, 
predict poor treatment outcome.   
 
Returning then to the main finding of the present study that failure of fewer 
trials of SRIs is predictive of response to antipsychotic augmentation. Aside of the 
point made above in relation to treatment resistance as a position a subgroup of 
patients will enter irrespective of treatment type, it is possible that true differences do 
underlie the differential responsivity to dopamine antagonists in some patients. We 
can only speculate on the potential for underlying differences in dopaminergic 
neurotransmission in “less refractory” OCD patients compared to those who have 
failed two or more SRI therapy trials to exist. It may of course be true that a lack of 
evidence for the efficacy of antipsychotic earlier in the course of OCD treatment 
reflects a masking effect by the larger effect size of SRIs over the small effect of 
antipsychotic augmentation. Whatever the underlying mechanism for the efficacy of 
antipsychotic augmentation in OCD, the present study provides some preliminary 
indications of the clinical and demographic variables that predict a response to 
quetiapine augmentation.   
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In conclusion, we have found that a number of clinical variables appear to 
predict response to augmentation with quetiapine, but that the psychobiological basis 
for refractoriness to SRIs remains unknown. Recent meta-analyses that support the 
use of antipsychotic augmentation in OCD do suggest that a dopaminergic 
contribution to treatment is needed in a sub-group of patients with OCD. It is notable 
that failed trials of SRIs predict worse response to both SRIs and quetiapine 
augmentation, and may suggest distinct, as yet to be defined psychobiological 
factors that characterize treatment refractoriness that lies in the interaction of the 
serotonergic and dopaminergic systems. While our findings must be regarded as 
preliminary that requiring further confirmation, they do begin to suggest that the 
currently accepted notion that switching to an alternative serotonergic antidepressant 
should precede a trial of an atypical antipsychotic in patients who fail to respond 
adequately to first-line treatment with an SRI. 
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Summary and Conclusions 
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 8.1 Executive Summary  
 
 The role effective treatments have played in driving scientific exploration 
of the serotonin and more recently the dopamine systems in OCD are significant. 
Despite emerging evidence for the involvement of neurotrophic factors, immune 
modulators, functional genetic polymorphisms and a range of other neurochemical 
systems in the pathogenesis of OCD, the prominence of investigations into the role 
of serotonin and dopamine persists. Despite this, the specific mechanisms through 
which components of these systems are involved in mediating OCD has not been 
clearly delineated. This fact is probably a testimony to the complexity of these and 
other central nervous system neurotransmitter systems.    
 
 The series of studies comprising this thesis represent an effort to explore 
three important and interlinked study areas. First, we explored an aspect of 
neurobiology with two studies. In the first of these we examined resting brain 
perfusion compared to healthy controls and in the second rCBF in response to a 
specific serotonin 1B autoreceptor agonist challenge.  These were followed by two 
further studies in which we first examined the differential impact of the selective 
serotonin re-uptake inhibitor (SSRI), citalopram on rCBF across anxiety disorders 
to examine the intersection of treatment with neurobiology. This was achieved 
through the delineation of distinct and overlapping brain effects of this single 
effective treatment strategy. In the second study in this area, we explored the 
impact of a novel second messenger precursor, inositol, on rCBF when 
administered as treatment for OCD. This enabled us to examine the intersection of 
brain functional responses to an effective treatment in OCD that arguably targets a 
downstream common pathway also activated by conventional SRIs.  
  
 Finally, in a series of two studies we explored treatment of OCD using a 
dopamine-serotonin antagonist, quetiapine, in SSRI refractory patients. While our 
study did not demonstrate a benefit for quetiapine, we have subsequently 
combined our data with other similar studies in a meta-analysis and together 
demonstrated efficacy for this strategy. We then proceeded to combine our data 
with another similar dataset to derive a best subsets model with the highest 
predictive value for a favourable outcome to augmentation with quetiapine in 
refractory OCD.  
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 In summary, this body of work has primarily contributed to our 
understanding of the neurobiology of OCD, its treatment and the intersection of the 
two. To this end, both the serotonin and the dopamine systems were impacted 
directly and indirectly through the range of treatments we administered to patients. 
Taken together, these studies lend further support to both the serotonin and 
dopamine hypotheses in OCD.   
 
8.2 Detailed Summary   
 
Part I:  
 In the first in this series (Chapter 2), we examined the differences in 
regional brain perfusion in OCD compared to matched healthy controls. Similar 
studies over a number of years have yielded highly variable results, such that 
evidence for the putative cortico-striatal-thalamic circuit in OCD, is not convincingly 
reinforced by this work. In most previous studies, analysis has focused on regions 
hypothesized to be involved in OCD, with relatively little attention being given to 
other brain regions. In this study we showed that patients with OCD have 
substantially different brain perfusion patterns compared to normal controls. These 
differences are most pronounced in orbito-frontal and pre-central frontal brain 
regions with increased perfusion correlating in the prefrontal region with illness 
severity. While this data is in line with previous findings that have gone on to show 
that serotonergic treatments attenuate frontal perfusion, we also found a number of 
brain regions, outside of the putative functional circuit in OCD, in which the pattern 
was reversed. These include the lingula, superior orbito-frontal cortex, cerebellum, 
precuneus, anterior cingulate, superior parietal cortex, and left hippocampus.  
 
 While anxiety circuitry implicates some of these regions, robust 
explanations for all of these findings have yet to be delineated. Together however, 
they do suggest that in OCD with characteristic clinical heterogeneity, clear 
evidence for the involvement of brain regions other than the frontal-striatal circuit 
requires further investigation. Furthermore, this line of investigation only seems 
likely to yield meaningful results if methods of imaging and analysis are 
increasingly standardized to enable more reliable pooling of data. This in turn will 
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 provide a useful neurobiological foundation for understanding the functional brain 
patterns of the resting state in OCD and also the brain functional patterns of 
treatment response. It is conceivable that in combination with pharmacogenetic 
data, this approach may assist in understanding the action of future treatment for 
OCD in vivo.   
 
 In the second study in this series of four in Part I (Chapter 3), we 
considered clinical, genetic, and pharmacological challenge data underpinning the 
serotonin 1B autoreceptor hypothesis in OCD. Specifically we examined the 
neurobiology of the clinical and brain functional responses to pharmacological 
challenge with sumatriptan, a specific 5HT1B autoreceptor agonist. This was 
executed using a double-blind, cross-over, and counterbalanced design with 
placebo. We then examined the rCBF in participants on placebo and compared this 
to the responses on sumatriptan.  
  
 We found that behavioural responses of obsessive-compulsive (OC) and 
anxiety symptoms did not differ significantly overall between placebo and 
sumatriptan. However, this masked a characteristically heterogeneous behavioural 
response in our cohort. A little over half of the participants had improved anxiety 
ratings while the remainder reported symptom exacerbation. For OC symptoms on 
the other hand improvement in around 20%, exacerbation in 20%, and no change 
in the balance was found. A clinical improvement following sumatriptan was 
associated with lower cingulate, superior and medial frontal, and higher occipital 
perfusion. Improved anxiety in response to sumatriptan challenge correlated with 
reduced brain perfusion in the fusiform gyrus and the precuneus. We argue that 
pre-treatment frontal perfusion which is attenuated with sumatriptan and clinical 
improvement is in line with published work suggesting similar findings in response 
to SSRI treatment. While SSRIs do not primarily target the 1B autoreceptor, these 
data are suggestive of a role for the 5HT1B autoreceptor in mediating the clinical 
response in OCD that correlates with brain functional changes in frontal brain 
regions. 
 
 In Chapter 4, the third study in Part I, we asked to what extent anxiety 
disorders that are held to have distinct neurobiological underpinnings, but that 
respond similarly well to SRIs, share changes in brain perfusion as a function of 
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 treatment response. To this end we studied a group of participants with one of 
OCD, posttraumatic stress disorder (PTSD), or social anxiety disorder (SAD). We 
found no pre-treatment perfusion pattern helped distinguish subsequent 
responders to the SSRI citalopram in the group as a whole. Citalopram treatment 
resulted in attenuated perfusion for the combined group in the anterior superior 
cingulate, the thalamus, and hippocampus. Clinical responders to treatment 
demonstrated greater attenuation of perfusion in pre-central, mid, inferior and 
prefrontal regions as well as the precuneus.  
 
 These data suggest that despite phenomenological and neurochemical 
evidence for the distinctiveness of anxiety disorders, that overlap in functional 
neurocircuitry involved in mediating a treatment response to an SSRI is 
noteworthy. The involvement of brain regions that include limbic circuits known to 
mediate cognitive-affective dimensions of these disorders are also known to be 
richly innervated by serotonergic neurons. It is possible that across the group, only 
changes in regions that mediate shared phenomenological aspects of these 
disorders such as the limbic and paralimbic cortices are detectable. As such we 
should be cautious about over-interpreting data suggesting an overlap in disorders 
with quite distinct core phenomenology. 
 
 In the fourth study in Part I (Chapter 5), we examined the impact of 
treatment with myo-inositol, a glucose isomer and crucial precursor to the 
phosphoinositol second messenger system on regional brain perfusion measured 
with SPECT in OCD. Inositol has been shown to have effects at many levels of the 
signal transduction pathway.  It has also been shown to be preferentially effective 
in disorders that are responsive to serotonergic drugs including OCD. This 
seemingly suggests that Inositol may mediate postsynaptic processes that overlap 
with those of the SSRIs, though the specific mechanisms of this interaction remain 
unclear.  
 
 We demonstrated that attenuated brain perfusion in the prefrontal, 
temporal and parietal cortices correlated with clinical response to inositol. 
Furthermore, higher medial prefrontal perfusion at baseline correlated with 
subsequent treatment response. The same has been shown to be true with 
treatment with SSRIs. Together with our finding here, these data would seem to 
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 support the notion of an overlap in the function of SRIs and inositol that is most 
likely to lie beyond the level of receptor-neurotransmitter interaction at the level of 
the second messenger and beyond in the signal transduction pathway. These data 
also implicate brain regions that have been less well studied in OCD, such as the 
temporal and parietal cortex. This finding may suggest that inositol effects a clinical 
response through activation of functional circuitry that is distinct from the frontal-
striatal circuit. These interesting data and the suggested efficacy of inositol in OCD 
deserve further examination that will further delineate both overlapping and distinct 
mechanisms through which it works to effect a clinical response.    
 
Part II: 
 
 In Chapter 6, we examined the efficacy of augmentation of SRIs with a 
dopamine antagonist quetiapine under double-blind placebo-controlled conditions 
for six weeks in patients who had failed to respond adequately to first-line therapy 
with a serotonin re-uptake inhibitor (SRI). We were not able to demonstrate 
superiority over placebo in this study; however, a significant treatment effect was 
noted in both treatment groups. Our cohort was required to have failed only a 
single trial of an SRI, of which only six weeks was required at the maximum 
tolerated dose. We argued that the large and unexpected placebo response we 
observed was possibly due to a “delayed” effect of the SRIs. This may have been 
he case as the later were only required to have been at the maximum tolerated 
doses for a minimum of six weeks. This delayed effect, may therefore have 
rendered the relatively small effect anticipated with the dopamine modulating drug 
quetiapine, difficult to detect.  
 
 We have subsequently combined these data with two similar data sets in a 
meta-analysis and an overall positive effect has been shown for this strategy in 
refractory OCD. Together with another meta-analysis this strategy has been found 
to be effective for drugs including haloperidol, risperidone and olanzapine, 
suggesting that this is a class effect, and one that strongly supports a 
dopaminergic basis for resistance to treatment with SRIs in OCD.  
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 In the final study (Chapter 7) we combined two of the three available 
data-sets of quetiapine augmentation mentioned above to address the primary 
questions of whether a model of clinical and demographic variables could be 
derived to reliably predict treatment outcome in this refractory population. We 
chose to use the primary outcome variable YBOCS change and endpoint scores 
respectively as dependent variables in two separate best-subsets regression 
analyses. We found that fewer previous failed SRI trials, higher baseline obsession 
scores, and having ordering and arranging compulsions, predicted better treatment 
outcome explaining some 45% of the variance in YBOCS change. Using YBOCS 
endpoint scores we found a lower number of previous SRI trials, higher baseline 
compulsion scores, counting/ordering and arranging compulsions together 
predicted 50% of the variance in treatment outcome. We argued that some 
convergence with clinical dimensions believed to have a dopaminergic basis is 
evident in our sample. The evidence suggests that less refractory patients (defined 
by a lower number of failed SRI trials) are more likely to respond to quetiapine. 
This may suggest a specific role of dopamine modulating drugs in more 
symptomatic patients with “dopaminergic” symptoms that are partially refractory to 
SRIs. This effect, however, appears to diminish in parallel with lower response 
rates to SRIs seen with successive therapy trials. This may suggest that with 
“increasing” refractoriness, symptoms of OCD seem equally intransigent to both 
serotonin and dopamine modulating therapies.  
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8.3 Conclusions and future directions  
 
 Through this series of clinical treatment and functional brain imaging 
studies in OCD, I have contributed to the neurobiological understanding of OCD, its 
treatment in refractory populations and explored the intersection of these two 
domains using novel treatments and treatment across other anxiety disorders. 
Treatment and pharmacological challenges studies all directly or indirectly 
impacted the monoamine systems serotonin and dopamine and advanced our 
understanding of their involvement in symptom generation through:      
1)  Demonstrating that resting brain perfusion in OCD differs significantly from 
normal controls, is correlated with severity in frontal brain regions, and 
remains an important line of investigation for OCD pathophysiology that has 
yet to fully delineated. Future studies should encourage standardized 
approaches to image processing to ensure that small studies can be 
meaningfully combined using original data. In time, larger sample sizes 
using whole brain approaches to analysis will provide useful and reliable 
insights into resting brain function in OCD and how this differs from the 
provoked symptomatic state. Future work will also then be able to focus on 
sub-regional differences in brain function.  
2) Demonstrating that the 5HT1B autoreceptor agonist sumatriptan results in 
heterogeneous behavioural and regional brain perfusion changes in OCD. 
Pre-frontal increases in pre-treatment perfusion are attenuated following 
5HT1B autoreceptor agonist challenge, a finding that is in line with SSRI 
effects. This is suggestive of direct or indirect effects of SRIs on the 5HT1B 
receptor in mediating a clinical response in OCD. Future pharmacological 
challenge studies such as this will benefit from detailed symptom dimension 
data complemented by 5HT1B allelic composition. In addition, the 
development of a specific labeled ligand for the 5HT1B receptor would 
make a significant contribution to our understanding of the role of 5HT1B in 
OCD. 
3) Demonstrating that brain functional changes parallel treatment response to 
an SSRI across a range of anxiety disorders. This suggests a degree of 
overlap in the neurobiology of treatment response across anxiety disorders, 
or indeed a component of shared neurobiology per se in these disorders. 
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Future studies across anxiety disorders would also benefit from the use of 
ligands for the serotonin transporter as well as the serotonin 2a receptor in 
order to delineate the specific impact of treatment on these components in 
each of the disorders alone and combined. 
4) Effective treatment with an alternative treatment inositol which results in 
brain functional changes in line with the effects of SRIs on brain perfusion. 
This suggests that second messengers may form part of the common 
pathway of action for effective anti-obsessional compounds. Future studies 
using inositol should also examine its impact on the 5HT2a receptor, the 
putative membrane receptor crucial to the activation of inositol derived 
second messenger pathways.  
5) Demonstrating an overall benefit for augmentation of SRIs with a 
serotonin/dopamine antagonist in refractory OCD in pooled analyses. 
Future studies should more carefully examine the time to treatment 
response as well as the long-term outcomes in patients who initially benefit 
from this intervention. Alternative treatments that target the dopamine and 
serotonin systems indirectly should also be explored in controlled studies.  
6) Demonstrating that apparently less refractory to treatment patients with 
more severe illness and clinical dimensions with a putative dopaminergic 
underpinning may derive preferential benefit from serotonin/dopamine 
antagonist augmentation of their SRI treatment. Future studies should 
include larger sample sizes and would be strengthened by the addition of 
detailed neuropsychological and genetic data.    
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